-DOCSTART- -X- -X- O

Clustering NN O O
of NN O O
missense NN O O
mutations NN O O
in NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
gene NN O O
in NN O O
a NN O O
sporadic NN O B-Disease
T NN O I-Disease
- NN O I-Disease
cell NN O I-Disease
leukaemia NN O I-Disease
. NN O O

Ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
is NN O O
a NN O O
recessive NN O B-Disease
multi NN O I-Disease
- NN O I-Disease
system NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
at NN O O
11q22 NN O O
- NN O O
q23 NN O O
( NN O O
ref NN O O
. NN O O
3 NN O O
) NN O O
. NN O O

The NN O O
risk NN O O
of NN O O
cancer NN O B-Disease
, NN O O
especially NN O O
lymphoid NN O B-Disease
neoplasias NN O I-Disease
, NN O O
is NN O O
substantially NN O O
elevated NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
and NN O O
has NN O O
long NN O O
been NN O O
associated NN O O
with NN O O
chromosomal NN O O
instability NN O O
. NN O O

By NN O O
analysing NN O O
tumour NN O B-Disease
DNA NN O O
from NN O O
patients NN O O
with NN O O
sporadic NN O B-Disease
T NN O I-Disease
- NN O I-Disease
cell NN O I-Disease
prolymphocytic NN O I-Disease
leukaemia NN O I-Disease
( NN O O
T NN O B-Disease
- NN O I-Disease
PLL NN O I-Disease
) NN O O
, NN O O
a NN O O
rare NN O O
clonal NN O B-Disease
malignancy NN O I-Disease
with NN O O
similarities NN O O
to NN O O
a NN O O
mature NN O B-Disease
T NN O I-Disease
- NN O I-Disease
cell NN O I-Disease
leukaemia NN O I-Disease
seen NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
, NN O O
we NN O O
demonstrate NN O O
a NN O O
high NN O O
frequency NN O O
of NN O O
ATM NN O O
mutations NN O O
in NN O O
T NN O B-Disease
- NN O I-Disease
PLL NN O I-Disease
. NN O O

In NN O O
marked NN O O
contrast NN O O
to NN O O
the NN O O
ATM NN O O
mutation NN O O
pattern NN O O
in NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
, NN O O
the NN O O
most NN O O
frequent NN O O
nucleotide NN O O
changes NN O O
in NN O O
this NN O O
leukaemia NN O B-Disease
were NN O O
missense NN O O
mutations NN O O
. NN O O

These NN O O
clustered NN O O
in NN O O
the NN O O
region NN O O
corresponding NN O O
to NN O O
the NN O O
kinase NN O O
domain NN O O
, NN O O
which NN O O
is NN O O
highly NN O O
conserved NN O O
in NN O O
ATM NN O O
- NN O O
related NN O O
proteins NN O O
in NN O O
mouse NN O O
, NN O O
yeast NN O O
and NN O O
Drosophila NN O O
. NN O O

The NN O O
resulting NN O O
amino NN O O
- NN O O
acid NN O O
substitutions NN O O
are NN O O
predicted NN O O
to NN O O
interfere NN O O
with NN O O
ATP NN O O
binding NN O O
or NN O O
substrate NN O O
recognition NN O O
. NN O O

Two NN O O
of NN O O
seventeen NN O O
mutated NN O O
T NN O B-Disease
- NN O I-Disease
PLL NN O I-Disease
samples NN O O
had NN O O
a NN O O
previously NN O O
reported NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
allele NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
no NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
p53 NN O O
gene NN O O
, NN O O
suggesting NN O O
that NN O O
this NN O O
tumour NN O B-Disease
suppressor NN O O
is NN O O
not NN O O
frequently NN O O
altered NN O O
in NN O O
this NN O O
leukaemia NN O B-Disease
. NN O O

Occasional NN O O
missense NN O O
mutations NN O O
in NN O O
ATM NN O O
were NN O O
also NN O O
found NN O O
in NN O O
tumour NN O B-Disease
DNA NN O O
from NN O O
patients NN O O
with NN O O
B NN O B-Disease
- NN O I-Disease
cell NN O I-Disease
non NN O I-Disease
- NN O I-Disease
Hodgkins NN O I-Disease
lymphomas NN O I-Disease
( NN O O
B NN O B-Disease
- NN O I-Disease
NHL NN O I-Disease
) NN O O
and NN O O
a NN O O
B NN O B-Disease
- NN O I-Disease
NHL NN O I-Disease
cell NN O O
line NN O O
. NN O O

The NN O O
evidence NN O O
of NN O O
a NN O O
significant NN O O
proportion NN O O
of NN O O
loss NN O O
- NN O O
of NN O O
- NN O O
function NN O O
mutations NN O O
and NN O O
a NN O O
complete NN O O
absence NN O O
of NN O O
the NN O O
normal NN O O
copy NN O O
of NN O O
ATM NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
mutated NN O O
tumours NN O B-Disease
establishes NN O O
somatic NN O O
inactivation NN O O
of NN O O
this NN O O
gene NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
sporadic NN O B-Disease
T NN O I-Disease
- NN O I-Disease
PLL NN O I-Disease
and NN O O
suggests NN O O
that NN O O
ATM NN O O
acts NN O O
as NN O O
a NN O O
tumour NN O B-Disease
suppressor NN O O
. NN O O

As NN O O
constitutional NN O O
DNA NN O O
was NN O O
not NN O O
available NN O O
, NN O O
a NN O O
putative NN O O
hereditary NN O O
predisposition NN O O
to NN O O
T NN O B-Disease
- NN O I-Disease
PLL NN O I-Disease
will NN O O
require NN O O
further NN O O
investigation NN O O
. NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
protein NN O O
kinase NN O O
is NN O O
involved NN O O
in NN O O
the NN O O
modulation NN O O
of NN O O
the NN O O
Ca2 NN O O
+ NN O O
homeostasis NN O O
in NN O O
skeletal NN O O
muscle NN O O
cells NN O O
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
, NN O O
the NN O O
most NN O O
prevalent NN O O
muscular NN O B-Disease
disorder NN O I-Disease
in NN O O
adults NN O O
, NN O O
is NN O O
caused NN O O
by NN O O
( NN O O
CTG NN O O
) NN O O
n NN O O
- NN O O
repeat NN O O
expansion NN O O
in NN O O
a NN O O
gene NN O O
encoding NN O O
a NN O O
protein NN O O
kinase NN O O
( NN O O
DM NN O B-Disease
protein NN O O
kinase NN O O
; NN O O
DMPK NN O O
) NN O O
and NN O O
involves NN O O
changes NN O O
in NN O O
cytoarchitecture NN O O
and NN O O
ion NN O O
homeostasis NN O O
. NN O O

To NN O O
obtain NN O O
clues NN O O
to NN O O
the NN O O
normal NN O O
biological NN O O
role NN O O
of NN O O
DMPK NN O O
in NN O O
cellular NN O O
ion NN O O
homeostasis NN O O
, NN O O
we NN O O
have NN O O
compared NN O O
the NN O O
resting NN O O
[ NN O O
Ca2 NN O O
+ NN O O
] NN O O
i NN O O
, NN O O
the NN O O
amplitude NN O O
and NN O O
shape NN O O
of NN O O
depolarization NN O O
- NN O O
induced NN O O
Ca2 NN O O
+ NN O O
transients NN O O
, NN O O
and NN O O
the NN O O
content NN O O
of NN O O
ATP NN O O
- NN O O
driven NN O O
ion NN O O
pumps NN O O
in NN O O
cultured NN O O
skeletal NN O O
muscle NN O O
cells NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
and NN O O
DMPK NN O O
[ NN O O
- NN O O
/ NN O O
- NN O O
] NN O O
knockout NN O O
mice NN O O
. NN O O

In NN O O
vitro NN O O
- NN O O
differentiated NN O O
DMPK NN O O
[ NN O O
- NN O O
/ NN O O
- NN O O
] NN O O
myotubes NN O O
exhibit NN O O
a NN O O
higher NN O O
resting NN O O
[ NN O O
Ca2 NN O O
+ NN O O
] NN O O
i NN O O
than NN O O
do NN O O
wild NN O O
- NN O O
type NN O O
myotubes NN O O
because NN O O
of NN O O
an NN O O
altered NN O O
open NN O O
probability NN O O
of NN O O
voltage NN O O
- NN O O
dependent NN O O
l NN O O
- NN O O
type NN O O
Ca2 NN O O
+ NN O O
and NN O O
Na NN O O
+ NN O O
channels NN O O
. NN O O

The NN O O
mutant NN O O
myotubes NN O O
exhibit NN O O
smaller NN O O
and NN O O
slower NN O O
Ca2 NN O O
+ NN O O
responses NN O O
upon NN O O
triggering NN O O
by NN O O
acetylcholine NN O O
or NN O O
high NN O O
external NN O O
K NN O O
+ NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
observed NN O O
that NN O O
these NN O O
Ca2 NN O O
+ NN O O
transients NN O O
partially NN O O
result NN O O
from NN O O
an NN O O
influx NN O O
of NN O O
extracellular NN O O
Ca2 NN O O
+ NN O O
through NN O O
the NN O O
l NN O O
- NN O O
type NN O O
Ca2 NN O O
+ NN O O
channel NN O O
. NN O O

Neither NN O O
the NN O O
content NN O O
nor NN O O
the NN O O
activity NN O O
of NN O O
Na NN O O
+ NN O O
/ NN O O
K NN O O
+ NN O O
ATPase NN O O
and NN O O
sarcoplasmic NN O O
reticulum NN O O
Ca2 NN O O
+ NN O O
- NN O O
ATPase NN O O
are NN O O
affected NN O O
by NN O O
DMPK NN O O
absence NN O O
. NN O O

In NN O O
conclusion NN O O
, NN O O
our NN O O
data NN O O
suggest NN O O
that NN O O
DMPK NN O O
is NN O O
involved NN O O
in NN O O
modulating NN O O
the NN O O
initial NN O O
events NN O O
of NN O O
excitation NN O O
- NN O O
contraction NN O O
coupling NN O O
in NN O O
skeletal NN O O
muscle NN O O
. NN O O
. NN O O

Constitutional NN O O
RB1 NN O O
- NN O O
gene NN O O
mutations NN O O
in NN O O
patients NN O O
with NN O O
isolated NN O O
unilateral NN O B-Disease
retinoblastoma NN O I-Disease
. NN O O

In NN O O
most NN O O
patients NN O O
with NN O O
isolated NN O O
unilateral NN O B-Disease
retinoblastoma NN O I-Disease
, NN O O
tumor NN O B-Disease
development NN O O
is NN O O
initiated NN O O
by NN O O
somatic NN O O
inactivation NN O O
of NN O O
both NN O O
alleles NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
. NN O O

However NN O O
, NN O O
some NN O O
of NN O O
these NN O O
patients NN O O
can NN O O
transmit NN O O
retinoblastoma NN O B-Disease
predisposition NN O O
to NN O O
their NN O O
offspring NN O O
. NN O O

To NN O O
determine NN O O
the NN O O
frequency NN O O
and NN O O
nature NN O O
of NN O O
constitutional NN O O
RB1 NN O O
- NN O O
gene NN O O
mutations NN O O
in NN O O
patients NN O O
with NN O O
isolated NN O O
unilateral NN O B-Disease
retinoblastoma NN O I-Disease
, NN O O
we NN O O
analyzed NN O O
DNA NN O O
from NN O O
peripheral NN O O
blood NN O O
and NN O O
from NN O O
tumor NN O B-Disease
tissue NN O O
. NN O O

The NN O O
analysis NN O O
of NN O O
tumors NN O B-Disease
from NN O O
54 NN O O
( NN O O
71 NN O O
% NN O O
) NN O O
of NN O O
76 NN O O
informative NN O O
patients NN O O
showed NN O O
loss NN O O
of NN O O
constitutional NN O O
heterozygosity NN O O
( NN O O
LOH NN O O
) NN O O
at NN O O
intragenic NN O O
loci NN O O
. NN O O

Three NN O O
of NN O O
13 NN O O
uninformative NN O O
patients NN O O
had NN O O
constitutional NN O O
deletions NN O O
. NN O O

For NN O O
39 NN O O
randomly NN O O
selected NN O O
tumors NN O B-Disease
, NN O O
SSCP NN O O
, NN O O
hetero NN O O
- NN O O
duplex NN O O
analysis NN O O
, NN O O
sequencing NN O O
, NN O O
and NN O O
Southern NN O O
blot NN O O
analysis NN O O
were NN O O
used NN O O
to NN O O
identify NN O O
mutations NN O O
. NN O O

Mutations NN O O
were NN O O
detected NN O O
in NN O O
21 NN O O
( NN O O
91 NN O O
% NN O O
) NN O O
of NN O O
23 NN O O
tumors NN O B-Disease
with NN O O
LOH NN O O
. NN O O

In NN O O
6 NN O O
( NN O O
38 NN O O
% NN O O
) NN O O
of NN O O
16 NN O O
tumors NN O B-Disease
without NN O O
LOH NN O O
, NN O O
one NN O O
mutation NN O O
was NN O O
detected NN O O
, NN O O
and NN O O
in NN O O
9 NN O O
( NN O O
56 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
tumors NN O B-Disease
without NN O O
LOH NN O O
, NN O O
both NN O O
mutations NN O O
were NN O O
found NN O O
. NN O O

Thus NN O O
, NN O O
a NN O O
total NN O O
of NN O O
45 NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
tumors NN O B-Disease
of NN O O
36 NN O O
patients NN O O
. NN O O

Thirty NN O O
- NN O O
nine NN O O
of NN O O
the NN O O
mutations NN O O
- NN O O
including NN O O
34 NN O O
small NN O O
mutations NN O O
, NN O O
2 NN O O
large NN O O
structural NN O O
alterations NN O O
, NN O O
and NN O O
hypermethylation NN O O
in NN O O
3 NN O O
tumors NN O O
- NN O O
were NN O O
not NN O O
detected NN O O
in NN O O
the NN O O
corresponding NN O O
peripheral NN O O
blood NN O O
DNA NN O O
. NN O O

In NN O O
6 NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
36 NN O O
patients NN O O
, NN O O
a NN O O
mutation NN O O
was NN O O
detected NN O O
in NN O O
constitutional NN O O
DNA NN O O
, NN O O
and NN O O
1 NN O O
of NN O O
these NN O O
mutations NN O O
is NN O O
known NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
reduced NN O O
expressivity NN O O
. NN O O

The NN O O
presence NN O O
of NN O O
a NN O O
constitutional NN O O
mutation NN O O
was NN O O
not NN O O
associated NN O O
with NN O O
an NN O O
early NN O O
age NN O O
at NN O O
treatment NN O O
. NN O O

In NN O O
1 NN O O
patient NN O O
, NN O O
somatic NN O O
mosaicism NN O O
was NN O O
demonstrated NN O O
by NN O O
molecular NN O O
analysis NN O O
of NN O O
DNA NN O O
and NN O O
RNA NN O O
from NN O O
peripheral NN O O
blood NN O O
. NN O O

In NN O O
2 NN O O
patients NN O O
without NN O O
a NN O O
detectable NN O O
mutation NN O O
in NN O O
peripheral NN O O
blood NN O O
, NN O O
mosaicism NN O O
was NN O O
suggested NN O O
because NN O O
1 NN O O
of NN O O
the NN O O
patients NN O O
showed NN O O
multifocal NN O O
tumors NN O B-Disease
and NN O O
the NN O O
other NN O O
later NN O O
developed NN O O
bilateral NN O B-Disease
retinoblastoma NN O I-Disease
. NN O O

In NN O O
conclusion NN O O
, NN O O
our NN O O
results NN O O
emphasize NN O O
that NN O O
the NN O O
manifestation NN O O
and NN O O
transmissibility NN O O
of NN O O
retinoblastoma NN O B-Disease
depend NN O O
on NN O O
the NN O O
nature NN O O
of NN O O
the NN O O
first NN O O
mutation NN O O
, NN O O
its NN O O
time NN O O
in NN O O
development NN O O
, NN O O
and NN O O
the NN O O
number NN O O
and NN O O
types NN O O
of NN O O
cells NN O O
that NN O O
are NN O O
affected NN O O
. NN O O
. NN O O

Hereditary NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
fifth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
in NN O O
man NN O O
. NN O O

I NN O O
. NN O O

Clinical NN O O
, NN O O
immunochemical NN O O
, NN O O
and NN O O
family NN O O
studies NN O O
. NN O O

The NN O O
first NN O O
recognized NN O O
human NN O O
kindred NN O O
with NN O O
hereditary NN O B-Disease
deficiency NN O I-Disease
of NN O I-Disease
the NN O I-Disease
fifth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
complement NN O I-Disease
( NN O O
C5 NN O O
) NN O O
is NN O O
described NN O O
. NN O O

The NN O O
proband NN O O
, NN O O
a NN O O
20 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
black NN O O
female NN O O
with NN O O
systemic NN O B-Disease
lupus NN O I-Disease
erythematosus NN O I-Disease
since NN O O
age NN O O
11 NN O O
, NN O O
lacked NN O O
serum NN O O
hemolytic NN O O
complement NN O O
activity NN O O
, NN O O
even NN O O
during NN O O
remission NN O O
. NN O O

C5 NN O O
was NN O O
undetectable NN O O
in NN O O
her NN O O
serum NN O O
by NN O O
both NN O O
immunodiffusion NN O O
and NN O O
hemolytic NN O O
assays NN O O
. NN O O

Other NN O O
complement NN O O
components NN O O
were NN O O
normal NN O O
during NN O O
remission NN O O
of NN O O
lupus NN O O
, NN O O
but NN O O
C1 NN O O
, NN O O
C4 NN O O
, NN O O
C2 NN O O
, NN O O
and NN O O
C3 NN O O
levels NN O O
fell NN O O
during NN O O
exacerbations NN O O
. NN O O

A NN O O
younger NN O O
half NN O O
- NN O O
sister NN O O
, NN O O
who NN O O
had NN O O
no NN O O
underlying NN O O
disease NN O O
, NN O O
was NN O O
also NN O O
found NN O O
to NN O O
lack NN O O
immunochemically NN O O
detectable NN O O
C5 NN O O
. NN O O

By NN O O
hemolytic NN O O
assay NN O O
, NN O O
she NN O O
exhibited NN O O
1 NN O O
- NN O O
2 NN O O
% NN O O
of NN O O
the NN O O
normal NN O O
serum NN O O
C5 NN O O
level NN O O
and NN O O
normal NN O O
concentrations NN O O
of NN O O
other NN O O
complement NN O O
components NN O O
. NN O O

C5 NN O O
levels NN O O
of NN O O
other NN O O
family NN O O
members NN O O
were NN O O
either NN O O
normal NN O O
or NN O O
approximately NN O O
half NN O O
- NN O O
normal NN O O
, NN O O
consistent NN O O
with NN O O
autosomal NN O O
codominant NN O O
inheritance NN O O
of NN O O
the NN O O
gene NN O O
determining NN O O
C5 NN O B-Disease
deficiency NN O I-Disease
. NN O O

Normal NN O O
hemolytic NN O O
titers NN O O
were NN O O
restored NN O O
to NN O O
both NN O O
homozygous NN O O
C5 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
( NN O O
C5D NN O B-Disease
) NN O O
sera NN O O
by NN O O
addition NN O O
of NN O O
highly NN O O
purified NN O O
human NN O O
C5 NN O O
. NN O O

In NN O O
specific NN O O
C5 NN O O
titrations NN O O
, NN O O
however NN O O
, NN O O
it NN O O
was NN O O
noted NN O O
that NN O O
when NN O O
limited NN O O
amounts NN O O
of NN O O
C5 NN O O
were NN O O
assayed NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
low NN O O
dilutions NN O O
of NN O O
either NN O O
C5D NN O B-Disease
serum NN O O
, NN O O
curving NN O O
rather NN O O
than NN O O
linear NN O O
dose NN O O
- NN O O
response NN O O
plots NN O O
were NN O O
consistently NN O O
obtained NN O O
, NN O O
suggesting NN O O
some NN O O
inhibitory NN O O
effect NN O O
. NN O O

Further NN O O
studies NN O O
suggested NN O O
that NN O O
low NN O O
dilutions NN O O
of NN O O
C5D NN O B-Disease
serum NN O O
contain NN O O
a NN O O
factor NN O O
( NN O O
or NN O O
factors NN O O
) NN O O
interfering NN O O
at NN O O
some NN O O
step NN O O
in NN O O
the NN O O
hemolytic NN O O
assay NN O O
of NN O O
C5 NN O O
, NN O O
rather NN O O
than NN O O
a NN O O
true NN O O
C5 NN O O
inhibitor NN O O
or NN O O
inactivator NN O O
. NN O O

Of NN O O
clinical NN O O
interest NN O O
are NN O O
( NN O O
a NN O O
) NN O O
the NN O O
documentation NN O O
of NN O O
membranous NN O O
glomerulonephritis NN O B-Disease
, NN O O
vasculitis NN O B-Disease
, NN O O
and NN O O
arthritis NN O B-Disease
in NN O O
an NN O O
individual NN O O
lacking NN O O
C5 NN O O
( NN O O
and NN O O
its NN O O
biologic NN O O
functions NN O O
) NN O O
, NN O O
and NN O O
( NN O O
b NN O O
) NN O O
a NN O O
remarkable NN O O
propensity NN O O
to NN O O
bacterial NN O B-Disease
infections NN O I-Disease
in NN O O
the NN O O
proband NN O O
, NN O O
even NN O O
during NN O O
periods NN O O
of NN O O
low NN O O
- NN O O
dose NN O O
or NN O O
alternate NN O O
- NN O O
day NN O O
corticosteroid NN O O
therapy NN O O
. NN O O

Other NN O O
observations NN O O
indicate NN O O
that NN O O
the NN O O
C5D NN O B-Disease
state NN O O
is NN O O
compatible NN O O
with NN O O
normal NN O O
coagulation NN O O
function NN O O
and NN O O
the NN O O
capacity NN O O
to NN O O
mount NN O O
a NN O O
neutrophilic NN O O
leukocytosis NN O O
during NN O O
pyogenic NN O B-Disease
infection NN O I-Disease
. NN O O
. NN O O

Susceptibility NN O O
to NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
in NN O O
twins NN O O
: NN O O
the NN O O
role NN O O
of NN O O
genes NN O O
, NN O O
HLA NN O O
, NN O O
and NN O O
the NN O O
environment NN O O
. NN O O

OBJECTIVE NN O O
To NN O O
determine NN O O
the NN O O
relative NN O O
effects NN O O
of NN O O
genetic NN O O
and NN O O
environmental NN O O
factors NN O O
in NN O O
susceptibility NN O O
to NN O O
ankylosing NN O B-Disease
spondylitis NN O I-Disease
( NN O O
AS NN O B-Disease
) NN O O
. NN O O

METHODS NN O O
Twins NN O O
with NN O O
AS NN O B-Disease
were NN O O
identified NN O O
from NN O O
the NN O O
Royal NN O O
National NN O O
Hospital NN O O
for NN O O
Rheumatic NN O B-Disease
Diseases NN O I-Disease
database NN O O
. NN O O

Clinical NN O O
and NN O O
radiographic NN O O
examinations NN O O
were NN O O
performed NN O O
to NN O O
establish NN O O
diagnoses NN O O
, NN O O
and NN O O
disease NN O O
severity NN O O
was NN O O
assessed NN O O
using NN O O
a NN O O
combination NN O O
of NN O O
validated NN O O
scoring NN O O
systems NN O O
. NN O O

HLA NN O O
typing NN O O
for NN O O
HLA NN O O
- NN O O
B27 NN O O
, NN O O
HLA NN O O
- NN O O
B60 NN O O
, NN O O
and NN O O
HLA NN O O
- NN O O
DR1 NN O O
was NN O O
performed NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
with NN O O
sequence NN O O
- NN O O
specific NN O O
primers NN O O
, NN O O
and NN O O
zygosity NN O O
was NN O O
assessed NN O O
using NN O O
microsatellite NN O O
markers NN O O
. NN O O

Genetic NN O O
and NN O O
environmental NN O O
variance NN O O
components NN O O
were NN O O
assessed NN O O
with NN O O
the NN O O
program NN O O
Mx NN O O
, NN O O
using NN O O
data NN O O
from NN O O
this NN O O
and NN O O
previous NN O O
studies NN O O
of NN O O
twins NN O O
with NN O O
AS NN O B-Disease
. NN O O

RESULTS NN O O
Six NN O O
of NN O O
8 NN O O
monozygotic NN O O
( NN O O
MZ NN O O
) NN O O
twin NN O O
pairs NN O O
were NN O O
disease NN O O
concordant NN O O
, NN O O
compared NN O O
with NN O O
4 NN O O
of NN O O
15 NN O O
B27 NN O O
- NN O O
positive NN O O
dizygotic NN O O
( NN O O
DZ NN O O
) NN O O
twin NN O O
pairs NN O O
( NN O O
27 NN O O
% NN O O
) NN O O
and NN O O
4 NN O O
of NN O O
32 NN O O
DZ NN O O
twin NN O O
pairs NN O O
overall NN O O
( NN O O
12 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
. NN O O

Nonsignificant NN O O
increases NN O O
in NN O O
similarity NN O O
with NN O O
regard NN O O
to NN O O
age NN O O
at NN O O
disease NN O O
onset NN O O
and NN O O
all NN O O
of NN O O
the NN O O
disease NN O O
severity NN O O
scores NN O O
assessed NN O O
were NN O O
noted NN O O
in NN O O
disease NN O O
- NN O O
concordant NN O O
MZ NN O O
twins NN O O
compared NN O O
with NN O O
concordant NN O O
DZ NN O O
twins NN O O
. NN O O

HLA NN O O
- NN O O
B27 NN O O
and NN O O
B60 NN O O
were NN O O
associated NN O O
with NN O O
the NN O O
disease NN O O
in NN O O
probands NN O O
, NN O O
and NN O O
the NN O O
rate NN O O
of NN O O
disease NN O O
concordance NN O O
was NN O O
significantly NN O O
increased NN O O
among NN O O
DZ NN O O
twin NN O O
pairs NN O O
in NN O O
which NN O O
the NN O O
co NN O O
- NN O O
twin NN O O
was NN O O
positive NN O O
for NN O O
both NN O O
B27 NN O O
and NN O O
DR1 NN O O
. NN O O

Additive NN O O
genetic NN O O
effects NN O O
were NN O O
estimated NN O O
to NN O O
contribute NN O O
97 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
variance NN O O
. NN O O

CONCLUSION NN O O
Susceptibility NN O O
to NN O O
AS NN O B-Disease
is NN O O
largely NN O O
genetically NN O O
determined NN O O
, NN O O
and NN O O
the NN O O
environmental NN O O
trigger NN O O
for NN O O
the NN O O
disease NN O O
is NN O O
probably NN O O
ubiquitous NN O O
. NN O O

HLA NN O O
- NN O O
B27 NN O O
accounts NN O O
for NN O O
a NN O O
minority NN O O
of NN O O
the NN O O
overall NN O O
genetic NN O O
susceptibility NN O O
to NN O O
AS NN O B-Disease
. NN O O

Cell NN O O
cycle NN O O
- NN O O
dependent NN O O
colocalization NN O O
of NN O O
BARD1 NN O O
and NN O O
BRCA1 NN O O
proteins NN O O
in NN O O
discrete NN O O
nuclear NN O O
domains NN O O
. NN O O

Germ NN O O
- NN O O
line NN O O
mutations NN O O
of NN O O
the NN O O
BRCA1 NN O O
gene NN O O
predispose NN O O
women NN O O
to NN O O
early NN O O
- NN O O
onset NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
by NN O O
compromising NN O O
the NN O O
genes NN O O
presumptive NN O O
function NN O O
as NN O O
a NN O O
tumor NN O B-Disease
suppressor NN O O
. NN O O

Although NN O O
the NN O O
biochemical NN O O
properties NN O O
of NN O O
BRCA1 NN O O
polypeptides NN O O
are NN O O
not NN O O
understood NN O O
, NN O O
their NN O O
expression NN O O
pattern NN O O
and NN O O
subcellular NN O O
localization NN O O
suggest NN O O
a NN O O
role NN O O
in NN O O
cell NN O O
- NN O O
cycle NN O O
regulation NN O O
. NN O O

When NN O O
resting NN O O
cells NN O O
are NN O O
induced NN O O
to NN O O
proliferate NN O O
, NN O O
the NN O O
steady NN O O
- NN O O
state NN O O
levels NN O O
of NN O O
BRCA1 NN O O
increase NN O O
in NN O O
late NN O O
G1 NN O O
and NN O O
reach NN O O
a NN O O
maximum NN O O
during NN O O
S NN O O
phase NN O O
. NN O O

Moreover NN O O
, NN O O
in NN O O
S NN O O
phase NN O O
cells NN O O
, NN O O
BRCA1 NN O O
polypeptides NN O O
are NN O O
hyperphosphorylated NN O O
and NN O O
accumulate NN O O
into NN O O
discrete NN O O
subnuclear NN O O
foci NN O O
termed NN O O
" NN O O
BRCA1 NN O O
nuclear NN O O
dots NN O O
. NN O O

" NN O O
BRCA1 NN O O
associates NN O O
in NN O O
vivo NN O O
with NN O O
a NN O O
structurally NN O O
related NN O O
protein NN O O
termed NN O O
BARD1 NN O O
. NN O O

Here NN O O
we NN O O
show NN O O
that NN O O
the NN O O
steady NN O O
- NN O O
state NN O O
levels NN O O
of NN O O
BARD1 NN O O
, NN O O
unlike NN O O
those NN O O
of NN O O
BRCA1 NN O O
, NN O O
remain NN O O
relatively NN O O
constant NN O O
during NN O O
cell NN O O
cycle NN O O
progression NN O O
. NN O O

However NN O O
, NN O O
immunostaining NN O O
revealed NN O O
that NN O O
BARD1 NN O O
resides NN O O
within NN O O
BRCA1 NN O O
nuclear NN O O
dots NN O O
during NN O O
S NN O O
phase NN O O
of NN O O
the NN O O
cell NN O O
cycle NN O O
, NN O O
but NN O O
not NN O O
during NN O O
the NN O O
G1 NN O O
phase NN O O
. NN O O

Nevertheless NN O O
, NN O O
BARD1 NN O O
polypeptides NN O O
are NN O O
found NN O O
exclusively NN O O
in NN O O
the NN O O
nuclear NN O O
fractions NN O O
of NN O O
both NN O O
G1 NN O O
- NN O O
and NN O O
S NN O O
- NN O O
phase NN O O
cells NN O O
. NN O O

Therefore NN O O
, NN O O
progression NN O O
to NN O O
S NN O O
phase NN O O
is NN O O
accompanied NN O O
by NN O O
the NN O O
aggregation NN O O
of NN O O
nuclear NN O O
BARD1 NN O O
polypeptides NN O O
into NN O O
BRCA1 NN O O
nuclear NN O O
dots NN O O
. NN O O

This NN O O
cell NN O O
cycle NN O O
- NN O O
dependent NN O O
colocalization NN O O
of NN O O
BARD1 NN O O
and NN O O
BRCA1 NN O O
indicates NN O O
a NN O O
role NN O O
for NN O O
BARD1 NN O O
in NN O O
BRCA1 NN O O
- NN O O
mediated NN O O
tumor NN O B-Disease
suppression NN O O
. NN O O

Ethnic NN O O
differences NN O O
in NN O O
the NN O O
HFE NN O O
codon NN O O
282 NN O O
( NN O O
Cys NN O O
/ NN O O
Tyr NN O O
) NN O O
polymorphism NN O O
. NN O O

Recent NN O O
studies NN O O
have NN O O
shown NN O O
that NN O O
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
( NN O O
HH NN O B-Disease
) NN O O
is NN O O
likely NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
homozygosity NN O O
for NN O O
a NN O O
Cys282Tyr NN O O
mutation NN O O
in NN O O
the NN O O
HFE NN O O
gene NN O O
located NN O O
4 NN O O
. NN O O

5 NN O O
Mb NN O O
telomeric NN O O
to NN O O
HLA NN O O
- NN O O
A NN O O
. NN O O

Population NN O O
studies NN O O
of NN O O
this NN O O
polymorphism NN O O
are NN O O
facilitated NN O O
by NN O O
the NN O O
fact NN O O
that NN O O
the NN O O
Cys282Tyr NN O O
mutation NN O O
creates NN O O
a NN O O
Rsal NN O O
restriction NN O O
site NN O O
. NN O O

We NN O O
have NN O O
studied NN O O
the NN O O
codon NN O O
282 NN O O
( NN O O
Cys NN O O
/ NN O O
Tyr NN O O
) NN O O
polymorphism NN O O
in NN O O
different NN O O
ethnic NN O O
groups NN O O
. NN O O

In NN O O
agreement NN O O
with NN O O
previous NN O O
observations NN O O
the NN O O
Tyr NN O O
allele NN O O
appeared NN O O
to NN O O
be NN O O
rare NN O O
or NN O O
absent NN O O
in NN O O
Asiatic NN O O
( NN O O
Indian NN O O
, NN O O
Chinese NN O O
) NN O O
populations NN O O
. NN O O

The NN O O
highest NN O O
allele NN O O
frequency NN O O
( NN O O
7 NN O O
. NN O O
5 NN O O
% NN O O
) NN O O
was NN O O
found NN O O
in NN O O
Swedes NN O O
. NN O O

Saamis NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
and NN O O
Mordvinians NN O O
( NN O O
1 NN O O
. NN O O
8 NN O O
% NN O O
) NN O O
had NN O O
significantly NN O O
lower NN O O
frequencies NN O O
of NN O O
the NN O O
Tyr NN O O
allele NN O O
. NN O O

Comparisons NN O O
with NN O O
allele NN O O
frequencies NN O O
based NN O O
on NN O O
prevalence NN O O
estimates NN O O
of NN O O
HH NN O B-Disease
showed NN O O
some NN O O
disagreements NN O O
with NN O O
the NN O O
RFLP NN O O
data NN O O
, NN O O
particularly NN O O
in NN O O
Finns NN O O
. NN O O

The NN O O
newly NN O O
described NN O O
HFE NN O O
marker NN O O
provides NN O O
a NN O O
new NN O O
approach NN O O
to NN O O
the NN O O
screening NN O O
of NN O O
HH NN O B-Disease
as NN O O
well NN O O
as NN O O
studies NN O O
of NN O O
the NN O O
relationship NN O O
between NN O O
the NN O O
HFE NN O O
Tyr NN O O
allele NN O O
and NN O O
different NN O O
disorders NN O O
including NN O O
cancer NN O B-Disease

Autosomal NN O B-Disease
dominant NN O I-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
associated NN O O
with NN O O
a NN O O
missense NN O O
mutation NN O O
encoding NN O O
Gly23 NN O O
- NN O O
- NN O O
> NN O O
Val NN O O
in NN O O
neurophysin NN O O
II NN O O
. NN O O

Autosomal NN O B-Disease
dominant NN O I-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
( NN O O
ADNDI NN O B-Disease
) NN O O
is NN O O
an NN O O
inherited NN O B-Disease
disease NN O I-Disease
caused NN O O
by NN O O
progressive NN O O
degeneration NN O O
of NN O O
the NN O O
magnocellular NN O O
neurons NN O O
of NN O O
the NN O O
hypothalamus NN O O
leading NN O O
to NN O O
decreased NN O O
ability NN O O
to NN O O
produce NN O O
the NN O O
hormone NN O O
arginine NN O O
vasopressin NN O O
( NN O O
AVP NN O O
) NN O O
. NN O O

Affected NN O O
individuals NN O O
are NN O O
not NN O O
symptomatic NN O O
at NN O O
birth NN O O
, NN O O
but NN O O
usually NN O O
develop NN O O
diabetes NN O B-Disease
insipidus NN O I-Disease
at NN O O
1 NN O O
- NN O O
6 NN O O
yr NN O O
of NN O O
age NN O O
. NN O O

The NN O O
genetic NN O O
locus NN O O
of NN O O
the NN O O
disease NN O O
is NN O O
the NN O O
AVP NN O O
- NN O O
neurophysin NN O O
II NN O O
( NN O O
NPII NN O O
) NN O O
gene NN O O
, NN O O
and NN O O
mutations NN O O
that NN O O
cause NN O O
ADNDI NN O B-Disease
have NN O O
been NN O O
found NN O O
in NN O O
both NN O O
the NN O O
signal NN O O
peptide NN O O
of NN O O
the NN O O
prepro NN O O
- NN O O
AVP NN O O
- NN O O
NPII NN O O
precursor NN O O
and NN O O
within NN O O
NPII NN O O
itself NN O O
. NN O O

An NN O O
affected NN O O
girl NN O O
who NN O O
presented NN O O
at NN O O
9 NN O O
months NN O O
of NN O O
age NN O O
and NN O O
her NN O O
similarly NN O O
affected NN O O
younger NN O O
brother NN O O
and NN O O
father NN O O
were NN O O
all NN O O
found NN O O
to NN O O
have NN O O
a NN O O
novel NN O O
missense NN O O
mutation NN O O
( NN O O
G1758 NN O O
- NN O O
- NN O O
> NN O O
T NN O O
) NN O O
encoding NN O O
the NN O O
amino NN O O
acid NN O O
substitution NN O O
Gly23 NN O O
- NN O O
- NN O O
> NN O O
Val NN O O
within NN O O
NPII NN O O
. NN O O

The NN O O
mutation NN O O
was NN O O
confirmed NN O O
by NN O O
restriction NN O O
endonuclease NN O O
analysis NN O O
. NN O O

A NN O O
T1 NN O O
- NN O O
weighted NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
of NN O O
the NN O O
fathers NN O O
pituitary NN O O
gland NN O O
demonstrates NN O O
an NN O O
attenuated NN O O
posterior NN O O
pituitary NN O O
bright NN O O
spot NN O O
. NN O O

This NN O O
mutation NN O O
may NN O O
be NN O O
valuable NN O O
for NN O O
developing NN O O
models NN O O
of NN O O
dominantly NN O B-Disease
inherited NN O I-Disease
neurodegeneration NN O I-Disease
, NN O O
as NN O O
the NN O O
early NN O O
age NN O O
of NN O O
onset NN O O
of NN O O
symptoms NN O O
suggests NN O O
that NN O O
this NN O O
mutation NN O O
may NN O O
be NN O O
particularly NN O O
deleterious NN O O
to NN O O
the NN O O
magnocellular NN O O
neuron NN O O
. NN O O
. NN O O

Frequent NN O O
inactivation NN O O
of NN O O
PTEN NN O O
/ NN O O
MMAC1 NN O O
in NN O O
primary NN O O
prostate NN O B-Disease
cancer NN O I-Disease
. NN O O

Sporadic NN O B-Disease
prostate NN O I-Disease
carcinoma NN O I-Disease
is NN O O
the NN O O
most NN O O
common NN O O
male NN O B-Disease
cancer NN O I-Disease
in NN O O
the NN O O
Western NN O O
world NN O O
, NN O O
yet NN O O
many NN O O
of NN O O
the NN O O
major NN O O
genetic NN O O
events NN O O
involved NN O O
in NN O O
the NN O O
progression NN O O
of NN O O
this NN O O
often NN O O
fatal NN O O
cancer NN O B-Disease
remain NN O O
to NN O O
be NN O O
elucidated NN O O
. NN O O

Numerous NN O O
cytogenetic NN O O
and NN O O
allelotype NN O O
studies NN O O
have NN O O
reported NN O O
frequent NN O O
loss NN O O
of NN O O
heterozygosity NN O O
on NN O O
chromosomal NN O O
arm NN O O
10q NN O O
in NN O O
sporadic NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
. NN O O

Deletion NN O O
mapping NN O O
studies NN O O
have NN O O
unambiguously NN O O
identified NN O O
a NN O O
region NN O O
of NN O O
chromosome NN O O
10q23 NN O O
to NN O O
be NN O O
the NN O O
minimal NN O O
area NN O O
of NN O O
loss NN O O
. NN O O

A NN O O
new NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
, NN O O
PTEN NN O O
/ NN O O
MMAC1 NN O O
, NN O O
was NN O O
isolated NN O O
recently NN O O
at NN O O
this NN O O
region NN O O
of NN O O
chromosome NN O O
10q23 NN O O
and NN O O
found NN O O
to NN O O
be NN O O
inactivated NN O O
by NN O O
mutation NN O O
in NN O O
three NN O O
prostate NN O B-Disease
cancer NN O I-Disease
cell NN O O
lines NN O O
. NN O O

We NN O O
screened NN O O
80 NN O O
prostate NN O B-Disease
tumors NN O I-Disease
by NN O O
microsatellite NN O O
analysis NN O O
and NN O O
found NN O O
chromosome NN O O
10q23 NN O O
to NN O O
be NN O O
deleted NN O O
in NN O O
23 NN O O
cases NN O O
. NN O O

We NN O O
then NN O O
proceeded NN O O
with NN O O
sequence NN O O
analysis NN O O
of NN O O
the NN O O
entire NN O O
PTEN NN O O
/ NN O O
MMAC1 NN O O
coding NN O O
region NN O O
and NN O O
tested NN O O
for NN O O
homozygous NN O O
deletion NN O O
with NN O O
new NN O O
intragenic NN O O
markers NN O O
in NN O O
these NN O O
23 NN O O
cases NN O O
with NN O O
10q23 NN O O
loss NN O O
of NN O O
heterozygosity NN O O
. NN O O

The NN O O
identification NN O O
of NN O O
the NN O O
second NN O O
mutational NN O O
event NN O O
in NN O O
10 NN O O
( NN O O
43 NN O O
% NN O O
) NN O O
tumors NN O B-Disease
establishes NN O O
PTEN NN O O
/ NN O O
MMAC1 NN O O
as NN O O
a NN O O
main NN O O
inactivation NN O O
target NN O O
of NN O O
10q NN O O
loss NN O O
in NN O O
sporadic NN O B-Disease
prostate NN O I-Disease
cancer NN O I-Disease
. NN O O
. NN O O

Risk NN O O
reversals NN O O
in NN O O
predictive NN O O
testing NN O O
for NN O O
Huntington NN O B-Disease
disease NN O I-Disease
. NN O O

The NN O O
first NN O O
predictive NN O O
testing NN O O
for NN O O
Huntington NN O B-Disease
disease NN O I-Disease
( NN O O
HD NN O B-Disease
) NN O O
was NN O O
based NN O O
on NN O O
analysis NN O O
of NN O O
linked NN O O
polymorphic NN O O
DNA NN O O
markers NN O O
to NN O O
estimate NN O O
the NN O O
likelihood NN O O
of NN O O
inheriting NN O O
the NN O O
mutation NN O O
for NN O O
HD NN O B-Disease
. NN O O

Limits NN O O
to NN O O
accuracy NN O O
included NN O O
recombination NN O O
between NN O O
the NN O O
DNA NN O O
markers NN O O
and NN O O
the NN O O
mutation NN O O
, NN O O
pedigree NN O O
structure NN O O
, NN O O
and NN O O
whether NN O O
DNA NN O O
samples NN O O
were NN O O
available NN O O
from NN O O
family NN O O
members NN O O
. NN O O

With NN O O
direct NN O O
tests NN O O
for NN O O
the NN O O
HD NN O B-Disease
mutation NN O O
, NN O O
we NN O O
have NN O O
assessed NN O O
the NN O O
accuracy NN O O
of NN O O
results NN O O
obtained NN O O
by NN O O
linkage NN O O
approaches NN O O
when NN O O
requested NN O O
to NN O O
do NN O O
so NN O O
by NN O O
the NN O O
test NN O O
individuals NN O O
. NN O O

For NN O O
six NN O O
such NN O O
individuals NN O O
, NN O O
there NN O O
was NN O O
significant NN O O
disparity NN O O
between NN O O
the NN O O
tests NN O O
. NN O O

Three NN O O
went NN O O
from NN O O
a NN O O
decreased NN O O
risk NN O O
to NN O O
an NN O O
increased NN O O
risk NN O O
, NN O O
while NN O O
in NN O O
another NN O O
three NN O O
the NN O O
risk NN O O
was NN O O
decreased NN O O
. NN O O

Knowledge NN O O
of NN O O
the NN O O
potential NN O O
reasons NN O O
for NN O O
these NN O O
changes NN O O
in NN O O
results NN O O
and NN O O
impact NN O O
of NN O O
these NN O O
risk NN O O
reversals NN O O
on NN O O
both NN O O
patients NN O O
and NN O O
the NN O O
counseling NN O O
team NN O O
can NN O O
assist NN O O
in NN O O
the NN O O
development NN O O
of NN O O
strategies NN O O
for NN O O
the NN O O
prevention NN O O
and NN O O
, NN O O
where NN O O
necessary NN O O
, NN O O
management NN O O
of NN O O
a NN O O
risk NN O O
reversal NN O O
in NN O O
any NN O O
predictive NN O O
testing NN O O
program NN O O
. NN O O
. NN O O

A NN O O
novel NN O O
common NN O O
missense NN O O
mutation NN O O
G301C NN O O
in NN O O
the NN O O
N NN O O
- NN O O
acetylgalactosamine NN O O
- NN O O
6 NN O O
- NN O O
sulfate NN O O
sulfatase NN O O
gene NN O O
in NN O O
mucopolysaccharidosis NN O B-Disease
IVA NN O I-Disease
. NN O O

Mucopolysaccharidosis NN O B-Disease
IVA NN O I-Disease
( NN O O
MPS NN O B-Disease
IVA NN O I-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
lysosomal NN O I-Disease
storage NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
a NN O O
genetic NN O B-Disease
defect NN O I-Disease
in NN O O
N NN O O
- NN O O
acetylgalactosamine NN O O
- NN O O
6 NN O O
- NN O O
sulfate NN O O
sulfatase NN O O
( NN O O
GALNS NN O O
) NN O O
. NN O O

In NN O O
previous NN O O
studies NN O O
, NN O O
we NN O O
have NN O O
found NN O O
two NN O O
common NN O O
mutations NN O O
in NN O O
Caucasians NN O O
and NN O O
Japanese NN O O
, NN O O
respectively NN O O
. NN O O

To NN O O
characterize NN O O
the NN O O
mutational NN O O
spectrum NN O O
in NN O O
various NN O O
ethnic NN O O
groups NN O O
, NN O O
mutations NN O O
in NN O O
the NN O O
GALNS NN O O
gene NN O O
in NN O O
Colombian NN O O
MPS NN O B-Disease
IVA NN O I-Disease
patients NN O O
were NN O O
investigated NN O O
, NN O O
and NN O O
genetic NN O O
backgrounds NN O O
were NN O O
extensively NN O O
analyzed NN O O
to NN O O
identify NN O O
racial NN O O
origin NN O O
, NN O O
based NN O O
on NN O O
mitochondrial NN O O
DNA NN O O
( NN O O
mtDNA NN O O
) NN O O
lineages NN O O
. NN O O

Three NN O O
novel NN O O
missense NN O O
mutations NN O O
never NN O O
identified NN O O
previously NN O O
in NN O O
other NN O O
populations NN O O
and NN O O
found NN O O
in NN O O
16 NN O O
out NN O O
of NN O O
19 NN O O
Colombian NN O O
MPS NN O B-Disease
IVA NN O I-Disease
unrelated NN O O
alleles NN O O
account NN O O
for NN O O
84 NN O O
. NN O O

2 NN O O
% NN O O
of NN O O
the NN O O
alleles NN O O
in NN O O
this NN O O
study NN O O
. NN O O

The NN O O
G301C NN O O
and NN O O
S162F NN O O
mutations NN O O
account NN O O
for NN O O
68 NN O O
. NN O O

4 NN O O
% NN O O
and NN O O
10 NN O O
. NN O O

5 NN O O
% NN O O
of NN O O
mutations NN O O
, NN O O
respectively NN O O
, NN O O
whereas NN O O
the NN O O
remaining NN O O
F69V NN O O
is NN O O
limited NN O O
to NN O O
a NN O O
single NN O O
allele NN O O
. NN O O

The NN O O
skewed NN O O
prevalence NN O O
of NN O O
G301C NN O O
in NN O O
only NN O O
Colombian NN O O
patients NN O O
and NN O O
haplotype NN O O
analysis NN O O
by NN O O
restriction NN O O
fragment NN O O
length NN O O
polymorphisms NN O O
in NN O O
the NN O O
GALNS NN O O
gene NN O O
suggest NN O O
that NN O O
G301C NN O O
originated NN O O
from NN O O
a NN O O
common NN O O
ancestor NN O O
. NN O O

Investigation NN O O
of NN O O
the NN O O
genetic NN O O
background NN O O
by NN O O
means NN O O
of NN O O
mtDNA NN O O
lineages NN O O
indicate NN O O
that NN O O
all NN O O
our NN O O
patients NN O O
are NN O O
probably NN O O
of NN O O
native NN O O
American NN O O
descent NN O O

Low NN O O
frequency NN O O
of NN O O
BRCA1 NN O O
germline NN O O
mutations NN O O
in NN O O
45 NN O O
German NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
. NN O O

In NN O O
this NN O O
study NN O O
we NN O O
investigated NN O O
45 NN O O
German NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
for NN O O
germline NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
gene NN O O
. NN O O

We NN O O
identified NN O O
four NN O O
germline NN O O
mutations NN O O
in NN O O
three NN O O
breast NN O B-Disease
cancer NN O I-Disease
families NN O O
and NN O O
in NN O O
one NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
family NN O O
. NN O O
among NN O O
these NN O O
were NN O O
one NN O O
frameshift NN O O
mutation NN O O
, NN O O
one NN O O
nonsense NN O O
mutation NN O O
, NN O O
one NN O O
novel NN O O
splice NN O O
site NN O O
mutation NN O O
, NN O O
and NN O O
one NN O O
missense NN O O
mutation NN O O
. NN O O

The NN O O
missense NN O O
mutation NN O O
was NN O O
also NN O O
found NN O O
in NN O O
2 NN O O
. NN O O

8 NN O O
% NN O O
of NN O O
the NN O O
general NN O O
population NN O O
, NN O O
suggesting NN O O
that NN O O
it NN O O
is NN O O
not NN O O
disease NN O O
associated NN O O
. NN O O

The NN O O
average NN O O
age NN O O
of NN O O
disease NN O O
onset NN O O
in NN O O
those NN O O
families NN O O
harbouring NN O O
causative NN O O
mutations NN O O
was NN O O
between NN O O
32 NN O O
. NN O O

3 NN O O
and NN O O
37 NN O O
. NN O O

4 NN O O
years NN O O
, NN O O
whereas NN O O
the NN O O
family NN O O
harbouring NN O O
the NN O O
missense NN O O
mutation NN O O
had NN O O
an NN O O
average NN O O
age NN O O
of NN O O
onset NN O O
of NN O O
51 NN O O
. NN O O

2 NN O O
years NN O O
. NN O O

These NN O O
findings NN O O
show NN O O
that NN O O
BRCA1 NN O O
is NN O O
implicated NN O O
in NN O O
a NN O O
small NN O O
fraction NN O O
of NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
suggesting NN O O
the NN O O
involvement NN O O
of NN O O
another NN O O
susceptibility NN O O
gene NN O O
( NN O O
s NN O O
) NN O O

Paternal NN O O
transmission NN O O
of NN O O
congenital NN O B-Disease
myotonic NN O I-Disease
dystrophy NN O I-Disease
. NN O O

We NN O O
report NN O O
a NN O O
rare NN O O
case NN O O
of NN O O
paternally NN O O
transmitted NN O O
congenital NN O B-Disease
myotonic NN O I-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
. NN O O

The NN O O
proband NN O O
is NN O O
a NN O O
23 NN O O
year NN O O
old NN O O
, NN O O
mentally NN O B-Disease
retarded NN O I-Disease
male NN O O
who NN O O
suffers NN O O
severe NN O O
muscular NN O B-Disease
weakness NN O I-Disease
. NN O O

He NN O O
presented NN O O
with NN O O
respiratory NN O O
and NN O O
feeding NN O O
difficulties NN O O
at NN O O
birth NN O O
. NN O O

His NN O O
two NN O O
sibs NN O O
suffer NN O O
from NN O O
childhood NN O O
onset NN O O
DM NN O B-Disease
. NN O O

Their NN O O
late NN O O
father NN O O
had NN O O
the NN O O
adult NN O O
type NN O O
of NN O O
DM NN O B-Disease
, NN O O
with NN O O
onset NN O O
around NN O O
30 NN O O
years NN O O
. NN O O

Only NN O O
six NN O O
other NN O O
cases NN O O
of NN O O
paternal NN O O
transmission NN O O
of NN O O
congenital NN O B-Disease
DM NN O I-Disease
have NN O O
been NN O O
reported NN O O
recently NN O O
. NN O O

We NN O O
review NN O O
the NN O O
sex NN O O
related NN O O
effects NN O O
on NN O O
transmission NN O O
of NN O O
congenital NN O B-Disease
DM NN O I-Disease
. NN O O

Decreased NN O O
fertility NN O O
of NN O O
males NN O O
with NN O O
adult NN O O
onset NN O O
DM NN O B-Disease
and NN O O
contraction NN O O
of NN O O
the NN O O
repeat NN O O
upon NN O O
male NN O O
transmission NN O O
contribute NN O O
to NN O O
the NN O O
almost NN O O
absent NN O O
occurrence NN O O
of NN O O
paternal NN O O
transmission NN O O
of NN O O
congenital NN O B-Disease
DM NN O I-Disease
. NN O O

Also NN O O
the NN O O
fathers NN O O
of NN O O
the NN O O
reported NN O O
congenitally NN O O
affected NN O O
children NN O O
showed NN O O
, NN O O
on NN O O
average NN O O
, NN O O
shorter NN O O
CTG NN O O
repeat NN O O
lengths NN O O
and NN O O
hence NN O O
less NN O O
severe NN O O
clinical NN O O
symptoms NN O O
than NN O O
the NN O O
mothers NN O O
of NN O O
children NN O O
with NN O O
congenital NN O B-Disease
DM NN O I-Disease
. NN O O

We NN O O
conclude NN O O
that NN O O
paternal NN O O
transmission NN O O
of NN O O
congenital NN O B-Disease
DM NN O I-Disease
is NN O O
rare NN O O
and NN O O
preferentially NN O O
occurs NN O O
with NN O O
onset NN O O
of NN O O
DM NN O B-Disease
past NN O O
30 NN O O
years NN O O
in NN O O
the NN O O
father NN O O
. NN O O
. NN O O

The NN O O
RB1 NN O O
gene NN O O
mutation NN O O
in NN O O
a NN O O
child NN O O
with NN O O
ectopic NN O B-Disease
intracranial NN O I-Disease
retinoblastoma NN O I-Disease
. NN O O

The NN O O
RB1 NN O O
gene NN O O
mutation NN O O
was NN O O
investigated NN O O
in NN O O
a NN O O
child NN O O
with NN O O
ectopic NN O B-Disease
intracranial NN O I-Disease
retinoblastoma NN O I-Disease
using NN O O
DNA NN O O
obtained NN O O
from NN O O
both NN O O
the NN O O
pineal NN O B-Disease
and NN O I-Disease
retinal NN O I-Disease
tumours NN O I-Disease
of NN O O
the NN O O
patient NN O O
. NN O O

A NN O O
nonsense NN O O
mutation NN O O
in NN O O
exon NN O O
17 NN O O
( NN O O
codon NN O O
556 NN O O
) NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
was NN O O
found NN O O
to NN O O
be NN O O
present NN O O
homozygously NN O O
in NN O O
both NN O O
the NN O O
retinal NN O B-Disease
and NN O I-Disease
the NN O I-Disease
pineal NN O I-Disease
tumours NN O I-Disease
. NN O O

The NN O O
same NN O O
mutation NN O O
was NN O O
present NN O O
heterozygously NN O O
in NN O O
the NN O O
DNA NN O O
from NN O O
the NN O O
constitutional NN O O
cells NN O O
of NN O O
the NN O O
patient NN O O
, NN O O
proving NN O O
it NN O O
to NN O O
be NN O O
of NN O O
germline NN O O
origin NN O O
. NN O O

The NN O O
initial NN O O
mutation NN O O
was NN O O
shown NN O O
to NN O O
have NN O O
occurred NN O O
in NN O O
the NN O O
paternally NN O O
derived NN O O
RB1 NN O O
allele NN O O
. NN O O

The NN O O
mutation NN O O
is NN O O
in NN O O
an NN O O
area NN O O
of NN O O
the NN O O
gene NN O O
that NN O O
encodes NN O O
the NN O O
protein NN O O
- NN O O
binding NN O O
region NN O O
known NN O O
as NN O O
the NN O O
pocket NN O O
region NN O O
and NN O O
has NN O O
been NN O O
detected NN O O
in NN O O
other NN O O
cases NN O O
of NN O O
retinoblastoma NN O B-Disease
. NN O O
. NN O O

Low NN O O
levels NN O O
of NN O O
beta NN O O
hexosaminidase NN O O
A NN O O
in NN O O
healthy NN O O
individuals NN O O
with NN O O
apparent NN O O
deficiency NN O O
of NN O O
this NN O O
enzyme NN O O
. NN O O

Appreciable NN O O
beta NN O O
hexosaminidase NN O O
A NN O O
( NN O O
hex NN O O
A NN O O
) NN O O
activity NN O O
has NN O O
been NN O O
detected NN O O
in NN O O
cultured NN O O
skin NN O O
fibroblasts NN O O
and NN O O
melanoma NN O B-Disease
tissue NN O O
from NN O O
healthy NN O O
individuals NN O O
previously NN O O
reported NN O O
as NN O O
having NN O O
deficiency NN O B-Disease
of NN O I-Disease
hex NN O I-Disease
A NN O I-Disease
activity NN O O
indistinguishable NN O O
from NN O O
that NN O O
of NN O O
patients NN O O
with NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
. NN O O

Identification NN O O
and NN O O
quantitation NN O O
of NN O O
hex NN O O
A NN O O
, NN O O
amounting NN O O
to NN O O
3 NN O O
. NN O O

5 NN O O
% NN O O
- NN O O
6 NN O O
. NN O O

9 NN O O
% NN O O
of NN O O
total NN O O
beta NN O O
hexosaminidase NN O O
activity NN O O
, NN O O
has NN O O
been NN O O
obtained NN O O
by NN O O
cellulose NN O O
acetate NN O O
gel NN O O
electrophoresis NN O O
, NN O O
DEAE NN O O
- NN O O
cellulose NN O O
ion NN O O
- NN O O
exchange NN O O
chromatography NN O O
, NN O O
radial NN O O
immunodiffusion NN O O
, NN O O
and NN O O
radioimmunoassay NN O O
. NN O O

Previous NN O O
family NN O O
studies NN O O
suggested NN O O
that NN O O
these NN O O
individuals NN O O
may NN O O
be NN O O
compound NN O O
heterozygotes NN O O
for NN O O
the NN O O
common NN O O
mutant NN O O
TSD NN O B-Disease
gene NN O O
and NN O O
a NN O O
rare NN O O
( NN O O
allelic NN O O
) NN O O
mutant NN O O
gene NN O O
. NN O O

Thus NN O O
, NN O O
the NN O O
postulated NN O O
rate NN O O
mutant NN O O
gene NN O O
appears NN O O
to NN O O
code NN O O
for NN O O
the NN O O
expression NN O O
of NN O O
low NN O O
amounts NN O O
of NN O O
hex NN O O
A NN O O
. NN O O

Heterozygotes NN O O
for NN O O
the NN O O
rare NN O O
mutant NN O O
may NN O O
be NN O O
indistinguishable NN O O
from NN O O
heterozygotes NN O O
for NN O O
the NN O O
common NN O O
TSD NN O B-Disease
mutant NN O O
. NN O O

However NN O O
, NN O O
direct NN O O
visualization NN O O
and NN O O
quantitation NN O O
of NN O O
hex NN O O
A NN O O
by NN O O
the NN O O
methods NN O O
described NN O O
may NN O O
prevent NN O O
false NN O O
- NN O O
positive NN O O
prenatal NN O O
diagnosis NN O O
of NN O O
TSD NN O B-Disease
in NN O O
fetuses NN O O
having NN O O
the NN O O
incomplete NN O O
hex NN O B-Disease
A NN O I-Disease
deficiency NN O I-Disease
of NN O O
the NN O O
type NN O O
described NN O O
in NN O O
the NN O O
four NN O O
healthy NN O O
individuals NN O O

The NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
Smad4 NN O O
/ NN O O
Dpc4 NN O O
is NN O O
required NN O O
for NN O O
gastrulation NN O O
and NN O O
later NN O O
for NN O O
anterior NN O O
development NN O O
of NN O O
the NN O O
mouse NN O O
embryo NN O O
. NN O O

Mutations NN O O
in NN O O
the NN O O
SMAD4 NN O O
/ NN O O
DPC4 NN O O
tumor NN O B-Disease
suppressor NN O O
gene NN O O
, NN O O
a NN O O
key NN O O
signal NN O O
transducer NN O O
in NN O O
most NN O O
TGFbeta NN O O
- NN O O
related NN O O
pathways NN O O
, NN O O
are NN O O
involved NN O O
in NN O O
50 NN O O
% NN O O
of NN O O
pancreatic NN O B-Disease
cancers NN O I-Disease
. NN O O

Homozygous NN O O
Smad4 NN O O
mutant NN O O
mice NN O O
die NN O O
before NN O O
day NN O O
7 NN O O
. NN O O

5 NN O O
of NN O O
embryogenesis NN O O
. NN O O

Mutant NN O O
embryos NN O O
have NN O O
reduced NN O O
size NN O O
, NN O O
fail NN O O
to NN O O
gastrulate NN O O
or NN O O
express NN O O
a NN O O
mesodermal NN O O
marker NN O O
, NN O O
and NN O O
show NN O O
abnormal NN O O
visceral NN O O
endoderm NN O O
development NN O O
. NN O O

Growth NN O B-Disease
retardation NN O I-Disease
of NN O O
the NN O O
Smad4 NN O O
- NN O O
deficient NN O O
embryos NN O O
results NN O O
from NN O O
reduced NN O O
cell NN O O
proliferation NN O O
rather NN O O
than NN O O
increased NN O O
apoptosis NN O O
. NN O O

Aggregation NN O O
of NN O O
mutant NN O O
Smad4 NN O O
ES NN O O
cells NN O O
with NN O O
wild NN O O
- NN O O
type NN O O
tetraploid NN O O
morulae NN O O
rescues NN O O
the NN O O
gastrulation NN O B-Disease
defect NN O I-Disease
. NN O O

These NN O O
results NN O O
indicate NN O O
that NN O O
Smad4 NN O O
is NN O O
initially NN O O
required NN O O
for NN O O
the NN O O
differentiation NN O O
of NN O O
the NN O O
visceral NN O O
endoderm NN O O
and NN O O
that NN O O
the NN O O
gastrulation NN O B-Disease
defect NN O I-Disease
in NN O O
the NN O O
epiblast NN O O
is NN O O
secondary NN O O
and NN O O
non NN O O
- NN O O
cell NN O O
autonomous NN O O
. NN O O

Rescued NN O O
embryos NN O O
show NN O O
severe NN O O
anterior NN O O
truncations NN O O
, NN O O
indicating NN O O
a NN O O
second NN O O
important NN O O
role NN O O
for NN O O
Smad4 NN O O
in NN O O
anterior NN O O
patterning NN O O
during NN O O
embryogenesis NN O O
. NN O O

Prevalence NN O O
of NN O O
p16 NN O O
and NN O O
CDK4 NN O O
germline NN O O
mutations NN O O
in NN O O
48 NN O O
melanoma NN O B-Disease
- NN O O
prone NN O O
families NN O O
in NN O O
France NN O O
. NN O O

The NN O O
French NN O O
Familial NN O B-Disease
Melanoma NN O I-Disease
Study NN O O
Group NN O O
. NN O O

Germline NN O O
mutations NN O O
in NN O O
the NN O O
p16 NN O O
and NN O O
CDK4 NN O O
genes NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
melanoma NN O B-Disease
pedigrees NN O O
, NN O O
but NN O O
their NN O O
prevalence NN O O
is NN O O
not NN O O
well NN O O
known NN O O
. NN O O

We NN O O
searched NN O O
for NN O O
such NN O O
germline NN O O
mutations NN O O
in NN O O
48 NN O O
French NN O O
melanoma NN O B-Disease
- NN O O
prone NN O O
families NN O O
selected NN O O
according NN O O
to NN O O
two NN O O
major NN O O
criteria NN O O
families NN O O
with NN O O
at NN O O
least NN O O
three NN O O
affected NN O O
members NN O O
( NN O O
n NN O O
= NN O O
20 NN O O
) NN O O
or NN O O
families NN O O
with NN O O
two NN O O
affected NN O O
members NN O O
, NN O O
one NN O O
of NN O O
them NN O O
affected NN O O
before NN O O
the NN O O
age NN O O
of NN O O
50 NN O O
( NN O O
n NN O O
= NN O O
28 NN O O
) NN O O
, NN O O
and NN O O
one NN O O
additional NN O O
minor NN O O
criterion NN O O
. NN O O

Sixteen NN O O
different NN O O
p16 NN O O
germline NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
21 NN O O
families NN O O
, NN O O
while NN O O
one NN O O
germline NN O O
mutation NN O O
, NN O O
Arg24His NN O O
, NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
CDK4 NN O O
gene NN O O
. NN O O

The NN O O
frequency NN O O
of NN O O
p16 NN O O
gene NN O O
mutation NN O O
in NN O O
our NN O O
sample NN O O
( NN O O
44 NN O O
% NN O O
) NN O O
is NN O O
among NN O O
the NN O O
highest NN O O
rates NN O O
yet NN O O
reported NN O O
and NN O O
the NN O O
CDK4 NN O O
mutation NN O O
is NN O O
the NN O O
second NN O O
mutation NN O O
detected NN O O
in NN O O
this NN O O
gene NN O O
worldwide NN O O
. NN O O

In NN O O
summary NN O O
, NN O O
our NN O O
results NN O O
show NN O O
frequent NN O O
involvement NN O O
of NN O O
the NN O O
p16 NN O O
gene NN O O
in NN O O
familial NN O B-Disease
melanoma NN O I-Disease
and NN O O
confirm NN O O
the NN O O
role NN O O
of NN O O
the NN O O
CDK4 NN O O
gene NN O O
as NN O O
a NN O O
melanoma NN O B-Disease
- NN O O
predisposing NN O O
gene NN O O
. NN O O
. NN O O

Progression NN O O
of NN O O
somatic NN O O
CTG NN O O
repeat NN O O
length NN O O
heterogeneity NN O O
in NN O O
the NN O O
blood NN O O
cells NN O O
of NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
patients NN O O
. NN O O

The NN O O
genetic NN O O
basis NN O O
of NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
the NN O O
expansion NN O O
of NN O O
an NN O O
unstable NN O O
CTG NN O O
repeat NN O O
in NN O O
the NN O O
34 NN O O
UTR NN O O
of NN O O
the NN O O
DM NN O B-Disease
protein NN O O
kinase NN O O
gene NN O O
on NN O O
chromosome NN O O
19 NN O O
. NN O O

One NN O O
of NN O O
the NN O O
principal NN O O
features NN O O
of NN O O
the NN O O
DM NN O B-Disease
mutation NN O O
is NN O O
an NN O O
extraordinarily NN O O
high NN O O
level NN O O
of NN O O
somatic NN O O
mosaicism NN O O
, NN O O
due NN O O
to NN O O
an NN O O
extremely NN O O
high NN O O
degree NN O O
of NN O O
somatic NN O O
instability NN O O
both NN O O
within NN O O
and NN O O
between NN O O
different NN O O
tissues NN O O
. NN O O

This NN O O
instability NN O O
appears NN O O
to NN O O
be NN O O
biased NN O O
towards NN O O
further NN O O
expansion NN O O
and NN O O
continuous NN O O
throughout NN O O
the NN O O
life NN O O
of NN O O
an NN O O
individual NN O O
, NN O O
features NN O O
that NN O O
could NN O O
be NN O O
associated NN O O
with NN O O
the NN O O
progressive NN O O
nature NN O O
of NN O O
the NN O O
disease NN O O
. NN O O

Although NN O O
increasing NN O O
measured NN O O
allele NN O O
size NN O O
between NN O O
patients NN O O
clearly NN O O
correlates NN O O
with NN O O
an NN O O
increased NN O O
severity NN O O
of NN O O
symptoms NN O O
and NN O O
an NN O O
earlier NN O O
age NN O O
of NN O O
onset NN O O
, NN O O
this NN O O
correlation NN O O
is NN O O
not NN O O
precise NN O O
and NN O O
measured NN O O
allele NN O O
length NN O O
cannot NN O O
be NN O O
used NN O O
as NN O O
an NN O O
accurate NN O O
predictor NN O O
of NN O O
age NN O O
of NN O O
onset NN O O
. NN O O

In NN O O
order NN O O
to NN O O
further NN O O
characterize NN O O
the NN O O
dynamics NN O O
of NN O O
DM NN O B-Disease
CTG NN O O
repeat NN O O
somatic NN O O
instability NN O O
, NN O O
we NN O O
have NN O O
studied NN O O
repeat NN O O
length NN O O
changes NN O O
over NN O O
time NN O O
in NN O O
111 NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
patients NN O O
with NN O O
varying NN O O
clinical NN O O
severity NN O O
and NN O O
CTG NN O O
repeat NN O O
size NN O O
over NN O O
time NN O O
intervals NN O O
of NN O O
1 NN O O
- NN O O
7 NN O O
years NN O O
. NN O O

We NN O O
have NN O O
found NN O O
a NN O O
direct NN O O
progression NN O O
of NN O O
the NN O O
size NN O O
heterogeneity NN O O
over NN O O
time NN O O
related NN O O
to NN O O
initial NN O O
CTG NN O O
repeat NN O O
size NN O O
and NN O O
the NN O O
time NN O O
interval NN O O
and NN O O
always NN O O
biased NN O O
towards NN O O
further NN O O
expansion NN O O
. NN O O

Attempts NN O O
to NN O O
mathematically NN O O
model NN O O
the NN O O
dynamics NN O O
have NN O O
proved NN O O
only NN O O
partially NN O O
successful NN O O
suggesting NN O O
that NN O O
individual NN O O
specific NN O O
genetic NN O O
and NN O O
/ NN O O
or NN O O
environmental NN O O
factors NN O O
also NN O O
play NN O O
a NN O O
role NN O O
in NN O O
somatic NN O O
mosaicism NN O O
. NN O O
. NN O O

Aspartylglucosaminuria NN O B-Disease
among NN O O
Palestinian NN O O
Arabs NN O O
. NN O O

Aspartylglucosaminuria NN O B-Disease
( NN O O
AGU NN O B-Disease
) NN O O
is NN O O
a NN O O
rare NN O O
disorder NN O B-Disease
of NN O I-Disease
glycoprotein NN O I-Disease
metabolism NN O I-Disease
caused NN O O
by NN O O
the NN O O
deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
lysosomal NN O I-Disease
enzyme NN O I-Disease
aspartylglucosaminidase NN O I-Disease
( NN O O
AGA NN O O
) NN O O
. NN O O

AGU NN O B-Disease
is NN O O
inherited NN O O
as NN O O
an NN O O
autosomal NN O O
recessive NN O O
trait NN O O
and NN O O
occurs NN O O
with NN O O
a NN O O
high NN O O
frequency NN O O
in NN O O
Finland NN O O
because NN O O
of NN O O
a NN O O
founder NN O O
effect NN O O
. NN O O

While NN O O
very NN O O
few NN O O
patients NN O O
with NN O O
AGU NN O B-Disease
have NN O O
been NN O O
reported NN O O
from NN O O
non NN O O
- NN O O
Finnish NN O O
origin NN O O
, NN O O
we NN O O
diagnosed NN O O
the NN O O
disorder NN O O
in NN O O
8 NN O O
patients NN O O
originating NN O O
from NN O O
3 NN O O
unrelated NN O O
families NN O O
, NN O O
all NN O O
Palestinian NN O O
Arabs NN O O
from NN O O
the NN O O
region NN O O
of NN O O
Jerusalem NN O O
. NN O O

The NN O O
clinical NN O O
diagnosis NN O O
of NN O O
AGU NN O B-Disease
is NN O O
often NN O O
difficult NN O O
, NN O O
in NN O O
particular NN O O
early NN O O
in NN O O
the NN O O
course NN O O
of NN O O
the NN O O
disease NN O O
, NN O O
and NN O O
most NN O O
of NN O O
the NN O O
patients NN O O
are NN O O
diagnosed NN O O
after NN O O
the NN O O
age NN O O
of NN O O
5 NN O O
years NN O O
. NN O O

However NN O O
, NN O O
since NN O O
these NN O O
patients NN O O
excrete NN O O
early NN O O
large NN O O
amounts NN O O
of NN O O
aspartylglucosamine NN O O
in NN O O
urine NN O O
, NN O O
biochemical NN O O
screening NN O O
is NN O O
easy NN O O
by NN O O
urine NN O O
chromatography NN O O
. NN O O
. NN O O

Detection NN O O
of NN O O
heterozygous NN O O
carriers NN O O
of NN O O
the NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
ATM NN O O
) NN O O
gene NN O O
by NN O O
G2 NN O O
phase NN O O
chromosomal NN O O
radiosensitivity NN O O
of NN O O
peripheral NN O O
blood NN O O
lymphocytes NN O O
. NN O O

In NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
patients NN O O
, NN O O
mutations NN O O
in NN O O
a NN O O
single NN O O
gene NN O O
, NN O O
ATM NN O O
, NN O O
result NN O O
in NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
syndrome NN O I-Disease
that NN O O
embraces NN O O
a NN O O
variety NN O O
of NN O O
clinical NN O O
features NN O O
and NN O O
manifests NN O O
extreme NN O O
radiosensitivity NN O O
and NN O O
a NN O O
strong NN O O
pre NN O O
- NN O O
disposition NN O O
to NN O O
malignancy NN O B-Disease
. NN O O

Heterozygotes NN O O
for NN O O
the NN O O
ATM NN O O
gene NN O O
have NN O O
no NN O O
clinical NN O O
expression NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
but NN O O
may NN O O
be NN O O
cancer NN O B-Disease
prone NN O O
with NN O O
a NN O O
moderate NN O O
increase NN O O
in NN O O
in NN O O
vitro NN O O
radiosensitivity NN O O
. NN O O

We NN O O
performed NN O O
a NN O O
blind NN O O
chromosomal NN O O
analysis NN O O
on NN O O
G2 NN O O
- NN O O
phase NN O O
lymphocytes NN O O
from NN O O
7 NN O O
unrelated NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
, NN O O
13 NN O O
obligate NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
heterozygotes NN O O
( NN O O
parents NN O O
of NN O O
the NN O O
patients NN O O
) NN O O
, NN O O
and NN O O
14 NN O O
normal NN O O
controls NN O O
following NN O O
X NN O O
- NN O O
irradiation NN O O
with NN O O
1 NN O O
Gy NN O O
in NN O O
order NN O O
to NN O O
evaluate NN O O
this NN O O
cytogenetic NN O O
method NN O O
as NN O O
a NN O O
tool NN O O
for NN O O
detection NN O O
of NN O O
ATM NN O O
carriers NN O O
. NN O O

Both NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
homozygotes NN O O
and NN O O
heterozygotes NN O O
showed NN O O
significantly NN O O
increased NN O O
levels NN O O
of NN O O
radiation NN O O
- NN O O
induced NN O O
chromatid NN O O
damage NN O O
relative NN O O
to NN O O
that NN O O
of NN O O
normal NN O O
controls NN O O
. NN O O

These NN O O
results NN O O
show NN O O
that NN O O
the NN O O
G2 NN O O
- NN O O
phase NN O O
chromosomal NN O O
radiosensitivity NN O O
assay NN O O
can NN O O
be NN O O
used NN O O
for NN O O
the NN O O
detection NN O O
of NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
heterozygotes NN O O
. NN O O

In NN O O
combination NN O O
with NN O O
molecular NN O O
genetic NN O O
analyses NN O O
, NN O O
this NN O O
test NN O O
may NN O O
be NN O O
of NN O O
value NN O O
in NN O O
studies NN O O
of NN O O
familial NN O B-Disease
and NN O I-Disease
sporadic NN O I-Disease
cancers NN O I-Disease
aimed NN O O
at NN O O
determination NN O O
of NN O O
the NN O O
potential NN O O
involvement NN O O
of NN O O
ATM NN O O
mutations NN O O
in NN O O
tumor NN O B-Disease
risk NN O O
or NN O O
development NN O O
. NN O O
. NN O O

Ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
: NN O O
identification NN O O
and NN O O
detection NN O O
of NN O O
founder NN O O
- NN O O
effect NN O O
mutations NN O O
in NN O O
the NN O O
ATM NN O O
gene NN O O
in NN O O
ethnic NN O O
populations NN O O
. NN O O

To NN O O
facilitate NN O O
the NN O O
evaluation NN O O
of NN O O
ATM NN O O
heterozygotes NN O O
for NN O O
susceptibility NN O O
to NN O O
other NN O O
diseases NN O O
, NN O O
such NN O O
as NN O O
breast NN O B-Disease
cancer NN O I-Disease
, NN O O
we NN O O
have NN O O
attempted NN O O
to NN O O
define NN O O
the NN O O
most NN O O
common NN O O
mutations NN O O
and NN O O
their NN O O
frequencies NN O O
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
homozygotes NN O O
from NN O O
10 NN O O
ethnic NN O O
populations NN O O
. NN O O

Both NN O O
genomic NN O O
mutations NN O O
and NN O O
their NN O O
effects NN O O
on NN O O
cDNA NN O O
were NN O O
characterized NN O O
. NN O O

Protein NN O O
- NN O O
truncation NN O O
testing NN O O
of NN O O
the NN O O
entire NN O O
ATM NN O O
cDNA NN O O
detected NN O O
92 NN O O
( NN O O
66 NN O O
% NN O O
) NN O O
truncating NN O O
mutations NN O O
in NN O O
140 NN O O
mutant NN O O
alleles NN O O
screened NN O O
. NN O O

The NN O O
haplotyping NN O O
of NN O O
patients NN O O
with NN O O
identical NN O O
mutations NN O O
indicates NN O O
that NN O O
almost NN O O
all NN O O
of NN O O
these NN O O
represent NN O O
common NN O O
ancestry NN O O
and NN O O
that NN O O
very NN O O
few NN O O
spontaneously NN O O
recurring NN O O
ATM NN O O
mutations NN O O
exist NN O O
. NN O O

Assays NN O O
requiring NN O O
minimal NN O O
amounts NN O O
of NN O O
genomic NN O O
DNA NN O O
were NN O O
designed NN O O
to NN O O
allow NN O O
rapid NN O O
screening NN O O
for NN O O
common NN O O
ethnic NN O O
mutations NN O O
. NN O O

These NN O O
rapid NN O O
assays NN O O
detected NN O O
mutations NN O O
in NN O O
76 NN O O
% NN O O
of NN O O
Costa NN O O
Rican NN O O
patients NN O O
( NN O O
3 NN O O
) NN O O
, NN O O
50 NN O O
% NN O O
of NN O O
Norwegian NN O O
patients NN O O
( NN O O
1 NN O O
) NN O O
, NN O O
25 NN O O
% NN O O
of NN O O
Polish NN O O
patients NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
and NN O O
14 NN O O
% NN O O
of NN O O
Italian NN O O
patients NN O O
( NN O O
1 NN O O
) NN O O
, NN O O
as NN O O
well NN O O
as NN O O
in NN O O
patients NN O O
of NN O O
Amish NN O O
/ NN O O
Mennonite NN O O
and NN O O
Irish NN O O
English NN O O
backgrounds NN O O
. NN O O

Additional NN O O
mutations NN O O
were NN O O
observed NN O O
in NN O O
Japanese NN O O
, NN O O
Utah NN O O
Mormon NN O O
, NN O O
and NN O O
African NN O O
American NN O O
patients NN O O
. NN O O

These NN O O
assays NN O O
should NN O O
facilitate NN O O
screening NN O O
for NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
heterozygotes NN O O
in NN O O
the NN O O
populations NN O O
studied NN O O
. NN O O
. NN O O

The NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
tumor NN O I-Disease
suppressor NN O O
gene NN O O
is NN O O
required NN O O
for NN O O
cell NN O O
cycle NN O O
exit NN O O
upon NN O O
serum NN O O
withdrawal NN O O
. NN O O

The NN O O
inactivation NN O O
of NN O O
the NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O I-Disease
VHL NN O I-Disease
) NN O I-Disease
tumor NN O I-Disease
suppressor NN O O
gene NN O O
predisposes NN O O
affected NN O O
individuals NN O O
to NN O O
the NN O O
human NN O O
VHL NN O B-Disease
cancer NN O I-Disease
syndrome NN O I-Disease
and NN O O
is NN O O
associated NN O O
with NN O O
sporadic NN O B-Disease
renal NN O I-Disease
cell NN O I-Disease
carcinomas NN O I-Disease
( NN O O
RCC NN O B-Disease
) NN O O
and NN O O
brain NN O B-Disease
hemangioblastomas NN O I-Disease
. NN O O

VHL NN O O
- NN O O
negative NN O O
786 NN O O
- NN O O
0 NN O O
RCC NN O B-Disease
cells NN O O
are NN O O
tumorigenic NN O O
in NN O O
nude NN O O
mice NN O O
which NN O O
is NN O O
suppressed NN O O
by NN O O
the NN O O
reintroduction NN O O
of NN O O
VHL NN O B-Disease
. NN O O

Remarkably NN O O
, NN O O
this NN O O
occurs NN O O
without NN O O
affecting NN O O
the NN O O
growth NN O O
rate NN O O
and NN O O
cell NN O O
cycle NN O O
profile NN O O
of NN O O
these NN O O
cells NN O O
in NN O O
culture NN O O
. NN O O

The NN O O
786 NN O O
- NN O O
0 NN O O
cell NN O O
line NN O O
, NN O O
like NN O O
many NN O O
cancer NN O B-Disease
cells NN O O
, NN O O
fails NN O O
to NN O O
exit NN O O
the NN O O
cell NN O O
cycle NN O O
upon NN O O
serum NN O O
withdrawal NN O O
. NN O O

Here NN O O
, NN O O
it NN O O
is NN O O
shown NN O O
that NN O O
reintroduction NN O O
of NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
VHL NN O B-Disease
gene NN O O
restores NN O O
the NN O O
ability NN O O
of NN O O
VHL NN O O
- NN O O
negative NN O O
RCC NN O B-Disease
cancer NN O I-Disease
cells NN O O
to NN O O
exit NN O O
the NN O O
cell NN O O
cycle NN O O
and NN O O
enter NN O O
G0 NN O O
/ NN O O
quiescence NN O O
in NN O O
low NN O O
serum NN O O
. NN O O

Both NN O O
VHL NN O O
- NN O O
positive NN O O
and NN O O
VHL NN O O
- NN O O
negative NN O O
RCC NN O B-Disease
cells NN O O
exit NN O O
the NN O O
cell NN O O
cycle NN O O
by NN O O
contact NN O O
inhibition NN O O
. NN O O

The NN O O
cyclin NN O O
- NN O O
dependent NN O O
kinase NN O O
inhibitor NN O O
, NN O O
p27 NN O O
, NN O O
accumulates NN O O
upon NN O O
serum NN O O
withdrawal NN O O
, NN O O
only NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
VHL NN O B-Disease
, NN O O
as NN O O
a NN O O
result NN O O
of NN O O
the NN O O
stabilization NN O O
of NN O O
the NN O O
protein NN O O
. NN O O

We NN O O
propose NN O O
that NN O O
the NN O O
loss NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
VHL NN O B-Disease
gene NN O O
results NN O O
in NN O O
a NN O O
specific NN O O
cellular NN O O
defect NN O O
in NN O O
serum NN O O
- NN O O
dependent NN O O
growth NN O O
control NN O O
, NN O O
which NN O O
may NN O O
initiate NN O O
tumor NN O B-Disease
formation NN O O
. NN O O

This NN O O
is NN O O
corrected NN O O
by NN O O
the NN O O
reintroduction NN O O
of NN O O
wild NN O O
- NN O O
type NN O O
VHL NN O B-Disease
, NN O O
implicating NN O O
VHL NN O B-Disease
as NN O O
the NN O O
first NN O O
tumor NN O B-Disease
suppressor NN O O
involved NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
cell NN O O
cycle NN O O
exit NN O O
, NN O O
which NN O O
is NN O O
consistent NN O O
with NN O O
its NN O O
gatekeeper NN O O
function NN O O
in NN O O
the NN O O
kidney NN O O
. NN O O
. NN O O

Piebaldism NN O B-Disease
with NN O O
deafness NN O B-Disease
: NN O O
molecular NN O O
evidence NN O O
for NN O O
an NN O O
expanded NN O O
syndrome NN O O
. NN O O

In NN O O
a NN O O
South NN O O
African NN O O
girl NN O O
of NN O O
Xhosa NN O O
stock NN O O
with NN O O
severe NN O O
piebaldism NN O B-Disease
and NN O O
profound NN O O
congenital NN O O
sensorineural NN O B-Disease
deafness NN O I-Disease
we NN O O
identified NN O O
a NN O O
novel NN O O
missense NN O O
substitution NN O O
at NN O O
a NN O O
highly NN O O
conserved NN O O
residue NN O O
in NN O O
the NN O O
intracellular NN O O
kinase NN O O
domain NN O O
of NN O O
the NN O O
KIT NN O O
proto NN O O
- NN O O
oncogene NN O O
, NN O O
R796G NN O O
. NN O O

Though NN O O
auditory NN O B-Disease
anomalies NN O I-Disease
have NN O O
been NN O O
observed NN O O
in NN O O
mice NN O O
with NN O O
dominant NN O O
white NN O O
spotting NN O O
( NN O O
W NN O O
) NN O O
due NN O O
to NN O O
KIT NN O O
mutations NN O O
, NN O O
deafness NN O B-Disease
is NN O O
not NN O O
typical NN O O
in NN O O
human NN O O
piebaldism NN O B-Disease
. NN O O

Thus NN O O
, NN O O
the NN O O
occurrence NN O O
of NN O O
sensorineural NN O B-Disease
deafness NN O I-Disease
in NN O O
this NN O O
patient NN O O
extends NN O O
considerably NN O O
the NN O O
phenotypic NN O O
range NN O O
of NN O O
piebaldism NN O B-Disease
due NN O O
to NN O O
KIT NN O O
gene NN O O
mutation NN O O
in NN O O
humans NN O O
and NN O O
tightens NN O O
the NN O O
clinical NN O O
similarity NN O O
between NN O O
piebaldism NN O B-Disease
and NN O O
the NN O O
various NN O O
forms NN O O
of NN O O
Waardenburg NN O B-Disease
syndrome NN O I-Disease
. NN O O
. NN O O

Cycloheximide NN O O
facilitates NN O O
the NN O O
identification NN O O
of NN O O
aberrant NN O O
transcripts NN O O
resulting NN O O
from NN O O
a NN O O
novel NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
in NN O O
COL17A1 NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
generalized NN O O
atrophic NN O B-Disease
benign NN O I-Disease
epidermolysis NN O I-Disease
bullosa NN O I-Disease
. NN O O

Patients NN O O
with NN O O
generalized NN O O
atrophic NN O B-Disease
benign NN O I-Disease
epidermolysis NN O I-Disease
bullosa NN O I-Disease
often NN O O
show NN O O
decreased NN O O
expression NN O O
of NN O O
type NN O O
XVII NN O O
collagen NN O O
, NN O O
a NN O O
transmembrane NN O O
hemidesmosomal NN O O
protein NN O O
encoded NN O O
by NN O O
COL17A1 NN O O
. NN O O

This NN O O
report NN O O
documents NN O O
a NN O O
novel NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
in NN O O
COL17A1 NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
generalized NN O O
atrophic NN O B-Disease
benign NN O I-Disease
epidermolysis NN O I-Disease
bullosa NN O I-Disease
, NN O O
and NN O O
applies NN O O
a NN O O
new NN O O
methodology NN O O
to NN O O
define NN O O
and NN O O
characterize NN O O
the NN O O
resulting NN O O
mRNA NN O O
splice NN O O
variants NN O O
. NN O O

Mutational NN O O
analysis NN O O
of NN O O
COL17A1 NN O O
identified NN O O
a NN O O
maternally NN O O
inherited NN O O
G NN O O
- NN O O
to NN O O
- NN O O
T NN O O
transversion NN O O
at NN O O
the NN O O
- NN O O
1 NN O O
position NN O O
of NN O O
exon NN O O
32 NN O O
. NN O O

This NN O O
acceptor NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
led NN O O
to NN O O
the NN O O
formation NN O O
of NN O O
aberrant NN O O
transcripts NN O O
present NN O O
at NN O O
extremely NN O O
low NN O O
levels NN O O
. NN O O

Based NN O O
on NN O O
our NN O O
recent NN O O
finding NN O O
that NN O O
cycloheximide NN O O
stabilized NN O O
mutant NN O O
COL17A1 NN O O
transcripts NN O O
in NN O O
keratinocytes NN O O
homozygous NN O O
for NN O O
a NN O O
frameshift NN O O
mutation NN O O
, NN O O
the NN O O
effects NN O O
of NN O O
the NN O O
splice NN O O
- NN O O
site NN O O
mutation NN O O
on NN O O
splicing NN O O
of NN O O
COL17A1 NN O O
transcripts NN O O
were NN O O
determined NN O O
using NN O O
reverse NN O O
transcriptase NN O O
polymerase NN O O
chain NN O O
reaction NN O O
of NN O O
total NN O O
RNA NN O O
from NN O O
keratinocytes NN O O
incubated NN O O
for NN O O
2 NN O O
. NN O O

5 NN O O
h NN O O
in NN O O
the NN O O
presence NN O O
or NN O O
absence NN O O
of NN O O
10 NN O O
microg NN O O
cycloheximide NN O O
per NN O O
ml NN O O
. NN O O

Using NN O O
this NN O O
approach NN O O
, NN O O
an NN O O
abnormally NN O O
spliced NN O O
transcript NN O O
was NN O O
identified NN O O
that NN O O
contains NN O O
an NN O O
extra NN O O
264 NN O O
bases NN O O
upstream NN O O
from NN O O
exon NN O O
32 NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
27 NN O O
bp NN O O
downstream NN O O
from NN O O
the NN O O
cryptic NN O O
splice NN O O
site NN O O
. NN O O

Three NN O O
other NN O O
splice NN O O
variants NN O O
, NN O O
including NN O O
one NN O O
derived NN O O
from NN O O
the NN O O
skipping NN O O
of NN O O
exon NN O O
32 NN O O
, NN O O
were NN O O
also NN O O
identified NN O O
. NN O O

These NN O O
results NN O O
indicate NN O O
the NN O O
usefulness NN O O
of NN O O
cycloheximide NN O O
treatment NN O O
in NN O O
evaluating NN O O
the NN O O
abnormal NN O O
processing NN O O
of NN O O
mRNA NN O O
due NN O O
to NN O O
splice NN O O
- NN O O
site NN O O
mutations NN O O
, NN O O
because NN O O
( NN O O
i NN O O
) NN O O
aberrant NN O O
splicing NN O O
often NN O O
generates NN O O
a NN O O
premature NN O O
termination NN O O
codon NN O O
, NN O O
( NN O O
ii NN O O
) NN O O
transcripts NN O O
with NN O O
premature NN O O
termination NN O O
codons NN O O
can NN O O
occur NN O O
at NN O O
low NN O O
or NN O O
undetectable NN O O
levels NN O O
due NN O O
to NN O O
nonsense NN O O
- NN O O
mediated NN O O
mRNA NN O O
decay NN O O
, NN O O
and NN O O
( NN O O
iii NN O O
) NN O O
the NN O O
levels NN O O
of NN O O
these NN O O
transcripts NN O O
can NN O O
be NN O O
increased NN O O
by NN O O
cycloheximide NN O O
. NN O O

A NN O O
deletion NN O O
mutation NN O O
in NN O O
COL17A1 NN O O
in NN O O
five NN O O
Austrian NN O O
families NN O O
with NN O O
generalized NN O O
atrophic NN O B-Disease
benign NN O I-Disease
epidermolysis NN O I-Disease
bullosa NN O I-Disease
represents NN O O
propagation NN O O
of NN O O
an NN O O
ancestral NN O O
allele NN O O
. NN O O

Patients NN O O
with NN O O
generalized NN O O
atrophic NN O B-Disease
benign NN O I-Disease
epidermolysis NN O I-Disease
bullosa NN O I-Disease
, NN O O
a NN O O
usually NN O O
nonlethal NN O O
form NN O O
of NN O O
junctional NN O B-Disease
epidermolysis NN O I-Disease
bullosa NN O I-Disease
, NN O O
have NN O O
generalized NN O O
blistering NN O B-Disease
, NN O O
nail NN O B-Disease
dystrophy NN O I-Disease
, NN O O
patchy NN O B-Disease
alopecia NN O I-Disease
, NN O O
and NN O O
dental NN O B-Disease
abnormalities NN O I-Disease
. NN O O

Skin NN O B-Disease
fragility NN O I-Disease
in NN O O
most NN O O
cases NN O O
is NN O O
due NN O O
to NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
type NN O O
XVII NN O O
collagen NN O O
( NN O O
COL17A1 NN O O
) NN O O
. NN O O

Recently NN O O
, NN O O
we NN O O
reported NN O O
five NN O O
Austrian NN O O
families NN O O
with NN O O
generalized NN O O
atrophic NN O B-Disease
benign NN O I-Disease
epidermolysis NN O I-Disease
bullosa NN O I-Disease
who NN O O
share NN O O
the NN O O
same NN O O
COL17A1 NN O O
mutation NN O O
. NN O O

Affected NN O O
individuals NN O O
in NN O O
three NN O O
families NN O O
are NN O O
homozygous NN O O
for NN O O
4003delTC NN O O
, NN O O
whereas NN O O
those NN O O
in NN O O
two NN O O
others NN O O
are NN O O
compound NN O O
heterozygotes NN O O
. NN O O

To NN O O
determine NN O O
if NN O O
the NN O O
occurrence NN O O
of NN O O
4003delTC NN O O
in NN O O
these NN O O
unrelated NN O O
families NN O O
signifies NN O O
propagation NN O O
of NN O O
an NN O O
ancestral NN O O
allele NN O O
or NN O O
a NN O O
mutational NN O O
hot NN O O
spot NN O O
, NN O O
haplotypes NN O O
were NN O O
determined NN O O
for NN O O
polymorphisms NN O O
both NN O O
within NN O O
and NN O O
flanking NN O O
COL17A1 NN O O
. NN O O

Five NN O O
intragenic NN O O
polymorphisms NN O O
were NN O O
chosen NN O O
based NN O O
on NN O O
their NN O O
informativeness NN O O
. NN O O

One NN O O
of NN O O
these NN O O
, NN O O
not NN O O
previously NN O O
reported NN O O
, NN O O
was NN O O
2988 NN O O
A NN O O
or NN O O
C NN O O
that NN O O
introduces NN O O
a NN O O
new NN O O
restriction NN O O
site NN O O
for NN O O
Eco0109 NN O O
I NN O O
. NN O O

All NN O O
the NN O O
4003delTC NN O O
alleles NN O O
showed NN O O
the NN O O
same NN O O
haplotype NN O O
for NN O O
these NN O O
five NN O O
polymorphic NN O O
markers NN O O
. NN O O

Fourteen NN O O
microsatellite NN O O
polymorphisms NN O O
were NN O O
selected NN O O
based NN O O
on NN O O
their NN O O
high NN O O
heterozygosity NN O O
and NN O O
their NN O O
location NN O O
within NN O O
10q23 NN O O
- NN O O
q25 NN O O
near NN O O
COL17A1 NN O O
. NN O O

Three NN O O
families NN O O
shared NN O O
microsatellite NN O O
polymorphisms NN O O
covering NN O O
at NN O O
most NN O O
19 NN O O
cM NN O O
, NN O O
whereas NN O O
the NN O O
others NN O O
shared NN O O
smaller NN O O
regions NN O O
consistent NN O O
with NN O O
cross NN O O
- NN O O
over NN O O
events NN O O
during NN O O
passage NN O O
of NN O O
this NN O O
mutation NN O O
through NN O O
several NN O O
generations NN O O
. NN O O

These NN O O
results NN O O
indicate NN O O
that NN O O
4003delTC NN O O
occurs NN O O
on NN O O
a NN O O
single NN O O
ancestral NN O O
allele NN O O
. NN O O
. NN O O

The NN O O
haptoglobin NN O O
- NN O O
gene NN O O
deletion NN O O
responsible NN O O
for NN O O
anhaptoglobinemia NN O B-Disease
. NN O O

We NN O O
have NN O O
found NN O O
an NN O O
allelic NN O O
deletion NN O O
of NN O O
the NN O O
haptoglobin NN O O
( NN O O
Hp NN O O
) NN O O
gene NN O O
from NN O O
an NN O O
individual NN O O
with NN O O
anhaptoglobinemia NN O B-Disease
. NN O O

The NN O O
Hp NN O O
gene NN O O
cluster NN O O
consists NN O O
of NN O O
coding NN O O
regions NN O O
of NN O O
the NN O O
alpha NN O O
chain NN O O
and NN O O
beta NN O O
chain NN O O
of NN O O
the NN O O
haptoglobin NN O O
gene NN O O
( NN O O
Hp NN O O
) NN O O
and NN O O
of NN O O
the NN O O
alpha NN O O
chain NN O O
and NN O O
beta NN O O
chain NN O O
of NN O O
the NN O O
haptoglobin NN O O
- NN O O
related NN O O
gene NN O O
( NN O O
Hpr NN O O
) NN O O
, NN O O
in NN O O
tandem NN O O
from NN O O
the NN O O
5 NN O O
side NN O O
. NN O O

Southern NN O O
blot NN O O
and NN O O
PCR NN O O
analyses NN O O
have NN O O
indicated NN O O
that NN O O
the NN O O
individual NN O O
with NN O O
anhaptoglobinemia NN O B-Disease
was NN O O
homozygous NN O O
for NN O O
the NN O O
gene NN O O
deletion NN O O
and NN O O
that NN O O
the NN O O
gene NN O O
deletion NN O O
was NN O O
included NN O O
at NN O O
least NN O O
from NN O O
the NN O O
promoter NN O O
region NN O O
of NN O O
Hp NN O O
to NN O O
Hpr NN O O
alpha NN O O
but NN O O
not NN O O
to NN O O
Hpr NN O O
beta NN O O
( NN O O
Hpdel NN O O
) NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
found NN O O
seven NN O O
individuals NN O O
with NN O O
hypohaptoglobinemia NN O B-Disease
in NN O O
three NN O O
families NN O O
, NN O O
and NN O O
the NN O O
genotypes NN O O
of NN O O
six NN O O
of NN O O
the NN O O
seven NN O O
individuals NN O O
were NN O O
found NN O O
to NN O O
be NN O O
Hp2 NN O O
/ NN O O
Hpdel NN O O
. NN O O

The NN O O
phenotypes NN O O
and NN O O
genotypes NN O O
in NN O O
one NN O O
of NN O O
these NN O O
three NN O O
families NN O O
showed NN O O
the NN O O
father NN O O
to NN O O
be NN O O
hypohaptoglobinemic NN O B-Disease
( NN O O
Hp2 NN O O
) NN O O
and NN O O
Hp2 NN O O
/ NN O O
Hpdel NN O O
, NN O O
the NN O O
mother NN O O
to NN O O
be NN O O
Hp2 NN O O
- NN O O
1 NN O O
and NN O O
Hp1 NN O O
/ NN O O
Hp2 NN O O
, NN O O
one NN O O
of NN O O
the NN O O
two NN O O
children NN O O
to NN O O
be NN O O
hypohaptoglobinemic NN O B-Disease
( NN O O
Hp2 NN O O
) NN O O
and NN O O
Hp2 NN O O
/ NN O O
Hpdel NN O O
, NN O O
and NN O O
the NN O O
other NN O O
child NN O O
to NN O O
be NN O O
Hp1 NN O O
and NN O O
Hp1 NN O O
/ NN O O
Hpdel NN O O
, NN O O
showing NN O O
an NN O O
anomalous NN O O
inheritance NN O O
of NN O O
Hp NN O O
phenotypes NN O O
in NN O O
the NN O O
child NN O O
with NN O O
Hp1 NN O O
. NN O O

The NN O O
Hp2 NN O O
/ NN O O
Hpdel NN O O
individuals NN O O
had NN O O
an NN O O
extremely NN O O
low NN O O
level NN O O
of NN O O
Hp NN O O
( NN O O
mean NN O O
+ NN O O
/ NN O O
- NN O O
SD NN O O
= NN O O
0 NN O O
. NN O O
049 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O
043 NN O O
mg NN O O
/ NN O O
ml NN O O
; NN O O
n NN O O
= NN O O
6 NN O O
) NN O O
, NN O O
compared NN O O
with NN O O
the NN O O
level NN O O
( NN O O
1 NN O O
. NN O O
64 NN O O
+ NN O O
/ NN O O
- NN O O
1 NN O O
. NN O O
07 NN O O
mg NN O O
/ NN O O
ml NN O O
) NN O O
obtained NN O O
from NN O O
52 NN O O
healthy NN O O
volunteers NN O O
having NN O O
phenotype NN O O
Hp2 NN O O
, NN O O
whereas NN O O
the NN O O
serum NN O O
Hp NN O O
level NN O O
of NN O O
an NN O O
individual NN O O
with NN O O
Hp1 NN O O
/ NN O O
Hpdel NN O O
was NN O O
0 NN O O
. NN O O

50 NN O O
mg NN O O
/ NN O O
ml NN O O
, NN O O
which NN O O
was NN O O
approximately NN O O
half NN O O
the NN O O
level NN O O
of NN O O
Hp NN O O
in NN O O
control NN O O
sera NN O O
from NN O O
the NN O O
Hp1 NN O O
phenotype NN O O
( NN O O
1 NN O O
. NN O O
26 NN O O
+ NN O O
/ NN O O
- NN O O
0 NN O O
. NN O O
33 NN O O
mg NN O O
/ NN O O
ml NN O O
; NN O O
n NN O O
= NN O O
9 NN O O
) NN O O
, NN O O
showing NN O O
a NN O O
gene NN O O
- NN O O
dosage NN O O
effect NN O O
. NN O O

The NN O O
other NN O O
allele NN O O
( NN O O
Hp2 NN O O
) NN O O
of NN O O
individuals NN O O
with NN O O
Hp2 NN O O
/ NN O O
Hpdel NN O O
was NN O O
found NN O O
to NN O O
have NN O O
, NN O O
in NN O O
all NN O O
exons NN O O
, NN O O
no NN O O
mutation NN O O
, NN O O
by NN O O
DNA NN O O
sequencing NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
present NN O O
study NN O O
, NN O O
the NN O O
mechanism NN O O
of NN O O
anhaptoglobinemia NN O B-Disease
and NN O O
the NN O O
mechanism NN O O
of NN O O
anomalous NN O O
inheritance NN O O
of NN O O
Hp NN O O
phenotypes NN O O
were NN O O
well NN O O
explained NN O O
. NN O O

However NN O O
, NN O O
the NN O O
mechanism NN O O
of NN O O
hypohaptoglobinemia NN O B-Disease
remains NN O O
unknown NN O O

ATM NN O O
mutations NN O O
and NN O O
phenotypes NN O O
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
families NN O O
in NN O O
the NN O O
British NN O O
Isles NN O O
: NN O O
expression NN O O
of NN O O
mutant NN O O
ATM NN O O
and NN O O
the NN O O
risk NN O O
of NN O O
leukemia NN O B-Disease
, NN O O
lymphoma NN O B-Disease
, NN O O
and NN O O
breast NN O B-Disease
cancer NN O I-Disease
. NN O O

We NN O O
report NN O O
the NN O O
spectrum NN O O
of NN O O
59 NN O O
ATM NN O O
mutations NN O O
observed NN O O
in NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
patients NN O O
in NN O O
the NN O O
British NN O O
Isles NN O O
. NN O O

Of NN O O
51 NN O O
ATM NN O O
mutations NN O O
identified NN O O
in NN O O
families NN O O
native NN O O
to NN O O
the NN O O
British NN O O
Isles NN O O
, NN O O
11 NN O O
were NN O O
founder NN O O
mutations NN O O
, NN O O
and NN O O
2 NN O O
of NN O O
these NN O O
11 NN O O
conferred NN O O
a NN O O
milder NN O O
clinical NN O O
phenotype NN O O
with NN O O
respect NN O O
to NN O O
both NN O O
cerebellar NN O B-Disease
degeneration NN O I-Disease
and NN O O
cellular NN O O
features NN O O
. NN O O

We NN O O
report NN O O
, NN O O
in NN O O
two NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
families NN O O
, NN O O
an NN O O
ATM NN O O
mutation NN O O
( NN O O
7271T NN O O
- NN O O
- NN O O
> NN O O
G NN O O
) NN O O
that NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
in NN O O
both NN O O
homozygotes NN O O
and NN O O
heterozygotes NN O O
( NN O O
relative NN O O
risk NN O O
12 NN O O
. NN O O
7 NN O O
; NN O O
P NN O O
= NN O O
. NN O O
0025 NN O O
) NN O O
, NN O O
although NN O O
there NN O O
is NN O O
a NN O O
less NN O O
severe NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
phenotype NN O O
in NN O O
terms NN O O
of NN O O
the NN O O
degree NN O O
of NN O O
cerebellar NN O B-Disease
degeneration NN O I-Disease
. NN O O

This NN O O
mutation NN O O
( NN O O
7271T NN O O
- NN O O
- NN O O
> NN O O
G NN O O
) NN O O
also NN O O
allows NN O O
expression NN O O
of NN O O
full NN O O
- NN O O
length NN O O
ATM NN O O
protein NN O O
at NN O O
a NN O O
level NN O O
comparable NN O O
with NN O O
that NN O O
in NN O O
unaffected NN O O
individuals NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
we NN O O
have NN O O
studied NN O O
18 NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
, NN O O
in NN O O
15 NN O O
families NN O O
, NN O O
who NN O O
developed NN O O
leukemia NN O B-Disease
, NN O O
lymphoma NN O B-Disease
, NN O O
preleukemic NN O O
T NN O O
- NN O O
cell NN O O
proliferation NN O O
, NN O O
or NN O O
Hodgkin NN O B-Disease
lymphoma NN O I-Disease
, NN O O
mostly NN O O
in NN O O
childhood NN O O
. NN O O

A NN O O
wide NN O O
variety NN O O
of NN O O
ATM NN O O
mutation NN O O
types NN O O
, NN O O
including NN O O
missense NN O O
mutations NN O O
and NN O O
in NN O O
- NN O O
frame NN O O
deletions NN O O
, NN O O
were NN O O
seen NN O O
in NN O O
these NN O O
patients NN O O
. NN O O

We NN O O
also NN O O
show NN O O
that NN O O
25 NN O O
% NN O O
of NN O O
all NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
carried NN O O
in NN O O
- NN O O
frame NN O O
deletions NN O O
or NN O O
missense NN O O
mutations NN O O
, NN O O
many NN O O
of NN O O
which NN O O
were NN O O
also NN O O
associated NN O O
with NN O O
expression NN O O
of NN O O
mutant NN O O
ATM NN O O
protein NN O O
. NN O O

The NN O O
DMPK NN O O
gene NN O O
of NN O O
severely NN O O
affected NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
patients NN O O
is NN O O
hypermethylated NN O O
proximal NN O O
to NN O O
the NN O O
largely NN O O
expanded NN O O
CTG NN O O
repeat NN O O
. NN O O

Using NN O O
methylation NN O O
- NN O O
sensitive NN O O
restriction NN O O
enzymes NN O O
, NN O O
we NN O O
characterized NN O O
the NN O O
methylation NN O O
pattern NN O O
on NN O O
the NN O O
5 NN O O
side NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
in NN O O
the NN O O
DMPK NN O O
gene NN O O
of NN O O
normal NN O O
individuals NN O O
and NN O O
of NN O O
patients NN O O
affected NN O O
with NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
, NN O O
showing NN O O
expansions NN O O
of NN O O
the NN O O
repetitive NN O O
sequence NN O O
. NN O O

The NN O O
gene NN O O
segment NN O O
analyzed NN O O
corresponds NN O O
to NN O O
the NN O O
genomic NN O O
SacI NN O O
- NN O O
HindIII NN O O
fragment NN O O
carrying NN O O
exons NN O O
11 NN O O
- NN O O
15 NN O O
. NN O O

There NN O O
is NN O O
constitutive NN O O
methylation NN O O
in NN O O
intron NN O O
12 NN O O
at NN O O
restriction NN O O
sites NN O O
of NN O O
SacII NN O O
and NN O O
HhaI NN O O
, NN O O
localized NN O O
1 NN O O
, NN O O
159 NN O O
- NN O O
1 NN O O
, NN O O
232 NN O O
bp NN O O
upstream NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
, NN O O
whereas NN O O
most NN O O
, NN O O
if NN O O
not NN O O
all NN O O
, NN O O
of NN O O
the NN O O
other NN O O
sites NN O O
of NN O O
SacII NN O O
, NN O O
HhaI NN O O
, NN O O
and NN O O
HpaII NN O O
in NN O O
this NN O O
region NN O O
are NN O O
unmethylated NN O O
, NN O O
in NN O O
normal NN O O
individuals NN O O
and NN O O
most NN O O
of NN O O
the NN O O
patients NN O O
. NN O O

In NN O O
a NN O O
number NN O O
of NN O O
young NN O O
and NN O O
severely NN O O
affected NN O O
patients NN O O
, NN O O
however NN O O
, NN O O
complete NN O O
methylation NN O O
of NN O O
these NN O O
restriction NN O O
sites NN O O
was NN O O
found NN O O
in NN O O
the NN O O
mutated NN O O
allele NN O O
. NN O O

In NN O O
most NN O O
of NN O O
these NN O O
patients NN O O
, NN O O
the NN O O
onset NN O O
of NN O O
the NN O O
disease NN O O
was NN O O
congenital NN O O
. NN O O

Preliminary NN O O
in NN O O
vivo NN O O
footprinting NN O O
data NN O O
gave NN O O
evidence NN O O
for NN O O
protein NN O O
- NN O O
DNA NN O O
contact NN O O
in NN O O
normal NN O O
genes NN O O
at NN O O
an NN O O
Sp1 NN O O
consensus NN O O
binding NN O O
site NN O O
upstream NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
and NN O O
for NN O O
a NN O O
significant NN O O
reduction NN O O
of NN O O
this NN O O
interaction NN O O
in NN O O
cells NN O O
with NN O O
a NN O O
hypermethylated NN O O
DMPK NN O O
gene NN O O
. NN O O
. NN O O

The NN O O
hemochromatosis NN O B-Disease
gene NN O O
product NN O O
complexes NN O O
with NN O O
the NN O O
transferrin NN O O
receptor NN O O
and NN O O
lowers NN O O
its NN O O
affinity NN O O
for NN O O
ligand NN O O
binding NN O O
. NN O O

We NN O O
recently NN O O
reported NN O O
the NN O O
positional NN O O
cloning NN O O
of NN O O
a NN O O
candidate NN O O
gene NN O O
for NN O O
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
called NN O O
HFE NN O O
. NN O O

The NN O O
gene NN O O
product NN O O
, NN O O
a NN O O
member NN O O
of NN O O
the NN O O
major NN O O
histocompatibility NN O O
complex NN O O
class NN O O
I NN O O
- NN O O
like NN O O
family NN O O
, NN O O
was NN O O
found NN O O
to NN O O
have NN O O
a NN O O
mutation NN O O
, NN O O
Cys NN O O
- NN O O
282 NN O O
- NN O O
- NN O O
> NN O O
Tyr NN O O
( NN O O
C282Y NN O O
) NN O O
, NN O O
in NN O O
85 NN O O
% NN O O
of NN O O
patient NN O O
chromosomes NN O O
. NN O O

This NN O O
mutation NN O O
eliminates NN O O
the NN O O
ability NN O O
of NN O O
HFE NN O O
to NN O O
associate NN O O
with NN O O
beta2 NN O O
- NN O O
microglobulin NN O O
( NN O O
beta2m NN O O
) NN O O
and NN O O
prevents NN O O
cell NN O O
- NN O O
surface NN O O
expression NN O O
. NN O O

A NN O O
second NN O O
mutation NN O O
that NN O O
has NN O O
no NN O O
effect NN O O
on NN O O
beta2m NN O O
association NN O O
, NN O O
H63D NN O O
, NN O O
was NN O O
found NN O O
in NN O O
eight NN O O
out NN O O
of NN O O
nine NN O O
patients NN O O
heterozygous NN O O
for NN O O
the NN O O
C282Y NN O O
mutant NN O O
. NN O O

In NN O O
this NN O O
report NN O O
, NN O O
we NN O O
demonstrate NN O O
in NN O O
cultured NN O O
293 NN O O
cells NN O O
overexpressing NN O O
wild NN O O
- NN O O
type NN O O
or NN O O
mutant NN O O
HFE NN O O
proteins NN O O
that NN O O
both NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
and NN O O
H63D NN O O
HFE NN O O
proteins NN O O
form NN O O
stable NN O O
complexes NN O O
with NN O O
the NN O O
transferrin NN O O
receptor NN O O
( NN O O
TfR NN O O
) NN O O
. NN O O

The NN O O
C282Y NN O O
mutation NN O O
nearly NN O O
completely NN O O
prevents NN O O
the NN O O
association NN O O
of NN O O
the NN O O
mutant NN O O
HFE NN O O
protein NN O O
with NN O O
the NN O O
TfR NN O O
. NN O O

Studies NN O O
on NN O O
cell NN O O
- NN O O
associated NN O O
transferrin NN O O
at NN O O
37 NN O O
degrees NN O O
C NN O O
suggest NN O O
that NN O O
the NN O O
overexpressed NN O O
wild NN O O
- NN O O
type NN O O
HFE NN O O
protein NN O O
decreases NN O O
the NN O O
affinity NN O O
of NN O O
the NN O O
TfR NN O O
for NN O O
transferrin NN O O
. NN O O

The NN O O
overexpressed NN O O
H63D NN O O
protein NN O O
does NN O O
not NN O O
have NN O O
this NN O O
effect NN O O
, NN O O
providing NN O O
the NN O O
first NN O O
direct NN O O
evidence NN O O
for NN O O
a NN O O
functional NN O O
consequence NN O O
of NN O O
the NN O O
H63D NN O O
mutation NN O O
. NN O O

Addition NN O O
of NN O O
soluble NN O O
wild NN O O
- NN O O
type NN O O
HFE NN O O
/ NN O O
beta2m NN O O
heterodimers NN O O
to NN O O
cultured NN O O
cells NN O O
also NN O O
decreased NN O O
the NN O O
apparent NN O O
affinity NN O O
of NN O O
the NN O O
TfR NN O O
for NN O O
its NN O O
ligand NN O O
under NN O O
steady NN O O
- NN O O
state NN O O
conditions NN O O
, NN O O
both NN O O
in NN O O
293 NN O O
cells NN O O
and NN O O
in NN O O
HeLa NN O O
cells NN O O
. NN O O

Furthermore NN O O
, NN O O
at NN O O
4 NN O O
degrees NN O O
C NN O O
, NN O O
the NN O O
added NN O O
soluble NN O O
complex NN O O
of NN O O
HFE NN O O
/ NN O O
beta2m NN O O
inhibited NN O O
binding NN O O
of NN O O
transferrin NN O O
to NN O O
HeLa NN O O
cell NN O O
TfR NN O O
in NN O O
a NN O O
concentration NN O O
- NN O O
dependent NN O O
manner NN O O
. NN O O

Scatchard NN O O
plots NN O O
of NN O O
these NN O O
data NN O O
indicate NN O O
that NN O O
the NN O O
added NN O O
heterodimer NN O O
substantially NN O O
reduced NN O O
the NN O O
affinity NN O O
of NN O O
TfR NN O O
for NN O O
transferrin NN O O
. NN O O

These NN O O
results NN O O
establish NN O O
a NN O O
molecular NN O O
link NN O O
between NN O O
HFE NN O O
and NN O O
a NN O O
key NN O O
protein NN O O
involved NN O O
in NN O O
iron NN O O
transport NN O O
, NN O O
the NN O O
TfR NN O O
, NN O O
and NN O O
raise NN O O
the NN O O
possibility NN O O
that NN O O
alterations NN O O
in NN O O
this NN O O
regulatory NN O O
mechanism NN O O
may NN O O
play NN O O
a NN O O
role NN O O
in NN O O
the NN O O
pathogenesis NN O O
of NN O O
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
. NN O O
. NN O O

Genomic NN O O
organization NN O O
of NN O O
the NN O O
UBE3A NN O O
/ NN O O
E6 NN O O
- NN O O
AP NN O O
gene NN O O
and NN O O
related NN O O
pseudogenes NN O O
. NN O O

The NN O O
UBE3A NN O O
gene NN O O
encodes NN O O
the NN O O
E6 NN O O
- NN O O
AP NN O O
ubiquitin NN O O
- NN O O
protein NN O O
ligase NN O O
and NN O O
has NN O O
recently NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
mutated NN O O
in NN O O
Angelman NN O B-Disease
syndrome NN O I-Disease
patients NN O O
who NN O O
lack NN O O
15q11 NN O O
- NN O O
q13 NN O O
deletions NN O O
or NN O O
chromosome NN O O
15 NN O O
paternal NN O O
uniparental NN O B-Disease
disomy NN O I-Disease
. NN O O

Previous NN O O
UBE3A NN O O
cDNA NN O O
analysis NN O O
has NN O O
shown NN O O
a NN O O
coding NN O O
region NN O O
of NN O O
approximately NN O O
2 NN O O
. NN O O

6 NN O O
kb NN O O
and NN O O
a NN O O
3 NN O O
- NN O O
untranslated NN O O
region NN O O
( NN O O
UTR NN O O
) NN O O
of NN O O
< NN O O
50 NN O O
bp NN O O
, NN O O
whereas NN O O
Northern NN O O
analysis NN O O
has NN O O
indicated NN O O
mRNA NN O O
sizes NN O O
of NN O O
5 NN O O
- NN O O
8 NN O O
kb NN O O
. NN O O

We NN O O
have NN O O
analyzed NN O O
additional NN O O
cDNA NN O O
clones NN O O
and NN O O
provide NN O O
evidence NN O O
for NN O O
an NN O O
additional NN O O
0 NN O O
. NN O O

5 NN O O
kb NN O O
of NN O O
5 NN O O
- NN O O
UTR NN O O
and NN O O
> NN O O
2 NN O O
kb NN O O
of NN O O
3 NN O O
- NN O O
UTR NN O O
. NN O O

We NN O O
have NN O O
established NN O O
the NN O O
genomic NN O O
organization NN O O
of NN O O
UBE3A NN O O
and NN O O
the NN O O
sequence NN O O
of NN O O
intron NN O O
- NN O O
exon NN O O
borders NN O O
. NN O O

We NN O O
have NN O O
also NN O O
mapped NN O O
two NN O O
highly NN O O
homologous NN O O
processed NN O O
pseudogenes NN O O
, NN O O
UBE3AP1 NN O O
and NN O O
UBE3AP2 NN O O
, NN O O
to NN O O
chromosomes NN O O
2 NN O O
and NN O O
21 NN O O
, NN O O
respectively NN O O
, NN O O
and NN O O
determined NN O O
their NN O O
genomic NN O O
organization NN O O
. NN O O

These NN O O
results NN O O
will NN O O
form NN O O
the NN O O
basis NN O O
for NN O O
studies NN O O
of NN O O
mutation NN O O
and NN O O
imprinting NN O O
of NN O O
UBE3A NN O O
. NN O O

Mutation NN O O
spectrum NN O O
and NN O O
genotype NN O O
- NN O O
phenotype NN O O
analyses NN O O
in NN O O
Cowden NN O B-Disease
disease NN O I-Disease
and NN O O
Bannayan NN O B-Disease
- NN O I-Disease
Zonana NN O I-Disease
syndrome NN O I-Disease
, NN O O
two NN O O
hamartoma NN O B-Disease
syndromes NN O I-Disease
with NN O O
germline NN O O
PTEN NN O O
mutation NN O O
. NN O O

The NN O O
tumour NN O B-Disease
suppressor NN O O
gene NN O O
PTEN NN O O
, NN O O
which NN O O
maps NN O O
to NN O O
10q23 NN O O
. NN O O

3 NN O O
and NN O O
encodes NN O O
a NN O O
403 NN O O
amino NN O O
acid NN O O
dual NN O O
specificity NN O O
phosphatase NN O O
( NN O O
protein NN O O
tyrosine NN O O
phosphatase NN O O
; NN O O
PTPase NN O O
) NN O O
, NN O O
was NN O O
shown NN O O
recently NN O O
to NN O O
play NN O O
a NN O O
broad NN O O
role NN O O
in NN O O
human NN O O
malignancy NN O B-Disease
. NN O O

Somatic NN O O
PTEN NN O O
deletions NN O O
and NN O O
mutations NN O O
were NN O O
observed NN O O
in NN O O
sporadic NN O B-Disease
breast NN O I-Disease
, NN O I-Disease
brain NN O I-Disease
, NN O I-Disease
prostate NN O I-Disease
and NN O I-Disease
kidney NN O I-Disease
cancer NN O I-Disease
cell NN O O
lines NN O O
and NN O O
in NN O O
several NN O O
primary NN O O
tumours NN O B-Disease
such NN O O
as NN O O
endometrial NN O B-Disease
carcinomas NN O I-Disease
, NN O O
malignant NN O B-Disease
melanoma NN O I-Disease
and NN O O
thyroid NN O B-Disease
tumours NN O I-Disease
. NN O O

In NN O O
addition NN O O
, NN O O
PTEN NN O O
was NN O O
identified NN O O
as NN O O
the NN O O
susceptibility NN O O
gene NN O O
for NN O O
two NN O O
hamartoma NN O B-Disease
syndromes NN O I-Disease
Cowden NN O B-Disease
disease NN O I-Disease
( NN O O
CD NN O B-Disease
; NN O O
MIM NN O O
158350 NN O O
) NN O O
and NN O O
Bannayan NN O B-Disease
- NN O I-Disease
Zonana NN O I-Disease
( NN O I-Disease
BZS NN O I-Disease
) NN O I-Disease
or NN O I-Disease
Ruvalcaba NN O I-Disease
- NN O I-Disease
Riley NN O I-Disease
- NN O I-Disease
Smith NN O I-Disease
syndrome NN O I-Disease
( NN O O
MIM NN O O
153480 NN O O
) NN O O
. NN O O

Constitutive NN O O
DNA NN O O
from NN O O
37 NN O O
CD NN O B-Disease
families NN O O
and NN O O
seven NN O O
BZS NN O B-Disease
families NN O O
was NN O O
screened NN O O
for NN O O
germline NN O O
PTEN NN O O
mutations NN O O
. NN O O

PTEN NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
30 NN O O
of NN O O
37 NN O O
( NN O O
81 NN O O
% NN O O
) NN O O
CD NN O B-Disease
families NN O O
, NN O O
including NN O O
missense NN O O
and NN O O
nonsense NN O O
point NN O O
mutations NN O O
, NN O O
deletions NN O O
, NN O O
insertions NN O O
, NN O O
a NN O O
deletion NN O O
/ NN O O
insertion NN O O
and NN O O
splice NN O O
site NN O O
mutations NN O O
. NN O O

These NN O O
mutations NN O O
were NN O O
scattered NN O O
over NN O O
the NN O O
entire NN O O
length NN O O
of NN O O
PTEN NN O O
, NN O O
with NN O O
the NN O O
exception NN O O
of NN O O
the NN O O
first NN O O
, NN O O
fourth NN O O
and NN O O
last NN O O
exons NN O O
. NN O O

A NN O O
hot NN O O
spot NN O O
for NN O O
PTEN NN O O
mutation NN O O
in NN O O
CD NN O B-Disease
was NN O O
identified NN O O
in NN O O
exon NN O O
5 NN O O
that NN O O
contains NN O O
the NN O O
PTPase NN O O
core NN O O
motif NN O O
, NN O O
with NN O O
13 NN O O
of NN O O
30 NN O O
( NN O O
43 NN O O
% NN O O
) NN O O
CD NN O B-Disease
mutations NN O O
identified NN O O
in NN O O
this NN O O
exon NN O O
. NN O O

Seven NN O O
of NN O O
30 NN O O
( NN O O
23 NN O O
% NN O O
) NN O O
were NN O O
within NN O O
the NN O O
core NN O O
motif NN O O
, NN O O
the NN O O
majority NN O O
( NN O O
five NN O O
of NN O O
seven NN O O
) NN O O
of NN O O
which NN O O
were NN O O
missense NN O O
mutations NN O O
, NN O O
possibly NN O O
pointing NN O O
to NN O O
the NN O O
functional NN O O
significance NN O O
of NN O O
this NN O O
region NN O O
. NN O O

Germline NN O O
PTEN NN O O
mutations NN O O
were NN O O
identified NN O O
in NN O O
four NN O O
of NN O O
seven NN O O
( NN O O
57 NN O O
% NN O O
) NN O O
BZS NN O B-Disease
families NN O O
studied NN O O
. NN O O

Interestingly NN O O
, NN O O
none NN O O
of NN O O
these NN O O
mutations NN O O
was NN O O
observed NN O O
in NN O O
the NN O O
PTPase NN O O
core NN O O
motif NN O O
. NN O O

It NN O O
is NN O O
also NN O O
worthy NN O O
of NN O O
note NN O O
that NN O O
a NN O O
single NN O O
nonsense NN O O
point NN O O
mutation NN O O
, NN O O
R233X NN O O
, NN O O
was NN O O
observed NN O O
in NN O O
the NN O O
germline NN O O
DNA NN O O
from NN O O
two NN O O
unrelated NN O O
CD NN O B-Disease
families NN O O
and NN O O
one NN O O
BZS NN O B-Disease
family NN O O
. NN O O

Genotype NN O O
- NN O O
phenotype NN O O
studies NN O O
were NN O O
not NN O O
performed NN O O
on NN O O
this NN O O
small NN O O
group NN O O
of NN O O
BZS NN O B-Disease
families NN O O
. NN O O

However NN O O
, NN O O
genotype NN O O
- NN O O
phenotype NN O O
analysis NN O O
inthe NN O O
group NN O O
of NN O O
CD NN O B-Disease
families NN O O
revealed NN O O
two NN O O
possible NN O O
associations NN O O
worthy NN O O
of NN O O
follow NN O O
- NN O O
up NN O O
in NN O O
independent NN O O
analyses NN O O
. NN O O

The NN O O
first NN O O
was NN O O
an NN O O
association NN O O
noted NN O O
in NN O O
the NN O O
group NN O O
of NN O O
CD NN O B-Disease
families NN O O
with NN O O
breast NN O B-Disease
disease NN O I-Disease
. NN O O

A NN O O
correlation NN O O
was NN O O
observed NN O O
between NN O O
the NN O O
presence NN O O
/ NN O O
absence NN O O
of NN O O
a NN O O
PTEN NN O O
mutation NN O O
and NN O O
the NN O O
type NN O O
of NN O O
breast NN O O
involvement NN O O
( NN O O
unaffected NN O O
versus NN O O
benign NN O O
versus NN O O
malignant NN O O
) NN O O
. NN O O

Specifically NN O O
and NN O O
more NN O O
directly NN O O
, NN O O
an NN O O
association NN O O
was NN O O
also NN O O
observed NN O O
between NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
PTEN NN O O
mutation NN O O
and NN O O
malignant NN O B-Disease
breast NN O I-Disease
disease NN O I-Disease
. NN O O

Secondly NN O O
, NN O O
there NN O O
appeared NN O O
to NN O O
be NN O O
an NN O O
interdependent NN O O
association NN O O
between NN O O
mutations NN O O
upstream NN O O
and NN O O
within NN O O
the NN O O
PTPase NN O O
core NN O O
motif NN O O
, NN O O
the NN O O
core NN O O
motif NN O O
containing NN O O
the NN O O
majority NN O O
of NN O O
missense NN O O
mutations NN O O
, NN O O
and NN O O
the NN O O
involvement NN O O
of NN O O
all NN O O
major NN O O
organ NN O O
systems NN O O
( NN O O
central NN O O
nervous NN O O
system NN O O
, NN O O
thyroid NN O O
, NN O O
breast NN O O
, NN O O
skin NN O O
and NN O O
gastrointestinal NN O O
tract NN O O
) NN O O
. NN O O

However NN O O
, NN O O
these NN O O
observations NN O O
would NN O O
need NN O O
to NN O O
be NN O O
confirmed NN O O
by NN O O
studying NN O O
a NN O O
larger NN O O
number NN O O
of NN O O
CD NN O B-Disease
families NN O O
. NN O O

Molecular NN O O
defects NN O O
leading NN O O
to NN O O
human NN O O
complement NN O B-Disease
component NN O I-Disease
C6 NN O I-Disease
deficiency NN O I-Disease
in NN O O
an NN O O
African NN O O
- NN O O
American NN O O
family NN O O
. NN O O

Complement NN O B-Disease
component NN O I-Disease
C6 NN O I-Disease
deficiency NN O I-Disease
( NN O O
C6D NN O B-Disease
) NN O O
was NN O O
diagnosed NN O O
in NN O O
a NN O O
16 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
African NN O O
- NN O O
American NN O O
male NN O O
with NN O O
meningococcal NN O B-Disease
meningitis NN O I-Disease
. NN O O

The NN O O
patients NN O O
father NN O O
and NN O O
two NN O O
brothers NN O O
also NN O O
had NN O O
C6D NN O B-Disease
, NN O O
but NN O O
gave NN O O
no NN O O
history NN O O
of NN O O
meningitis NN O B-Disease
or NN O O
other NN O O
neisserial NN O B-Disease
infection NN O I-Disease
. NN O O

By NN O O
using NN O O
exon NN O O
- NN O O
specific NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
/ NN O O
single NN O O
- NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
as NN O O
a NN O O
screening NN O O
step NN O O
and NN O O
nucleotide NN O O
sequencing NN O O
of NN O O
target NN O O
exons NN O O
, NN O O
we NN O O
determined NN O O
that NN O O
the NN O O
proband NN O O
was NN O O
a NN O O
compound NN O O
heterozygote NN O O
for NN O O
two NN O O
C6 NN O O
gene NN O O
mutations NN O O
. NN O O

The NN O O
first NN O O
, NN O O
1195delC NN O O
located NN O O
in NN O O
exon NN O O
7 NN O O
, NN O O
is NN O O
a NN O O
novel NN O O
mutation NN O O
, NN O O
while NN O O
the NN O O
second NN O O
, NN O O
1936delG NN O O
in NN O O
exon NN O O
12 NN O O
, NN O O
has NN O O
been NN O O
described NN O O
before NN O O
to NN O O
cause NN O O
C6D NN O B-Disease
in NN O O
an NN O O
unrelated NN O O
African NN O O
- NN O O
American NN O O
individual NN O O
. NN O O

Both NN O O
mutations NN O O
result NN O O
in NN O O
premature NN O O
termination NN O O
codons NN O O
and NN O O
C6 NN O O
null NN O O
alleles NN O O
. NN O O

Allele NN O O
- NN O O
specific NN O O
PCR NN O O
indicated NN O O
that NN O O
the NN O O
probands NN O O
two NN O O
brothers NN O O
also NN O O
inherited NN O O
the NN O O
1195delC NN O O
mutation NN O O
from NN O O
their NN O O
heterozygous NN O O
mother NN O O
and NN O O
the NN O O
1936delG NN O O
mutation NN O O
from NN O O
their NN O O
homozygous NN O O
father NN O O
. NN O O
. NN O O

PAX6 NN O O
mutations NN O O
reviewed NN O O
. NN O O

Mutations NN O O
in NN O O
PAX6 NN O O
are NN O O
responsible NN O O
for NN O O
human NN O O
aniridia NN O B-Disease
and NN O O
have NN O O
also NN O O
been NN O O
found NN O O
in NN O O
patients NN O O
with NN O O
Peters NN O B-Disease
anomaly NN O I-Disease
, NN O O
with NN O O
congenital NN O B-Disease
cataracts NN O I-Disease
, NN O O
with NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
keratitis NN O I-Disease
, NN O O
and NN O O
with NN O O
isolated NN O B-Disease
foveal NN O I-Disease
hypoplasia NN O I-Disease
. NN O O

No NN O O
locus NN O O
other NN O O
than NN O O
chromosome NN O O
11p13 NN O O
has NN O O
been NN O O
implicated NN O O
in NN O O
aniridia NN O B-Disease
, NN O O
and NN O O
PAX6 NN O O
is NN O O
clearly NN O O
the NN O O
major NN O O
, NN O O
if NN O O
not NN O O
only NN O O
, NN O O
gene NN O O
responsible NN O O
. NN O O

Twenty NN O O
- NN O O
eight NN O O
percent NN O O
of NN O O
identified NN O O
PAX6 NN O O
mutations NN O O
are NN O O
C NN O O
- NN O O
T NN O O
changes NN O O
at NN O O
CpG NN O O
dinucleotides NN O O
, NN O O
20 NN O O
% NN O O
are NN O O
splicing NN O O
errors NN O O
, NN O O
and NN O O
more NN O O
than NN O O
30 NN O O
% NN O O
are NN O O
deletion NN O O
or NN O O
insertion NN O O
events NN O O
. NN O O

There NN O O
is NN O O
a NN O O
noticeably NN O O
elevated NN O O
level NN O O
of NN O O
mutation NN O O
in NN O O
the NN O O
paired NN O O
domain NN O O
compared NN O O
with NN O O
the NN O O
rest NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

Increased NN O O
mutation NN O O
in NN O O
the NN O O
homeodomain NN O O
is NN O O
accounted NN O O
for NN O O
by NN O O
the NN O O
hypermutable NN O O
CpG NN O O
dinucleotide NN O O
in NN O O
codon NN O O
240 NN O O
. NN O O

Very NN O O
nearly NN O O
all NN O O
mutations NN O O
appear NN O O
to NN O O
cause NN O O
loss NN O O
of NN O O
function NN O O
of NN O O
the NN O O
mutant NN O O
allele NN O O
, NN O O
and NN O O
more NN O O
than NN O O
80 NN O O
% NN O O
of NN O O
exonic NN O O
substitutions NN O O
result NN O O
in NN O O
nonsense NN O O
codons NN O O
. NN O O

In NN O O
a NN O O
gene NN O O
with NN O O
such NN O O
extraordinarily NN O O
high NN O O
sequence NN O O
conservation NN O O
throughout NN O O
evolution NN O O
, NN O O
there NN O O
are NN O O
presumed NN O O
undiscovered NN O O
missense NN O O
mutations NN O O
, NN O O
these NN O O
are NN O O
hypothesized NN O O
to NN O O
exist NN O O
in NN O O
as NN O O
- NN O O
yet NN O O
unidentified NN O O
phenotypes NN O O
. NN O O
. NN O O

Genetic NN O O
heterogeneity NN O O
and NN O O
penetrance NN O O
analysis NN O O
of NN O O
the NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
genes NN O O
in NN O O
breast NN O B-Disease
cancer NN O I-Disease
families NN O O
. NN O O

The NN O O
Breast NN O B-Disease
Cancer NN O I-Disease
Linkage NN O O
Consortium NN O O
. NN O O

The NN O O
contribution NN O O
of NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
to NN O O
inherited NN O B-Disease
breast NN O I-Disease
cancer NN O I-Disease
was NN O O
assessed NN O O
by NN O O
linkage NN O O
and NN O O
mutation NN O O
analysis NN O O
in NN O O
237 NN O O
families NN O O
, NN O O
each NN O O
with NN O O
at NN O O
least NN O O
four NN O O
cases NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
, NN O O
collected NN O O
by NN O O
the NN O O
Breast NN O B-Disease
Cancer NN O I-Disease
Linkage NN O O
Consortium NN O O
. NN O O

Families NN O O
were NN O O
included NN O O
without NN O O
regard NN O O
to NN O O
the NN O O
occurrence NN O O
of NN O O
ovarian NN O B-Disease
or NN O I-Disease
other NN O I-Disease
cancers NN O I-Disease
. NN O O

Overall NN O O
, NN O O
disease NN O O
was NN O O
linked NN O O
to NN O O
BRCA1 NN O O
in NN O O
an NN O O
estimated NN O O
52 NN O O
% NN O O
of NN O O
families NN O O
, NN O O
to NN O O
BRCA2 NN O O
in NN O O
32 NN O O
% NN O O
of NN O O
families NN O O
, NN O O
and NN O O
to NN O O
neither NN O O
gene NN O O
in NN O O
16 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
6 NN O O
% NN O O
- NN O O
28 NN O O
% NN O O
) NN O O
, NN O O
suggesting NN O O
other NN O O
predisposition NN O O
genes NN O O
. NN O O

The NN O O
majority NN O O
( NN O O
81 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
breast NN O B-Disease
- NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
families NN O O
were NN O O
due NN O O
to NN O O
BRCA1 NN O O
, NN O O
with NN O O
most NN O O
others NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
due NN O O
to NN O O
BRCA2 NN O O
. NN O O

Conversely NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
families NN O O
with NN O O
male NN O B-Disease
and NN O I-Disease
female NN O I-Disease
breast NN O I-Disease
cancer NN O I-Disease
were NN O O
due NN O O
to NN O O
BRCA2 NN O O
( NN O O
76 NN O O
% NN O O
) NN O O
. NN O O

The NN O O
largest NN O O
proportion NN O O
( NN O O
67 NN O O
% NN O O
) NN O O
of NN O O
families NN O O
due NN O O
to NN O O
other NN O O
genes NN O O
was NN O O
found NN O O
in NN O O
families NN O O
with NN O O
four NN O O
or NN O O
five NN O O
cases NN O O
of NN O O
female NN O O
breast NN O B-Disease
cancer NN O I-Disease
only NN O O
. NN O O

These NN O O
estimates NN O O
were NN O O
not NN O O
substantially NN O O
affected NN O O
either NN O O
by NN O O
changing NN O O
the NN O O
assumed NN O O
penetrance NN O O
model NN O O
for NN O O
BRCA1 NN O O
or NN O O
by NN O O
including NN O O
or NN O O
excluding NN O O
BRCA1 NN O O
mutation NN O O
data NN O O
. NN O O

Among NN O O
those NN O O
families NN O O
with NN O O
disease NN O O
due NN O O
to NN O O
BRCA1 NN O O
that NN O O
were NN O O
tested NN O O
by NN O O
one NN O O
of NN O O
the NN O O
standard NN O O
screening NN O O
methods NN O O
, NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
coding NN O O
sequence NN O O
or NN O O
splice NN O O
sites NN O O
in NN O O
an NN O O
estimated NN O O
63 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
51 NN O O
% NN O O
- NN O O
77 NN O O
% NN O O
) NN O O
. NN O O

The NN O O
estimated NN O O
sensitivity NN O O
was NN O O
identical NN O O
for NN O O
direct NN O O
sequencing NN O O
and NN O O
other NN O O
techniques NN O O
. NN O O

The NN O O
penetrance NN O O
of NN O O
BRCA2 NN O O
was NN O O
estimated NN O O
by NN O O
maximizing NN O O
the NN O O
LOD NN O O
score NN O O
in NN O O
BRCA2 NN O O
- NN O O
mutation NN O O
families NN O O
, NN O O
over NN O O
all NN O O
possible NN O O
penetrance NN O O
functions NN O O
. NN O O

The NN O O
estimated NN O O
cumulative NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
reached NN O O
28 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
9 NN O O
% NN O O
- NN O O
44 NN O O
% NN O O
) NN O O
by NN O O
age NN O O
50 NN O O
years NN O O
and NN O O
84 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
43 NN O O
% NN O O
- NN O O
95 NN O O
% NN O O
) NN O O
by NN O O
age NN O O
70 NN O O
years NN O O
. NN O O

The NN O O
corresponding NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
risks NN O O
were NN O O
0 NN O O
. NN O O

4 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0 NN O O
% NN O O
- NN O O
1 NN O O
% NN O O
) NN O O
by NN O O
age NN O O
50 NN O O
years NN O O
and NN O O
27 NN O O
% NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0 NN O O
% NN O O
- NN O O
47 NN O O
% NN O O
) NN O O
by NN O O
age NN O O
70 NN O O
years NN O O
. NN O O

The NN O O
lifetime NN O O
risk NN O O
of NN O O
breast NN O B-Disease
cancer NN O I-Disease
appears NN O O
similar NN O O
to NN O O
the NN O O
risk NN O O
in NN O O
BRCA1 NN O O
carriers NN O O
, NN O O
but NN O O
there NN O O
was NN O O
some NN O O
suggestion NN O O
of NN O O
a NN O O
lower NN O O
risk NN O O
in NN O O
BRCA2 NN O O
carriers NN O O
< NN O O
50 NN O O
years NN O O
of NN O O
age NN O O
. NN O O

Eye NN O B-Disease
movement NN O I-Disease
abnormalities NN O I-Disease
correlate NN O O
with NN O O
genotype NN O O
in NN O O
autosomal NN O O
dominant NN O O
cerebellar NN O B-Disease
ataxia NN O I-Disease
type NN O I-Disease
I NN O I-Disease
. NN O O

We NN O O
compared NN O O
horizontal NN O O
eye NN O O
movements NN O O
( NN O O
visually NN O O
guided NN O O
saccades NN O O
, NN O O
antisaccades NN O O
, NN O O
and NN O O
smooth NN O O
pursuit NN O O
) NN O O
in NN O O
control NN O O
subjects NN O O
( NN O O
n NN O O
= NN O O
14 NN O O
) NN O O
and NN O O
patients NN O O
with NN O O
three NN O O
forms NN O O
of NN O O
autosomal NN O O
dominant NN O O
cerebellar NN O B-Disease
ataxias NN O I-Disease
type NN O I-Disease
I NN O I-Disease
spinocerebellar NN O B-Disease
ataxias NN O I-Disease
1 NN O I-Disease
and NN O I-Disease
2 NN O I-Disease
( NN O O
SCA1 NN O B-Disease
, NN O O
n NN O O
= NN O O
11 NN O O
; NN O O
SCA2 NN O B-Disease
, NN O O
n NN O O
= NN O O
10 NN O O
) NN O O
and NN O O
SCA3 NN O B-Disease
/ NN O O
Machado NN O B-Disease
- NN O I-Disease
Joseph NN O I-Disease
disease NN O I-Disease
( NN O O
MJD NN O B-Disease
) NN O O
( NN O O
n NN O O
= NN O O
16 NN O O
) NN O O
. NN O O

In NN O O
SCA1 NN O B-Disease
, NN O O
saccade NN O O
amplitude NN O O
was NN O O
significantly NN O O
increased NN O O
, NN O O
resulting NN O O
in NN O O
hypermetria NN O B-Disease
. NN O O

The NN O O
smooth NN O O
pursuit NN O O
gain NN O O
was NN O O
decreased NN O O
. NN O O

In NN O O
SCA2 NN O B-Disease
, NN O O
saccade NN O O
velocity NN O O
was NN O O
markedly NN O O
decreased NN O O
. NN O O

The NN O O
percentage NN O O
of NN O O
errors NN O O
in NN O O
antisaccades NN O O
was NN O O
greatly NN O O
increased NN O O
and NN O O
was NN O O
significantly NN O O
correlated NN O O
with NN O O
age NN O O
at NN O O
disease NN O O
onset NN O O
. NN O O

In NN O O
addition NN O O
, NN O O
a NN O O
correlation NN O O
between NN O O
smooth NN O O
pursuit NN O O
gain NN O O
and NN O O
the NN O O
number NN O O
of NN O O
trinucleotide NN O O
repeats NN O O
was NN O O
found NN O O
. NN O O

In NN O O
SCA3 NN O B-Disease
, NN O O
gaze NN O B-Disease
- NN O I-Disease
evoked NN O I-Disease
nystagmus NN O I-Disease
was NN O O
often NN O O
present NN O O
as NN O O
was NN O O
saccade NN O O
hypometria NN O O
and NN O O
smooth NN O O
pursuit NN O O
gain NN O O
was NN O O
markedly NN O O
decreased NN O O
. NN O O

Three NN O O
major NN O O
criteria NN O O
, NN O O
saccade NN O O
amplitude NN O O
, NN O O
saccade NN O O
velocity NN O O
, NN O O
and NN O O
presence NN O O
of NN O O
gaze NN O B-Disease
- NN O I-Disease
evoked NN O I-Disease
nystagmus NN O I-Disease
, NN O O
permitted NN O O
the NN O O
correct NN O O
assignment NN O O
of NN O O
90 NN O O
% NN O O
of NN O O
the NN O O
SCA1 NN O B-Disease
, NN O O
90 NN O O
% NN O O
of NN O O
the NN O O
SCA2 NN O B-Disease
, NN O O
and NN O O
93 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
with NN O O
SCA3 NN O B-Disease
to NN O O
their NN O O
genetically NN O O
confirmed NN O O
patient NN O O
group NN O O
and NN O O
, NN O O
therefore NN O O
, NN O O
may NN O O
help NN O O
orient NN O O
diagnoses NN O O
of NN O O
SCA1 NN O B-Disease
, NN O O
SCA2 NN O B-Disease
, NN O O
and NN O O
SCA3 NN O B-Disease
at NN O O
early NN O O
clinical NN O O
stages NN O O
of NN O O
the NN O O
diseases NN O O
. NN O O
. NN O O

Genetic NN O O
basis NN O O
and NN O O
molecular NN O O
mechanism NN O O
for NN O O
idiopathic NN O B-Disease
ventricular NN O I-Disease
fibrillation NN O I-Disease
. NN O O

Ventricular NN O B-Disease
fibrillation NN O I-Disease
causes NN O O
more NN O O
than NN O O
300 NN O O
, NN O O
000 NN O O
sudden NN O O
deaths NN O O
each NN O O
year NN O O
in NN O O
the NN O O
USA NN O O
alone NN O O
. NN O O

In NN O O
approximately NN O O
5 NN O O
- NN O O
12 NN O O
% NN O O
of NN O O
these NN O O
cases NN O O
, NN O O
there NN O O
are NN O O
no NN O O
demonstrable NN O O
cardiac NN O O
or NN O O
non NN O O
- NN O O
cardiac NN O O
causes NN O O
to NN O O
account NN O O
for NN O O
the NN O O
episode NN O O
, NN O O
which NN O O
is NN O O
therefore NN O O
classified NN O O
as NN O O
idiopathic NN O B-Disease
ventricular NN O I-Disease
fibrillation NN O I-Disease
( NN O O
IVF NN O B-Disease
) NN O O
. NN O O

A NN O O
distinct NN O O
group NN O O
of NN O O
IVF NN O B-Disease
patients NN O O
has NN O O
been NN O O
found NN O O
to NN O O
present NN O O
with NN O O
a NN O O
characteristic NN O O
electrocardiographic NN O O
pattern NN O O
. NN O O

Because NN O O
of NN O O
the NN O O
small NN O O
size NN O O
of NN O O
most NN O O
pedigrees NN O O
and NN O O
the NN O O
high NN O O
incidence NN O O
of NN O O
sudden NN O B-Disease
death NN O I-Disease
, NN O O
however NN O O
, NN O O
molecular NN O O
genetic NN O O
studies NN O O
of NN O O
IVF NN O B-Disease
have NN O O
not NN O O
yet NN O O
been NN O O
done NN O O
. NN O O

Because NN O O
IVF NN O B-Disease
causes NN O O
cardiac NN O O
rhythm NN O O
disturbance NN O O
, NN O O
we NN O O
investigated NN O O
whether NN O O
malfunction NN O O
of NN O O
ion NN O O
channels NN O O
could NN O O
cause NN O O
the NN O O
disorder NN O O
by NN O O
studying NN O O
mutations NN O O
in NN O O
the NN O O
cardiac NN O O
sodium NN O O
channel NN O O
gene NN O O
SCN5A NN O O
. NN O O

We NN O O
have NN O O
now NN O O
identified NN O O
a NN O O
missense NN O O
mutation NN O O
, NN O O
a NN O O
splice NN O O
- NN O O
donor NN O O
mutation NN O O
, NN O O
and NN O O
a NN O O
frameshift NN O O
mutation NN O O
in NN O O
the NN O O
coding NN O O
region NN O O
of NN O O
SCN5A NN O O
in NN O O
three NN O O
IVF NN O B-Disease
families NN O O
. NN O O

We NN O O
show NN O O
that NN O O
sodium NN O O
channels NN O O
with NN O O
the NN O O
missense NN O O
mutation NN O O
recover NN O O
from NN O O
inactivation NN O O
more NN O O
rapidly NN O O
than NN O O
normal NN O O
and NN O O
that NN O O
the NN O O
frameshift NN O O
mutation NN O O
causes NN O O
the NN O O
sodium NN O O
channel NN O O
to NN O O
be NN O O
non NN O O
- NN O O
functional NN O O
. NN O O

Our NN O O
results NN O O
indicate NN O O
that NN O O
mutations NN O O
in NN O O
cardiac NN O O
ion NN O O
- NN O O
channel NN O O
genes NN O O
contribute NN O O
to NN O O
the NN O O
risk NN O O
of NN O O
developing NN O O
IVF NN O B-Disease
. NN O O
. NN O O

Molecular NN O O
heterogeneity NN O O
in NN O O
mucopolysaccharidosis NN O B-Disease
IVA NN O I-Disease
in NN O O
Australia NN O O
and NN O O
Northern NN O O
Ireland NN O O
: NN O O
nine NN O O
novel NN O O
mutations NN O O
including NN O O
T312S NN O O
, NN O O
a NN O O
common NN O O
allele NN O O
that NN O O
confers NN O O
a NN O O
mild NN O O
phenotype NN O O
. NN O O

Mucopolysaccharidosis NN O B-Disease
IVA NN O I-Disease
( NN O O
MPS NN O B-Disease
IVA NN O I-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
lysosomal NN O I-Disease
storage NN O I-Disease
disorder NN O I-Disease
caused NN O O
by NN O O
a NN O O
genetic NN O B-Disease
defect NN O I-Disease
in NN O O
N NN O O
- NN O O
acetylgalactosamine NN O O
- NN O O
6 NN O O
- NN O O
sulfate NN O O
sulfatase NN O O
( NN O O
GALNS NN O O
) NN O O
. NN O O

Previous NN O O
studies NN O O
of NN O O
patients NN O O
from NN O O
a NN O O
British NN O O
- NN O O
Irish NN O O
population NN O O
showed NN O O
that NN O O
the NN O O
I113F NN O O
mutation NN O O
is NN O O
the NN O O
most NN O O
common NN O O
single NN O O
mutation NN O O
among NN O O
MPS NN O B-Disease
IVA NN O I-Disease
patients NN O O
and NN O O
produces NN O O
a NN O O
severe NN O O
clinical NN O O
phenotype NN O O
. NN O O

We NN O O
studied NN O O
mutations NN O O
in NN O O
the NN O O
GALNS NN O O
gene NN O O
from NN O O
23 NN O O
additional NN O O
MPS NN O B-Disease
IVA NN O I-Disease
patients NN O O
( NN O O
15 NN O O
from NN O O
Australia NN O O
, NN O O
8 NN O O
from NN O O
Northern NN O O
Ireland NN O O
) NN O O
, NN O O
with NN O O
various NN O O
clinical NN O O
phenotypes NN O O
( NN O O
severe NN O O
, NN O O
16 NN O O
cases NN O O
; NN O O
intermediate NN O O
, NN O O
4 NN O O
cases NN O O
; NN O O
mild NN O O
, NN O O
3 NN O O
cases NN O O
) NN O O
. NN O O

We NN O O
found NN O O
two NN O O
common NN O O
mutations NN O O
that NN O O
together NN O O
accounted NN O O
for NN O O
32 NN O O
% NN O O
of NN O O
the NN O O
44 NN O O
unrelated NN O O
alleles NN O O
in NN O O
these NN O O
patients NN O O
. NN O O

One NN O O
is NN O O
the NN O O
T312S NN O O
mutation NN O O
, NN O O
a NN O O
novel NN O O
mutation NN O O
found NN O O
exclusively NN O O
in NN O O
milder NN O O
patients NN O O
. NN O O

The NN O O
other NN O O
is NN O O
the NN O O
previously NN O O
described NN O O
I113F NN O O
that NN O O
produces NN O O
a NN O O
severe NN O O
phenotype NN O O
. NN O O

The NN O O
I113F NN O O
and NN O O
T312S NN O O
mutations NN O O
accounted NN O O
for NN O O
8 NN O O
( NN O O
18 NN O O
% NN O O
) NN O O
and NN O O
6 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
of NN O O
44 NN O O
unrelated NN O O
alleles NN O O
, NN O O
respectively NN O O
. NN O O

The NN O O
relatively NN O O
high NN O O
residual NN O O
GALNS NN O O
activity NN O O
seen NN O O
when NN O O
the NN O O
T312S NN O O
mutant NN O O
cDNA NN O O
is NN O O
overexpressed NN O O
in NN O O
mutant NN O O
cells NN O O
provides NN O O
an NN O O
explanation NN O O
for NN O O
the NN O O
mild NN O O
phenotype NN O O
in NN O O
patients NN O O
with NN O O
this NN O O
mutation NN O O
. NN O O

The NN O O
distribution NN O O
and NN O O
relative NN O O
frequencies NN O O
of NN O O
the NN O O
I113F NN O O
and NN O O
T312S NN O O
mutations NN O O
in NN O O
Australia NN O O
corresponded NN O O
to NN O O
those NN O O
observed NN O O
in NN O O
Northern NN O O
Ireland NN O O
and NN O O
are NN O O
unique NN O O
to NN O O
these NN O O
two NN O O
populations NN O O
, NN O O
suggesting NN O O
that NN O O
both NN O O
mutations NN O O
were NN O O
probably NN O O
introduced NN O O
to NN O O
Australia NN O O
by NN O O
Irish NN O O
migrants NN O O
during NN O O
the NN O O
19th NN O O
century NN O O
. NN O O

Haplotype NN O O
analysis NN O O
using NN O O
6 NN O O
RFLPs NN O O
provides NN O O
additional NN O O
data NN O O
that NN O O
the NN O O
I113F NN O O
mutation NN O O
originated NN O O
from NN O O
a NN O O
common NN O O
ancestor NN O O
. NN O O

The NN O O
other NN O O
9 NN O O
novel NN O O
mutations NN O O
identified NN O O
in NN O O
these NN O O
23 NN O O
patients NN O O
were NN O O
each NN O O
limited NN O O
to NN O O
a NN O O
single NN O O
family NN O O
. NN O O

These NN O O
data NN O O
provide NN O O
further NN O O
evidence NN O O
for NN O O
extensive NN O O
allelic NN O O
heterogeneity NN O O
in NN O O
MPS NN O B-Disease
IVA NN O I-Disease
in NN O O
British NN O O
- NN O O
Irish NN O O
patients NN O O
and NN O O
provide NN O O
evidence NN O O
for NN O O
their NN O O
transmission NN O O
to NN O O
Australia NN O O
by NN O O
British NN O O
- NN O O
Irish NN O O
migrants NN O O
. NN O O
. NN O O

Identification NN O O
of NN O O
constitutional NN O O
WT1 NN O O
mutations NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
isolated NN O O
diffuse NN O B-Disease
mesangial NN O I-Disease
sclerosis NN O I-Disease
, NN O O
and NN O O
analysis NN O O
of NN O O
genotype NN O O
/ NN O O
phenotype NN O O
correlations NN O O
by NN O O
use NN O O
of NN O O
a NN O O
computerized NN O O
mutation NN O O
database NN O O
. NN O O

Constitutional NN O O
mutations NN O O
of NN O O
the NN O O
WT1 NN O O
gene NN O O
, NN O O
encoding NN O O
a NN O O
zinc NN O O
- NN O O
finger NN O O
transcription NN O O
factor NN O O
involved NN O O
in NN O O
renal NN O O
and NN O O
gonadal NN O O
development NN O O
, NN O O
are NN O O
found NN O O
in NN O O
most NN O O
patients NN O O
with NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
( NN O O
DDS NN O B-Disease
) NN O O
, NN O O
or NN O O
diffuse NN O B-Disease
mesangial NN O I-Disease
sclerosis NN O I-Disease
( NN O O
DMS NN O B-Disease
) NN O O
associated NN O O
with NN O O
pseudohermaphroditism NN O B-Disease
and NN O O
/ NN O O
or NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
( NN O O
WT NN O B-Disease
) NN O O
. NN O O

Most NN O O
mutations NN O O
in NN O O
DDS NN O B-Disease
patients NN O O
lie NN O O
in NN O O
exon NN O O
8 NN O O
or NN O O
exon NN O O
9 NN O O
, NN O O
encoding NN O O
zinc NN O O
finger NN O O
2 NN O O
or NN O O
zinc NN O O
finger NN O O
3 NN O O
, NN O O
respectively NN O O
, NN O O
with NN O O
a NN O O
hot NN O O
spot NN O O
( NN O O
R394W NN O O
) NN O O
in NN O O
exon NN O O
9 NN O O
. NN O O

We NN O O
analyzed NN O O
a NN O O
series NN O O
of NN O O
24 NN O O
patients NN O O
, NN O O
10 NN O O
with NN O O
isolated NN O B-Disease
DMS NN O I-Disease
( NN O O
IDMS NN O B-Disease
) NN O O
, NN O O
10 NN O O
with NN O O
DDS NN O B-Disease
, NN O O
and NN O O
4 NN O O
with NN O O
urogenital NN O B-Disease
abnormalities NN O I-Disease
and NN O O
/ NN O O
or NN O O
WT NN O B-Disease
. NN O O

We NN O O
report NN O O
WT1 NN O O
heterozygous NN O O
mutations NN O O
in NN O O
16 NN O O
patients NN O O
, NN O O
4 NN O O
of NN O O
whom NN O O
presented NN O O
with NN O O
IDMS NN O B-Disease
. NN O O

One NN O O
male NN O O
and NN O O
two NN O O
female NN O O
IDMS NN O B-Disease
patients NN O O
with NN O O
WT1 NN O O
mutations NN O O
underwent NN O O
normal NN O O
puberty NN O O
. NN O O

Two NN O O
mutations NN O O
associated NN O O
with NN O O
IDMS NN O B-Disease
are NN O O
different NN O O
from NN O O
those NN O O
described NN O O
in NN O O
DDS NN O B-Disease
patients NN O O
. NN O O

No NN O O
WT1 NN O O
mutations NN O O
were NN O O
detected NN O O
in NN O O
the NN O O
six NN O O
other NN O O
IDMS NN O B-Disease
patients NN O O
, NN O O
suggesting NN O O
genetic NN O O
heterogeneity NN O O
of NN O O
this NN O O
disease NN O O
. NN O O

We NN O O
analyzed NN O O
genotype NN O O
/ NN O O
phenotype NN O O
correlations NN O O
, NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
constitution NN O O
of NN O O
a NN O O
WT1 NN O O
mutation NN O O
database NN O O
of NN O O
84 NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
, NN O O
to NN O O
compare NN O O
the NN O O
distribution NN O O
and NN O O
type NN O O
of NN O O
mutations NN O O
, NN O O
according NN O O
to NN O O
the NN O O
different NN O O
symptoms NN O O
. NN O O

This NN O O
demonstrated NN O O
( NN O O
1 NN O O
) NN O O
the NN O O
association NN O O
between NN O O
mutations NN O O
in NN O O
exons NN O O
8 NN O O
and NN O O
9 NN O O
and NN O O
DMS NN O B-Disease
; NN O O
( NN O O
2 NN O O
) NN O O
among NN O O
patients NN O O
with NN O O
DMS NN O B-Disease
, NN O O
a NN O O
higher NN O O
frequency NN O O
of NN O O
exon NN O O
8 NN O O
mutations NN O O
among NN O O
46 NN O O
, NN O O
XY NN O O
patients NN O O
with NN O O
female NN O O
phenotype NN O O
than NN O O
among NN O O
46 NN O O
, NN O O
XY NN O O
patients NN O O
with NN O O
sexual NN O O
ambiguity NN O O
or NN O O
male NN O O
phenotype NN O O
; NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
statistically NN O O
significant NN O O
evidence NN O O
that NN O O
mutations NN O O
in NN O O
exons NN O O
8 NN O O
and NN O O
9 NN O O
preferentially NN O O
affect NN O O
amino NN O O
acids NN O O
with NN O O
different NN O O
functions NN O O
. NN O O
. NN O O

The NN O O
185delAG NN O O
BRCA1 NN O O
mutation NN O O
originated NN O O
before NN O O
the NN O O
dispersion NN O O
of NN O O
Jews NN O O
in NN O O
the NN O O
diaspora NN O O
and NN O O
is NN O O
not NN O O
limited NN O O
to NN O O
Ashkenazim NN O O
. NN O O

The NN O O
185delAG NN O O
mutation NN O O
in NN O O
BRCA1 NN O O
is NN O O
detected NN O O
in NN O O
Ashkenazi NN O O
Jews NN O O
both NN O O
in NN O O
familial NN O B-Disease
breast NN O I-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
and NN O O
in NN O O
the NN O O
general NN O O
population NN O O
. NN O O

All NN O O
tested NN O O
Ashkenazi NN O O
mutation NN O O
carriers NN O O
share NN O O
the NN O O
same NN O O
allelic NN O O
pattern NN O O
at NN O O
the NN O O
BRCA1 NN O O
locus NN O O
. NN O O

Our NN O O
previous NN O O
study NN O O
showed NN O O
that NN O O
this NN O O
Ashkenazi NN O O
mutation NN O O
also NN O O
occurs NN O O
in NN O O
Iraqi NN O O
Jews NN O O
with NN O O
a NN O O
similar NN O O
allelic NN O O
pattern NN O O
. NN O O

We NN O O
extended NN O O
our NN O O
analysis NN O O
to NN O O
other NN O O
non NN O O
- NN O O
Ashkenazi NN O O
subsets NN O O
354 NN O O
of NN O O
Moroccan NN O O
origin NN O O
, NN O O
200 NN O O
Yemenites NN O O
and NN O O
150 NN O O
Iranian NN O O
Jews NN O O
. NN O O

Heteroduplex NN O O
analysis NN O O
complemented NN O O
by NN O O
direct NN O O
DNA NN O O
sequencing NN O O
of NN O O
abnormally NN O O
migrating NN O O
bands NN O O
were NN O O
employed NN O O
. NN O O

Four NN O O
of NN O O
Moroccan NN O O
origin NN O O
( NN O O
1 NN O O
. NN O O
1 NN O O
% NN O O
) NN O O
and NN O O
none NN O O
of NN O O
the NN O O
Yemenites NN O O
or NN O O
Iranians NN O O
was NN O O
a NN O O
carrier NN O O
of NN O O
the NN O O
185delAG NN O O
mutation NN O O
. NN O O

BRCA1 NN O O
allelic NN O O
patterns NN O O
were NN O O
determined NN O O
for NN O O
four NN O O
of NN O O
these NN O O
individuals NN O O
and NN O O
for NN O O
12 NN O O
additional NN O O
non NN O O
- NN O O
Ashkenazi NN O O
185delAG NN O O
mutation NN O O
carriers NN O O
who NN O O
had NN O O
breast NN O B-Disease
/ NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

Six NN O O
non NN O O
- NN O O
Ashkenazi NN O O
individuals NN O O
shared NN O O
the NN O O
common NN O O
Ashkenazi NN O O
haplotype NN O O
, NN O O
four NN O O
had NN O O
a NN O O
closely NN O O
related NN O O
pattern NN O O
, NN O O
and NN O O
the NN O O
rest NN O O
( NN O O
n NN O O
= NN O O
6 NN O O
) NN O O
displayed NN O O
a NN O O
distinct NN O O
BRCA1 NN O O
allelic NN O O
pattern NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
the NN O O
185delAG NN O O
BRCA1 NN O O
mutation NN O O
occurs NN O O
in NN O O
some NN O O
non NN O O
- NN O O
Ashkenazi NN O O
populations NN O O
at NN O O
rates NN O O
comparable NN O O
with NN O O
that NN O O
of NN O O
Ashkenazim NN O O
. NN O O

The NN O O
majority NN O O
of NN O O
Jewish NN O O
185delAG NN O O
mutation NN O O
carriers NN O O
have NN O O
a NN O O
common NN O O
allelic NN O O
pattern NN O O
, NN O O
supporting NN O O
the NN O O
founder NN O O
effect NN O O
notion NN O O
, NN O O
but NN O O
dating NN O O
the NN O O
mutations NN O O
origin NN O O
to NN O O
an NN O O
earlier NN O O
date NN O O
than NN O O
currently NN O O
estimated NN O O
. NN O O

However NN O O
, NN O O
the NN O O
different NN O O
allelic NN O O
pattern NN O O
at NN O O
the NN O O
BRCA1 NN O O
locus NN O O
even NN O O
in NN O O
some NN O O
Jewish NN O O
mutation NN O O
carriers NN O O
, NN O O
might NN O O
suggest NN O O
that NN O O
the NN O O
mutation NN O O
arose NN O O
independently NN O O
. NN O O
. NN O O

Crystal NN O O
structure NN O O
of NN O O
the NN O O
hemochromatosis NN O B-Disease
protein NN O O
HFE NN O O
and NN O O
characterization NN O O
of NN O O
its NN O O
interaction NN O O
with NN O O
transferrin NN O O
receptor NN O O
. NN O O

HFE NN O O
is NN O O
an NN O O
MHC NN O O
- NN O O
related NN O O
protein NN O O
that NN O O
is NN O O
mutated NN O O
in NN O O
the NN O O
iron NN O B-Disease
- NN O I-Disease
overload NN O I-Disease
disease NN O I-Disease
hereditary NN O B-Disease
hemochromatosis NN O I-Disease
. NN O O

HFE NN O O
binds NN O O
to NN O O
transferrin NN O O
receptor NN O O
( NN O O
TfR NN O O
) NN O O
and NN O O
reduces NN O O
its NN O O
affinity NN O O
for NN O O
iron NN O O
- NN O O
loaded NN O O
transferrin NN O O
, NN O O
implicating NN O O
HFE NN O O
in NN O O
iron NN O O
metabolism NN O O
. NN O O

The NN O O
2 NN O O
. NN O O

6 NN O O
A NN O O
crystal NN O O
structure NN O O
of NN O O
HFE NN O O
reveals NN O O
the NN O O
locations NN O O
of NN O O
hemochromatosis NN O B-Disease
mutations NN O O
and NN O O
a NN O O
patch NN O O
of NN O O
histidines NN O O
that NN O O
could NN O O
be NN O O
involved NN O O
in NN O O
pH NN O O
- NN O O
dependent NN O O
interactions NN O O
. NN O O

We NN O O
also NN O O
demonstrate NN O O
that NN O O
soluble NN O O
TfR NN O O
and NN O O
HFE NN O O
bind NN O O
tightly NN O O
at NN O O
the NN O O
basic NN O O
pH NN O O
of NN O O
the NN O O
cell NN O O
surface NN O O
, NN O O
but NN O O
not NN O O
at NN O O
the NN O O
acidic NN O O
pH NN O O
of NN O O
intracellular NN O O
vesicles NN O O
. NN O O

TfR NN O O
HFE NN O O
stoichiometry NN O O
( NN O O
2 NN O O
1 NN O O
) NN O O
differs NN O O
from NN O O
TfR NN O O
transferrin NN O O
stoichiometry NN O O
( NN O O
2 NN O O
2 NN O O
) NN O O
, NN O O
implying NN O O
a NN O O
different NN O O
mode NN O O
of NN O O
binding NN O O
for NN O O
HFE NN O O
and NN O O
transferrin NN O O
to NN O O
TfR NN O O
, NN O O
consistent NN O O
with NN O O
our NN O O
demonstration NN O O
that NN O O
HFE NN O O
, NN O O
transferrin NN O O
, NN O O
and NN O O
TfR NN O O
form NN O O
a NN O O
ternary NN O O
complex NN O O
. NN O O

Identification NN O O
of NN O O
three NN O O
novel NN O O
mutations NN O O
and NN O O
a NN O O
high NN O O
frequency NN O O
of NN O O
the NN O O
Arg778Leu NN O O
mutation NN O O
in NN O O
Korean NN O O
patients NN O O
with NN O O
Wilson NN O B-Disease
disease NN O I-Disease
. NN O O

Four NN O O
mutations NN O O
- NN O O
- NN O O
R778L NN O O
, NN O O
A874V NN O O
, NN O O
L1083F NN O O
, NN O O
and NN O O
2304delC NN O O
- NN O O
- NN O O
in NN O O
the NN O O
copper NN O O
- NN O O
transporting NN O O
enzyme NN O O
, NN O O
P NN O O
- NN O O
type NN O O
ATPase NN O O
( NN O O
ATP7B NN O O
) NN O O
, NN O O
were NN O O
identified NN O O
in NN O O
Korean NN O O
Patients NN O O
with NN O O
Wilson NN O B-Disease
disease NN O I-Disease
. NN O O

Arg778Leu NN O O
, NN O O
the NN O O
most NN O O
frequently NN O O
reported NN O O
mutation NN O O
of NN O O
this NN O O
enzyme NN O O
, NN O O
was NN O O
found NN O O
in NN O O
six NN O O
of NN O O
eight NN O O
unrelated NN O O
patients NN O O
studied NN O O
, NN O O
an NN O O
allele NN O O
frequency NN O O
of NN O O
37 NN O O
. NN O O

5 NN O O
% NN O O
, NN O O
which NN O O
is NN O O
considerably NN O O
higher NN O O
than NN O O
those NN O O
in NN O O
other NN O O
Asian NN O O
populations NN O O
. NN O O

The NN O O
novel NN O O
single NN O O
nucleotide NN O O
deletion NN O O
, NN O O
2304delC NN O O
, NN O O
was NN O O
found NN O O
in NN O O
one NN O O
patient NN O O
. NN O O

Since NN O O
a NN O O
mutation NN O O
at NN O O
cDNA NN O O
nucleotide NN O O
2302 NN O O
( NN O O
2302insC NN O O
) NN O O
had NN O O
been NN O O
previously NN O O
described NN O O
, NN O O
this NN O O
region NN O O
of NN O O
the NN O O
ATP7B NN O O
gene NN O O
may NN O O
be NN O O
susceptible NN O O
to NN O O
gene NN O O
rearrangements NN O O
causing NN O O
Wilson NN O B-Disease
disease NN O I-Disease
. NN O O

Disruption NN O O
of NN O O
splicing NN O O
regulated NN O O
by NN O O
a NN O O
CUG NN O O
- NN O O
binding NN O O
protein NN O O
in NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
. NN O O

Myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
a NN O O
CTG NN O O
expansion NN O O
in NN O O
the NN O O
3 NN O O
untranslated NN O O
region NN O O
of NN O O
the NN O O
DM NN O B-Disease
gene NN O O
. NN O O

One NN O O
model NN O O
of NN O O
DM NN O B-Disease
pathogenesis NN O O
suggests NN O O
that NN O O
RNAs NN O O
from NN O O
the NN O O
expanded NN O O
allele NN O O
create NN O O
a NN O O
gain NN O O
- NN O O
of NN O O
- NN O O
function NN O O
mutation NN O O
by NN O O
the NN O O
inappropriate NN O O
binding NN O O
of NN O O
proteins NN O O
to NN O O
the NN O O
CUG NN O O
repeats NN O O
. NN O O

Data NN O O
presented NN O O
here NN O O
indicate NN O O
that NN O O
the NN O O
conserved NN O O
heterogeneous NN O O
nuclear NN O O
ribonucleoprotein NN O O
, NN O O
CUG NN O O
- NN O O
binding NN O O
protein NN O O
( NN O O
CUG NN O O
- NN O O
BP NN O O
) NN O O
, NN O O
may NN O O
mediate NN O O
the NN O O
trans NN O O
- NN O O
dominant NN O O
effect NN O O
of NN O O
the NN O O
RNA NN O O
. NN O O

CUG NN O O
- NN O O
BP NN O O
was NN O O
found NN O O
to NN O O
bind NN O O
to NN O O
the NN O O
human NN O O
cardiac NN O O
troponin NN O O
T NN O O
( NN O O
cTNT NN O O
) NN O O
pre NN O O
- NN O O
messenger NN O O
RNA NN O O
and NN O O
regulate NN O O
its NN O O
alternative NN O O
splicing NN O O
. NN O O

Splicing NN O O
of NN O O
cTNT NN O O
was NN O O
disrupted NN O O
in NN O O
DM NN O B-Disease
striated NN O O
muscle NN O O
and NN O O
in NN O O
normal NN O O
cells NN O O
expressing NN O O
transcripts NN O O
that NN O O
contain NN O O
CUG NN O O
repeats NN O O
. NN O O

Altered NN O O
expression NN O O
of NN O O
genes NN O O
regulated NN O O
posttranscriptionally NN O O
by NN O O
CUG NN O O
- NN O O
BP NN O O
therefore NN O O
may NN O O
contribute NN O O
to NN O O
DM NN O B-Disease
pathogenesis NN O O
. NN O O
. NN O O

Identification NN O O
of NN O O
a NN O O
novel NN O O
nonsense NN O O
mutation NN O O
and NN O O
a NN O O
missense NN O O
substitution NN O O
in NN O O
the NN O O
vasopressin NN O O
- NN O O
neurophysin NN O O
II NN O O
gene NN O O
in NN O O
two NN O O
Spanish NN O O
kindreds NN O O
with NN O O
familial NN O B-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
. NN O O

Familial NN O B-Disease
neurohypophyseal NN O I-Disease
diabetes NN O I-Disease
insipidus NN O I-Disease
( NN O O
FNDI NN O B-Disease
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disease NN O I-Disease
caused NN O O
by NN O O
deficiency NN O O
in NN O O
the NN O O
antidiuretic NN O O
hormone NN O O
arginine NN O O
vasopressin NN O O
( NN O O
AVP NN O O
) NN O O
encoded NN O O
by NN O O
the NN O O
AVP NN O O
- NN O O
neurophysin NN O O
II NN O O
( NN O O
AVP NN O O
- NN O O
NPII NN O O
) NN O O
gene NN O O
on NN O O
chromosome NN O O
20p13 NN O O
. NN O O

In NN O O
this NN O O
study NN O O
, NN O O
we NN O O
analyzed NN O O
two NN O O
families NN O O
with NN O O
FNDI NN O B-Disease
using NN O O
direct NN O O
automated NN O O
fluorescent NN O O
, NN O O
solid NN O O
phase NN O O
, NN O O
single NN O O
- NN O O
stranded NN O O
DNA NN O O
sequencing NN O O
of NN O O
PCR NN O O
- NN O O
amplified NN O O
AVP NN O O
- NN O O
NPII NN O O
DNA NN O O
. NN O O

In NN O O
one NN O O
of NN O O
the NN O O
families NN O O
, NN O O
affected NN O O
individuals NN O O
presented NN O O
a NN O O
novel NN O O
nonsense NN O O
mutation NN O O
in NN O O
exon NN O O
3 NN O O
of NN O O
the NN O O
gene NN O O
, NN O O
consisting NN O O
in NN O O
a NN O O
G NN O O
to NN O O
T NN O O
transition NN O O
at NN O O
nucleotide NN O O
2101 NN O O
, NN O O
which NN O O
produces NN O O
a NN O O
stop NN O O
signal NN O O
in NN O O
codon NN O O
82 NN O O
( NN O O
Glu NN O O
) NN O O
of NN O O
NPII NN O O
. NN O O

The NN O O
premature NN O O
termination NN O O
eliminates NN O O
part NN O O
of NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
domain NN O O
of NN O O
NPII NN O O
, NN O O
including NN O O
a NN O O
cysteine NN O O
residue NN O O
in NN O O
position NN O O
85 NN O O
, NN O O
which NN O O
could NN O O
be NN O O
involved NN O O
in NN O O
the NN O O
correct NN O O
folding NN O O
of NN O O
the NN O O
prohormone NN O O
. NN O O

In NN O O
the NN O O
second NN O O
family NN O O
, NN O O
a NN O O
G279A NN O O
substitution NN O O
at NN O O
position NN O O
- NN O O
1 NN O O
of NN O O
the NN O O
signal NN O O
peptide NN O O
was NN O O
observed NN O O
in NN O O
all NN O O
affected NN O O
individuals NN O O
. NN O O

This NN O O
missense NN O O
mutation NN O O
, NN O O
which NN O O
replaces NN O O
Ala NN O O
with NN O O
Thr NN O O
, NN O O
is NN O O
frequent NN O O
among NN O O
FNDI NN O B-Disease
patients NN O O
and NN O O
is NN O O
thought NN O O
to NN O O
reduce NN O O
the NN O O
efficiency NN O O
of NN O O
cleavage NN O O
by NN O O
signal NN O O
peptidases NN O O
. NN O O
. NN O O

Genetic NN O O
heterogeneity NN O O
of NN O O
Saethre NN O B-Disease
- NN O I-Disease
Chotzen NN O I-Disease
syndrome NN O I-Disease
, NN O O
due NN O O
to NN O O
TWIST NN O O
and NN O O
FGFR NN O O
mutations NN O O
. NN O O

Thirty NN O O
- NN O O
two NN O O
unrelated NN O O
patients NN O O
with NN O O
features NN O O
of NN O O
Saethre NN O B-Disease
- NN O I-Disease
Chotzen NN O I-Disease
syndrome NN O I-Disease
, NN O O
a NN O O
common NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
condition NN O I-Disease
of NN O O
craniosynostosis NN O B-Disease
and NN O O
limb NN O B-Disease
anomalies NN O I-Disease
, NN O O
were NN O O
screened NN O O
for NN O O
mutations NN O O
in NN O O
TWIST NN O O
, NN O O
FGFR2 NN O O
, NN O O
and NN O O
FGFR3 NN O O
. NN O O

Nine NN O O
novel NN O O
and NN O O
three NN O O
recurrent NN O O
TWIST NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
12 NN O O
families NN O O
. NN O O

Seven NN O O
families NN O O
were NN O O
found NN O O
to NN O O
have NN O O
the NN O O
FGFR3 NN O O
P250R NN O O
mutation NN O O
, NN O O
and NN O O
one NN O O
individual NN O O
was NN O O
found NN O O
to NN O O
have NN O O
an NN O O
FGFR2 NN O O
VV269 NN O O
- NN O O
270 NN O O
deletion NN O O
. NN O O

To NN O O
date NN O O
, NN O O
our NN O O
detection NN O O
rate NN O O
for NN O O
TWIST NN O O
or NN O O
FGFR NN O O
mutations NN O O
is NN O O
68 NN O O
% NN O O
in NN O O
our NN O O
Saethre NN O B-Disease
- NN O I-Disease
Chotzen NN O I-Disease
syndrome NN O I-Disease
patients NN O O
, NN O O
including NN O O
our NN O O
five NN O O
patients NN O O
elsewhere NN O O
reported NN O O
with NN O O
TWIST NN O O
mutations NN O O
. NN O O

More NN O O
than NN O O
35 NN O O
different NN O O
TWIST NN O O
mutations NN O O
are NN O O
now NN O O
known NN O O
in NN O O
the NN O O
literature NN O O
. NN O O

The NN O O
most NN O O
common NN O O
phenotypic NN O O
features NN O O
, NN O O
present NN O O
in NN O O
more NN O O
than NN O O
a NN O O
third NN O O
of NN O O
our NN O O
patients NN O O
with NN O O
TWIST NN O O
mutations NN O O
, NN O O
are NN O O
coronal NN O B-Disease
synostosis NN O I-Disease
, NN O O
brachycephaly NN O B-Disease
, NN O O
low NN O B-Disease
frontal NN O I-Disease
hairline NN O I-Disease
, NN O O
facial NN O B-Disease
asymmetry NN O I-Disease
, NN O O
ptosis NN O B-Disease
, NN O O
hypertelorism NN O B-Disease
, NN O O
broad NN O B-Disease
great NN O I-Disease
toes NN O I-Disease
, NN O O
and NN O O
clinodactyly NN O B-Disease
. NN O O

Significant NN O O
intra NN O O
- NN O O
and NN O O
interfamilial NN O O
phenotypic NN O O
variability NN O O
is NN O O
present NN O O
for NN O O
either NN O O
TWIST NN O O
mutations NN O O
or NN O O
FGFR NN O O
mutations NN O O
. NN O O

The NN O O
overlap NN O O
in NN O O
clinical NN O O
features NN O O
and NN O O
the NN O O
presence NN O O
, NN O O
in NN O O
the NN O O
same NN O O
genes NN O O
, NN O O
of NN O O
mutations NN O O
for NN O O
more NN O O
than NN O O
one NN O O
craniosynostotic NN O B-Disease
condition NN O I-Disease
- NN O O
such NN O O
as NN O O
Saethre NN O B-Disease
- NN O I-Disease
Chotzen NN O I-Disease
, NN O I-Disease
Crouzon NN O I-Disease
, NN O I-Disease
and NN O I-Disease
Pfeiffer NN O I-Disease
syndromes NN O I-Disease
- NN O O
support NN O O
the NN O O
hypothesis NN O O
that NN O O
TWIST NN O O
and NN O O
FGFRs NN O O
are NN O O
components NN O O
of NN O O
the NN O O
same NN O O
molecular NN O O
pathway NN O O
involved NN O O
in NN O O
the NN O O
modulation NN O O
of NN O O
craniofacial NN O O
and NN O O
limb NN O O
development NN O O
in NN O O
humans NN O O
. NN O O
. NN O O

Mutation NN O O
analysis NN O O
of NN O O
UBE3A NN O O
in NN O O
Angelman NN O B-Disease
syndrome NN O I-Disease
patients NN O O
. NN O O

Angelman NN O B-Disease
syndrome NN O I-Disease
( NN O O
AS NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
chromosome NN O O
15q11 NN O O
- NN O O
q13 NN O O
deletions NN O O
of NN O O
maternal NN O O
origin NN O O
, NN O O
by NN O O
paternal NN O O
uniparental NN O B-Disease
disomy NN O I-Disease
( NN O O
UPD NN O B-Disease
) NN O O
15 NN O O
, NN O O
by NN O O
imprinting NN O O
defects NN O O
, NN O O
and NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
UBE3A NN O O
gene NN O O
. NN O O

UBE3A NN O O
encodes NN O O
a NN O O
ubiquitin NN O O
- NN O O
protein NN O O
ligase NN O O
and NN O O
shows NN O O
brain NN O O
- NN O O
specific NN O O
imprinting NN O O
. NN O O

Here NN O O
we NN O O
describe NN O O
UBE3A NN O O
coding NN O O
- NN O O
region NN O O
mutations NN O O
detected NN O O
by NN O O
SSCP NN O O
analysis NN O O
in NN O O
13 NN O O
AS NN O B-Disease
individuals NN O O
or NN O O
families NN O O
. NN O O

Two NN O O
identical NN O O
de NN O O
novo NN O O
5 NN O O
- NN O O
bp NN O O
duplications NN O O
in NN O O
exon NN O O
16 NN O O
were NN O O
found NN O O
. NN O O

Among NN O O
the NN O O
other NN O O
11 NN O O
unique NN O O
mutations NN O O
, NN O O
8 NN O O
were NN O O
small NN O O
deletions NN O O
or NN O O
insertions NN O O
predicted NN O O
to NN O O
cause NN O O
frameshifts NN O O
, NN O O
1 NN O O
was NN O O
a NN O O
mutation NN O O
to NN O O
a NN O O
stop NN O O
codon NN O O
, NN O O
1 NN O O
was NN O O
a NN O O
missense NN O O
mutation NN O O
, NN O O
and NN O O
1 NN O O
was NN O O
predicted NN O O
to NN O O
cause NN O O
insertion NN O O
of NN O O
an NN O O
isoleucine NN O O
in NN O O
the NN O O
hect NN O O
domain NN O O
of NN O O
the NN O O
UBE3A NN O O
protein NN O O
, NN O O
which NN O O
functions NN O O
in NN O O
E2 NN O O
binding NN O O
and NN O O
ubiquitin NN O O
transfer NN O O
. NN O O

Eight NN O O
of NN O O
the NN O O
cases NN O O
were NN O O
familial NN O O
, NN O O
and NN O O
five NN O O
were NN O O
sporadic NN O O
. NN O O

In NN O O
two NN O O
familial NN O O
cases NN O O
and NN O O
one NN O O
sporadic NN O O
case NN O O
, NN O O
mosaicism NN O O
for NN O O
UBE3A NN O O
mutations NN O O
was NN O O
detected NN O O
in NN O O
the NN O O
mother NN O O
of NN O O
three NN O O
AS NN O B-Disease
sons NN O O
, NN O O
in NN O O
the NN O O
maternal NN O O
grandfather NN O O
of NN O O
two NN O O
AS NN O B-Disease
first NN O O
cousins NN O O
, NN O O
and NN O O
in NN O O
the NN O O
mother NN O O
of NN O O
an NN O O
AS NN O B-Disease
daughter NN O O
. NN O O

The NN O O
frequencies NN O O
with NN O O
which NN O O
we NN O O
detected NN O O
mutations NN O O
were NN O O
5 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
of NN O O
35 NN O O
in NN O O
sporadic NN O O
cases NN O O
and NN O O
8 NN O O
( NN O O
80 NN O O
% NN O O
) NN O O
of NN O O
10 NN O O
in NN O O
familial NN O O
cases NN O O
. NN O O
. NN O O

The NN O O
hemochromatosis NN O B-Disease
845 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
and NN O O
187 NN O O
C NN O O
- NN O O
- NN O O
> NN O O
G NN O O
mutations NN O O
: NN O O
prevalence NN O O
in NN O O
non NN O O
- NN O O
Caucasian NN O O
populations NN O O
. NN O O

Hemochromatosis NN O B-Disease
, NN O O
the NN O O
inherited NN O B-Disease
disorder NN O I-Disease
of NN O I-Disease
iron NN O I-Disease
metabolism NN O I-Disease
, NN O O
leads NN O O
, NN O O
if NN O O
untreated NN O O
, NN O O
to NN O O
progressive NN O O
iron NN O B-Disease
overload NN O I-Disease
and NN O O
premature NN O B-Disease
death NN O I-Disease
. NN O O

The NN O O
hemochromatosis NN O B-Disease
gene NN O O
, NN O O
HFE NN O O
, NN O O
recently NN O O
has NN O O
been NN O O
identified NN O O
, NN O O
and NN O O
characterization NN O O
of NN O O
this NN O O
gene NN O O
has NN O O
shown NN O O
that NN O O
it NN O O
contains NN O O
two NN O O
mutations NN O O
that NN O O
result NN O O
in NN O O
amino NN O O
acid NN O O
substitutions NN O O
- NN O O
cDNA NN O O
nucleotides NN O O
845 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
( NN O O
C282Y NN O O
) NN O O
and NN O O
187 NN O O
C NN O O
- NN O O
- NN O O
> NN O O
G NN O O
( NN O O
H63D NN O O
) NN O O
. NN O O

Although NN O O
hemochromatosis NN O B-Disease
is NN O O
common NN O O
in NN O O
Caucasians NN O O
, NN O O
affecting NN O O
> NN O O
= NN O O
1 NN O O
/ NN O O
300 NN O O
individuals NN O O
of NN O O
northern NN O O
European NN O O
origin NN O O
, NN O O
it NN O O
has NN O O
not NN O O
been NN O O
recognized NN O O
in NN O O
other NN O O
populations NN O O
. NN O O

The NN O O
present NN O O
study NN O O
used NN O O
PCR NN O O
and NN O O
restriction NN O O
- NN O O
enzyme NN O O
digestion NN O O
to NN O O
analyze NN O O
the NN O O
frequency NN O O
of NN O O
the NN O O
845 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
and NN O O
187 NN O O
C NN O O
- NN O O
- NN O O
> NN O O
G NN O O
mutations NN O O
in NN O O
HLA NN O O
- NN O O
typed NN O O
samples NN O O
from NN O O
non NN O O
- NN O O
Caucasian NN O O
populations NN O O
, NN O O
comprising NN O O
Australian NN O O
Aboriginal NN O O
, NN O O
Chinese NN O O
, NN O O
and NN O O
Pacific NN O O
Islanders NN O O
. NN O O

Results NN O O
showed NN O O
that NN O O
the NN O O
845 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
mutation NN O O
was NN O O
present NN O O
in NN O O
these NN O O
populations NN O O
( NN O O
allele NN O O
frequency NN O O
0 NN O O
. NN O O
32 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
, NN O O
furthermore NN O O
, NN O O
it NN O O
was NN O O
always NN O O
seen NN O O
in NN O O
conjunction NN O O
with NN O O
HLA NN O O
haplotypes NN O O
common NN O O
in NN O O
Caucasians NN O O
, NN O O
suggesting NN O O
that NN O O
845 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
may NN O O
have NN O O
been NN O O
introduced NN O O
into NN O O
these NN O O
populations NN O O
by NN O O
Caucasian NN O O
admixture NN O O
. NN O O

187 NN O O
C NN O O
- NN O O
- NN O O
> NN O O
G NN O O
was NN O O
present NN O O
at NN O O
an NN O O
allele NN O O
frequency NN O O
of NN O O
2 NN O O
. NN O O

68 NN O O
% NN O O
in NN O O
the NN O O
two NN O O
populations NN O O
analyzed NN O O
( NN O O
Australian NN O O
Aboriginal NN O O
and NN O O
Chinese NN O O
) NN O O
. NN O O

In NN O O
the NN O O
Australian NN O O
Aboriginal NN O O
samples NN O O
, NN O O
187 NN O O
C NN O O
- NN O O
- NN O O
> NN O O
G NN O O
was NN O O
found NN O O
to NN O O
be NN O O
associated NN O O
with NN O O
HLA NN O O
haplotypes NN O O
common NN O O
in NN O O
Caucasians NN O O
, NN O O
suggesting NN O O
that NN O O
it NN O O
was NN O O
introduced NN O O
by NN O O
recent NN O O
admixture NN O O
. NN O O

In NN O O
the NN O O
Chinese NN O O
samples NN O O
analyzed NN O O
, NN O O
187 NN O O
C NN O O
- NN O O
- NN O O
> NN O O
G NN O O
was NN O O
present NN O O
in NN O O
association NN O O
with NN O O
a NN O O
wide NN O O
variety NN O O
of NN O O
HLA NN O O
haplotypes NN O O
, NN O O
showing NN O O
this NN O O
mutation NN O O
to NN O O
be NN O O
widespread NN O O
and NN O O
likely NN O O
to NN O O
predate NN O O
the NN O O
more NN O O
genetically NN O O
restricted NN O O
845 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
A NN O O
mutation NN O O
. NN O O

Genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
in NN O O
attenuated NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
. NN O O

Germ NN O O
- NN O O
line NN O O
mutations NN O O
of NN O O
the NN O O
tumor NN O B-Disease
suppressor NN O O
APC NN O O
are NN O O
implicated NN O O
in NN O O
attenuated NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
( NN O O
AAPC NN O B-Disease
) NN O O
, NN O O
a NN O O
variant NN O O
of NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
. NN O O

AAPC NN O B-Disease
is NN O O
recognized NN O O
by NN O O
the NN O O
occurrence NN O O
of NN O O
< NN O O
100 NN O O
colonic NN O B-Disease
adenomas NN O I-Disease
and NN O O
a NN O O
later NN O O
onset NN O O
of NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
( NN O O
age NN O O
> NN O O
40 NN O O
years NN O O
) NN O O
. NN O O

The NN O O
aim NN O O
of NN O O
this NN O O
study NN O O
was NN O O
to NN O O
assess NN O O
genotype NN O O
- NN O O
phenotype NN O O
correlations NN O O
in NN O O
AAPC NN O B-Disease
families NN O O
. NN O O

By NN O O
protein NN O O
- NN O O
truncation NN O O
test NN O O
( NN O O
PTT NN O O
) NN O O
assay NN O O
, NN O O
the NN O O
entire NN O O
coding NN O O
region NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
was NN O O
screened NN O O
in NN O O
affected NN O O
individuals NN O O
from NN O O
11 NN O O
AAPC NN O B-Disease
kindreds NN O O
, NN O O
and NN O O
their NN O O
phenotypic NN O O
differences NN O O
were NN O O
examined NN O O
. NN O O

Five NN O O
novel NN O O
germ NN O O
- NN O O
line NN O O
APC NN O B-Disease
mutations NN O O
were NN O O
identified NN O O
in NN O O
seven NN O O
kindreds NN O O
. NN O O

Mutations NN O O
were NN O O
located NN O O
in NN O O
three NN O O
different NN O O
regions NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
( NN O O
1 NN O O
) NN O O
at NN O O
the NN O O
5 NN O O
end NN O O
spanning NN O O
exons NN O O
4 NN O O
and NN O O
5 NN O O
, NN O O
( NN O O
2 NN O O
) NN O O
within NN O O
exon NN O O
9 NN O O
, NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
at NN O O
the NN O O
3 NN O O
distal NN O O
end NN O O
of NN O O
the NN O O
gene NN O O
. NN O O

Variability NN O O
in NN O O
the NN O O
number NN O O
of NN O O
colorectal NN O B-Disease
adenomas NN O I-Disease
was NN O O
most NN O O
apparent NN O O
in NN O O
individuals NN O O
with NN O O
mutations NN O O
in NN O O
region NN O O
1 NN O O
, NN O O
and NN O O
upper NN O O
- NN O O
gastrointestinal NN O O
manifestations NN O O
were NN O O
more NN O O
severe NN O O
in NN O O
them NN O O
. NN O O

In NN O O
individuals NN O O
with NN O O
mutations NN O O
in NN O O
either NN O O
region NN O O
2 NN O O
or NN O O
region NN O O
3 NN O O
, NN O O
the NN O O
average NN O O
number NN O O
of NN O O
adenomas NN O B-Disease
tended NN O O
to NN O O
be NN O O
lower NN O O
than NN O O
those NN O O
in NN O O
individuals NN O O
with NN O O
mutations NN O O
in NN O O
region NN O O
1 NN O O
, NN O O
although NN O O
age NN O O
at NN O O
diagnosis NN O O
was NN O O
similar NN O O
. NN O O

In NN O O
all NN O O
AAPC NN O B-Disease
kindreds NN O O
, NN O O
a NN O O
predominance NN O O
of NN O O
right NN O O
- NN O O
sided NN O O
colorectal NN O B-Disease
adenomas NN O I-Disease
and NN O O
rectal NN O B-Disease
polyp NN O I-Disease
sparing NN O O
was NN O O
observed NN O O
. NN O O

No NN O O
desmoid NN O B-Disease
tumors NN O I-Disease
were NN O O
found NN O O
in NN O O
these NN O O
kindreds NN O O
. NN O O

Our NN O O
data NN O O
suggest NN O O
that NN O O
, NN O O
in NN O O
AAPC NN O B-Disease
families NN O O
, NN O O
the NN O O
location NN O O
of NN O O
the NN O O
APC NN O B-Disease
mutation NN O O
may NN O O
partially NN O O
predict NN O O
specific NN O O
phenotypic NN O O
expression NN O O
. NN O O

This NN O O
should NN O O
help NN O O
in NN O O
the NN O O
design NN O O
of NN O O
tailored NN O O
clinical NN O O
- NN O O
management NN O O
protocols NN O O
in NN O O
this NN O O
subset NN O O
of NN O O
FAP NN O B-Disease
patients NN O O
. NN O O
. NN O O

Wilms NN O B-Disease
' NN O I-Disease
tumor NN O I-Disease
1 NN O O
and NN O O
Dax NN O O
- NN O O
1 NN O O
modulate NN O O
the NN O O
orphan NN O O
nuclear NN O O
receptor NN O O
SF NN O O
- NN O O
1 NN O O
in NN O O
sex NN O O
- NN O O
specific NN O O
gene NN O O
expression NN O O
. NN O O

Products NN O O
of NN O O
steroidogenic NN O O
factor NN O O
1 NN O O
( NN O O
SF NN O O
- NN O O
1 NN O O
) NN O O
and NN O O
Wilms NN O B-Disease
tumor NN O I-Disease
1 NN O O
( NN O O
WT1 NN O O
) NN O O
genes NN O O
are NN O O
essential NN O O
for NN O O
mammalian NN O O
gonadogenesis NN O O
prior NN O O
to NN O O
sexual NN O O
differentiation NN O O
. NN O O

In NN O O
males NN O O
, NN O O
SF NN O O
- NN O O
1 NN O O
participates NN O O
in NN O O
sexual NN O O
development NN O O
by NN O O
regulating NN O O
expression NN O O
of NN O O
the NN O O
polypeptide NN O O
hormone NN O O
Mullerian NN O O
inhibiting NN O O
substance NN O O
( NN O O
MIS NN O O
) NN O O
. NN O O

Here NN O O
, NN O O
we NN O O
show NN O O
that NN O O
WT1 NN O O
- NN O O
KTS NN O O
isoforms NN O O
associate NN O O
and NN O O
synergize NN O O
with NN O O
SF NN O O
- NN O O
1 NN O O
to NN O O
promote NN O O
MIS NN O O
expression NN O O
. NN O O

In NN O O
contrast NN O O
, NN O O
WT1 NN O O
missense NN O O
mutations NN O O
, NN O O
associated NN O O
with NN O O
male NN O B-Disease
pseudohermaphroditism NN O I-Disease
in NN O O
Denys NN O B-Disease
- NN O I-Disease
Drash NN O I-Disease
syndrome NN O I-Disease
, NN O O
fail NN O O
to NN O O
synergize NN O O
with NN O O
SF NN O O
- NN O O
1 NN O O
. NN O O

Additionally NN O O
, NN O O
the NN O O
X NN O O
- NN O O
linked NN O O
, NN O O
candidate NN O O
dosage NN O O
- NN O O
sensitive NN O O
sex NN O O
- NN O O
reversal NN O O
gene NN O O
, NN O O
Dax NN O O
- NN O O
1 NN O O
, NN O O
antagonizes NN O O
synergy NN O O
between NN O O
SF NN O O
- NN O O
1 NN O O
and NN O O
WT1 NN O O
, NN O O
most NN O O
likely NN O O
through NN O O
a NN O O
direct NN O O
interaction NN O O
with NN O O
SF NN O O
- NN O O
1 NN O O
. NN O O

We NN O O
propose NN O O
that NN O O
WT1 NN O O
and NN O O
Dax NN O O
- NN O O
1 NN O O
functionally NN O O
oppose NN O O
each NN O O
other NN O O
in NN O O
testis NN O O
development NN O O
by NN O O
modulating NN O O
SF NN O O
- NN O O
1 NN O O
- NN O O
mediated NN O O
transactivation NN O O
. NN O O
. NN O O

A NN O O
mouse NN O O
model NN O O
for NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
imprinting NN O O
- NN O O
centre NN O O
mutations NN O O
. NN O O

Imprinting NN O O
in NN O O
the NN O O
15q11 NN O O
- NN O O
q13 NN O O
region NN O O
involves NN O O
an NN O O
imprinting NN O O
centre NN O O
( NN O O
IC NN O O
) NN O O
, NN O O
mapping NN O O
in NN O O
part NN O O
to NN O O
the NN O O
promoter NN O O
and NN O O
first NN O O
exon NN O O
of NN O O
SNRPN NN O O
. NN O O

Deletion NN O O
of NN O O
this NN O O
IC NN O O
abolishes NN O O
local NN O O
paternally NN O O
derived NN O O
gene NN O O
expression NN O O
and NN O O
results NN O O
in NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

We NN O O
have NN O O
created NN O O
two NN O O
deletion NN O O
mutations NN O O
in NN O O
mice NN O O
to NN O O
understand NN O O
PWS NN O B-Disease
and NN O O
the NN O O
mechanism NN O O
of NN O O
this NN O O
IC NN O O
. NN O O

Mice NN O O
harbouring NN O O
an NN O O
intragenic NN O O
deletion NN O O
in NN O O
Snrpn NN O O
are NN O O
phenotypically NN O O
normal NN O O
, NN O O
suggesting NN O O
that NN O O
mutations NN O O
of NN O O
SNRPN NN O O
are NN O O
not NN O O
sufficient NN O O
to NN O O
induce NN O O
PWS NN O B-Disease
. NN O O

Mice NN O O
with NN O O
a NN O O
larger NN O O
deletion NN O O
involving NN O O
both NN O O
Snrpn NN O O
and NN O O
the NN O O
putative NN O O
PWS NN O O
- NN O O
IC NN O O
lack NN O O
expression NN O O
of NN O O
the NN O O
imprinted NN O O
genes NN O O
Zfp127 NN O O
( NN O O
mouse NN O O
homologue NN O O
of NN O O
ZNF127 NN O O
) NN O O
, NN O O
Ndn NN O O
and NN O O
Ipw NN O O
, NN O O
and NN O O
manifest NN O O
several NN O O
phenotypes NN O O
common NN O O
to NN O O
PWS NN O B-Disease
infants NN O O
. NN O O

These NN O O
data NN O O
demonstrate NN O O
that NN O O
both NN O O
the NN O O
position NN O O
of NN O O
the NN O O
IC NN O O
and NN O O
its NN O O
role NN O O
in NN O O
the NN O O
coordinate NN O O
expression NN O O
of NN O O
genes NN O O
is NN O O
conserved NN O O
between NN O O
mouse NN O O
and NN O O
human NN O O
, NN O O
and NN O O
indicate NN O O
that NN O O
the NN O O
mouse NN O O
is NN O O
a NN O O
suitable NN O O
model NN O O
system NN O O
in NN O O
which NN O O
to NN O O
investigate NN O O
the NN O O
molecular NN O O
mechanisms NN O O
of NN O O
imprinting NN O O
in NN O O
this NN O O
region NN O O
of NN O O
the NN O O
genome NN O O
. NN O O
. NN O O

Mutations NN O O
of NN O O
the NN O O
ATM NN O O
gene NN O O
detected NN O O
in NN O O
Japanese NN O O
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
patients NN O O
: NN O O
possible NN O O
preponderance NN O O
of NN O O
the NN O O
two NN O O
founder NN O O
mutations NN O O
4612del165 NN O O
and NN O O
7883del5 NN O O
. NN O O

The NN O O
ATM NN O O
( NN O O
A NN O O
- NN O O
T NN O O
, NN O O
mutated NN O O
) NN O O
gene NN O O
on NN O O
human NN O O
chromosome NN O O
11q22 NN O O
. NN O O

3 NN O O
has NN O O
recently NN O O
been NN O O
identified NN O O
as NN O O
the NN O O
gene NN O O
responsible NN O O
for NN O O
the NN O O
human NN O O
recessive NN O B-Disease
disease NN O I-Disease
ataxia NN O B-Disease
- NN O I-Disease
telangiectasia NN O I-Disease
( NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
) NN O O
. NN O O

In NN O O
order NN O O
to NN O O
define NN O O
the NN O O
types NN O O
of NN O O
disease NN O O
- NN O O
causing NN O O
ATM NN O O
mutations NN O O
in NN O O
Japanese NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
patients NN O O
as NN O O
well NN O O
as NN O O
to NN O O
look NN O O
for NN O O
possible NN O O
mutational NN O O
hotspots NN O O
, NN O O
reverse NN O O
- NN O O
transcribed NN O O
RNA NN O O
derived NN O O
from NN O O
ten NN O O
patients NN O O
belonging NN O O
to NN O O
eight NN O O
unrelated NN O O
Japanese NN O O
A NN O B-Disease
- NN O I-Disease
T NN O I-Disease
families NN O O
was NN O O
analyzed NN O O
for NN O O
mutations NN O O
by NN O O
the NN O O
restriction NN O O
endonuclease NN O O
fingerprinting NN O O
method NN O O
. NN O O

As NN O O
has NN O O
been NN O O
reported NN O O
by NN O O
others NN O O
, NN O O
mutations NN O O
that NN O O
lead NN O O
to NN O O
exon NN O O
skipping NN O O
or NN O O
premature NN O O
protein NN O O
truncation NN O O
were NN O O
also NN O O
predominant NN O O
in NN O O
our NN O O
mutants NN O O
. NN O O

Six NN O O
different NN O O
mutations NN O O
were NN O O
identified NN O O
on NN O O
12 NN O O
of NN O O
the NN O O
16 NN O O
alleles NN O O
examined NN O O
. NN O O

Four NN O O
were NN O O
deletions NN O O
involving NN O O
a NN O O
loss NN O O
of NN O O
a NN O O
single NN O O
exon NN O O
exon NN O O
7 NN O O
, NN O O
exon NN O O
16 NN O O
, NN O O
exon NN O O
33 NN O O
or NN O O
exon NN O O
35 NN O O
. NN O O

The NN O O
others NN O O
were NN O O
minute NN O O
deletions NN O O
, NN O O
4649delA NN O O
in NN O O
exon NN O O
33 NN O O
and NN O O
7883del5 NN O O
in NN O O
exon NN O O
55 NN O O
. NN O O

The NN O O
mutations NN O O
4612del165 NN O O
and NN O O
7883del5 NN O O
were NN O O
found NN O O
in NN O O
more NN O O
than NN O O
two NN O O
unrelated NN O O
families NN O O
; NN O O
44 NN O O
% NN O O
( NN O O
7 NN O O
of NN O O
16 NN O O
) NN O O
of NN O O
the NN O O
mutant NN O O
alleles NN O O
had NN O O
one NN O O
of NN O O
the NN O O
two NN O O
mutations NN O O
. NN O O

The NN O O
4612del165 NN O O
mutations NN O O
in NN O O
three NN O O
different NN O O
families NN O O
were NN O O
all NN O O
ascribed NN O O
to NN O O
the NN O O
same NN O O
T NN O O
- NN O O
- NN O O
> NN O O
A NN O O
substitution NN O O
at NN O O
the NN O O
splice NN O O
donor NN O O
site NN O O
in NN O O
intron NN O O
33 NN O O
. NN O O

Microsatellite NN O O
genotyping NN O O
around NN O O
the NN O O
ATM NN O O
locus NN O O
also NN O O
indicated NN O O
that NN O O
a NN O O
common NN O O
haplotype NN O O
was NN O O
shared NN O O
by NN O O
the NN O O
mutant NN O O
alleles NN O O
in NN O O
both NN O O
mutations NN O O
. NN O O

This NN O O
suggests NN O O
that NN O O
these NN O O
two NN O O
founder NN O O
mutations NN O O
may NN O O
be NN O O
predominant NN O O
among NN O O
Japanese NN O O
ATM NN O O
mutant NN O O
alleles NN O O
. NN O O

W474C NN O O
amino NN O O
acid NN O O
substitution NN O O
affects NN O O
early NN O O
processing NN O O
of NN O O
the NN O O
alpha NN O O
- NN O O
subunit NN O O
of NN O O
beta NN O O
- NN O O
hexosaminidase NN O O
A NN O O
and NN O O
is NN O O
associated NN O O
with NN O O
subacute NN O O
G NN O B-Disease
( NN O I-Disease
M2 NN O I-Disease
) NN O I-Disease
gangliosidosis NN O I-Disease
. NN O O

Mutations NN O O
in NN O O
the NN O O
HEXA NN O O
gene NN O O
, NN O O
encoding NN O O
the NN O O
alpha NN O O
- NN O O
subunit NN O O
of NN O O
beta NN O O
- NN O O
hexosaminidase NN O O
A NN O O
( NN O O
Hex NN O O
A NN O O
) NN O O
, NN O O
that NN O O
abolish NN O O
Hex NN O O
A NN O O
enzyme NN O O
activity NN O O
cause NN O O
Tay NN O B-Disease
- NN O I-Disease
Sachs NN O I-Disease
disease NN O I-Disease
( NN O O
TSD NN O B-Disease
) NN O O
, NN O O
the NN O O
fatal NN O O
infantile NN O B-Disease
form NN O I-Disease
of NN O I-Disease
G NN O I-Disease
( NN O I-Disease
M2 NN O I-Disease
) NN O I-Disease
gangliosidosis NN O I-Disease
, NN O I-Disease
Type NN O I-Disease
1 NN O I-Disease
. NN O O

Less NN O O
severe NN O O
, NN O O
subacute NN O O
( NN O O
juvenile NN O O
- NN O O
onset NN O O
) NN O O
and NN O O
chronic NN O O
( NN O O
adult NN O O
- NN O O
onset NN O O
) NN O O
variants NN O O
are NN O O
characterized NN O O
by NN O O
a NN O O
broad NN O O
spectrum NN O O
of NN O O
clinical NN O O
manifestations NN O O
and NN O O
are NN O O
associated NN O O
with NN O O
residual NN O O
levels NN O O
of NN O O
Hex NN O O
A NN O O
enzyme NN O O
activity NN O O
. NN O O

We NN O O
identified NN O O
a NN O O
1422 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
C NN O O
( NN O O
amino NN O O
acid NN O O
W474C NN O O
) NN O O
substitution NN O O
in NN O O
the NN O O
first NN O O
position NN O O
of NN O O
exon NN O O
13 NN O O
of NN O O
HEXA NN O O
of NN O O
a NN O O
non NN O O
- NN O O
Jewish NN O O
proband NN O O
who NN O O
manifested NN O O
a NN O O
subacute NN O O
variant NN O O
of NN O O
G NN O B-Disease
( NN O I-Disease
M2 NN O I-Disease
) NN O I-Disease
gangliosidosis NN O I-Disease
. NN O O

On NN O O
the NN O O
second NN O O
maternally NN O O
inherited NN O O
allele NN O O
, NN O O
we NN O O
identified NN O O
the NN O O
common NN O O
infantile NN O O
disease NN O O
- NN O O
causing NN O O
4 NN O O
- NN O O
bp NN O O
insertion NN O O
, NN O O
+ NN O O
TATC NN O O
1278 NN O O
, NN O O
in NN O O
exon NN O O
11 NN O O
. NN O O

Pulse NN O O
- NN O O
chase NN O O
analysis NN O O
using NN O O
proband NN O O
fibroblasts NN O O
revealed NN O O
that NN O O
the NN O O
W474C NN O O
- NN O O
containing NN O O
alpha NN O O
- NN O O
subunit NN O O
precursor NN O O
was NN O O
normally NN O O
synthesized NN O O
, NN O O
but NN O O
not NN O O
phosphorylated NN O O
or NN O O
secreted NN O O
, NN O O
and NN O O
the NN O O
mature NN O O
lysosomal NN O O
alpha NN O O
- NN O O
subunit NN O O
was NN O O
not NN O O
detected NN O O
. NN O O

When NN O O
the NN O O
W474C NN O O
- NN O O
containing NN O O
alpha NN O O
- NN O O
subunit NN O O
was NN O O
transiently NN O O
co NN O O
- NN O O
expressed NN O O
with NN O O
the NN O O
beta NN O O
- NN O O
subunit NN O O
to NN O O
produce NN O O
Hex NN O O
A NN O O
( NN O O
alphabeta NN O O
) NN O O
in NN O O
COS NN O O
- NN O O
7 NN O O
cells NN O O
, NN O O
the NN O O
mature NN O O
alpha NN O O
- NN O O
subunit NN O O
was NN O O
present NN O O
, NN O O
but NN O O
its NN O O
level NN O O
was NN O O
much NN O O
lower NN O O
than NN O O
that NN O O
from NN O O
normal NN O O
alpha NN O O
- NN O O
subunit NN O O
transfections NN O O
, NN O O
although NN O O
higher NN O O
than NN O O
in NN O O
those NN O O
cells NN O O
transfected NN O O
with NN O O
an NN O O
alpha NN O O
- NN O O
subunit NN O O
associated NN O O
with NN O O
infantile NN O O
TSD NN O B-Disease
. NN O O

Furthermore NN O O
, NN O O
the NN O O
precursor NN O O
level NN O O
of NN O O
the NN O O
W474C NN O O
alpha NN O O
- NN O O
subunit NN O O
was NN O O
found NN O O
to NN O O
accumulate NN O O
in NN O O
comparison NN O O
to NN O O
the NN O O
normal NN O O
alpha NN O O
- NN O O
subunit NN O O
precursor NN O O
levels NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
the NN O O
1422 NN O O
G NN O O
- NN O O
- NN O O
> NN O O
C NN O O
mutation NN O O
is NN O O
the NN O O
cause NN O O
of NN O O
Hex NN O B-Disease
A NN O I-Disease
enzyme NN O I-Disease
deficiency NN O I-Disease
in NN O O
the NN O O
proband NN O O
. NN O O

The NN O O
resulting NN O O
W474C NN O O
substitution NN O O
clearly NN O O
interferes NN O O
with NN O O
alpha NN O O
- NN O O
subunit NN O O
processing NN O O
, NN O O
but NN O O
because NN O O
the NN O O
base NN O O
substitution NN O O
falls NN O O
at NN O O
the NN O O
first NN O O
position NN O O
of NN O O
exon NN O O
13 NN O O
, NN O O
aberrant NN O O
splicing NN O O
may NN O O
also NN O O
contribute NN O O
to NN O O
Hex NN O B-Disease
A NN O I-Disease
deficiency NN O I-Disease
in NN O O
this NN O O
proband NN O O
. NN O O
. NN O O

Two NN O O
frequent NN O O
missense NN O O
mutations NN O O
in NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
. NN O O

Pendred NN O B-Disease
syndrome NN O I-Disease
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
early NN O O
childhood NN O O
deafness NN O B-Disease
and NN O O
goiter NN O B-Disease
. NN O O

A NN O O
century NN O O
after NN O O
its NN O O
recognition NN O O
as NN O O
a NN O O
syndrome NN O O
by NN O O
Vaughan NN O O
Pendred NN O O
, NN O O
the NN O O
disease NN O O
gene NN O O
( NN O O
PDS NN O O
) NN O O
was NN O O
mapped NN O O
to NN O O
chromosome NN O O
7q22 NN O O
- NN O O
q31 NN O O
. NN O O

1 NN O O
and NN O O
, NN O O
recently NN O O
, NN O O
found NN O O
to NN O O
encode NN O O
a NN O O
putative NN O O
sulfate NN O O
transporter NN O O
. NN O O

We NN O O
performed NN O O
mutation NN O O
analysis NN O O
of NN O O
the NN O O
PDS NN O B-Disease
gene NN O O
in NN O O
patients NN O O
from NN O O
14 NN O O
Pendred NN O B-Disease
families NN O O
originating NN O O
from NN O O
seven NN O O
countries NN O O
and NN O O
identified NN O O
all NN O O
mutations NN O O
. NN O O

The NN O O
mutations NN O O
include NN O O
three NN O O
single NN O O
base NN O O
deletions NN O O
, NN O O
one NN O O
splice NN O O
site NN O O
mutation NN O O
and NN O O
10 NN O O
missense NN O O
mutations NN O O
. NN O O

One NN O O
missense NN O O
mutation NN O O
( NN O O
L236P NN O O
) NN O O
was NN O O
found NN O O
in NN O O
a NN O O
homozygous NN O O
state NN O O
in NN O O
two NN O O
consanguineous NN O O
families NN O O
and NN O O
in NN O O
a NN O O
heterozygous NN O O
state NN O O
in NN O O
five NN O O
additional NN O O
non NN O O
- NN O O
consanguineous NN O O
families NN O O
. NN O O

Another NN O O
missense NN O O
mutation NN O O
( NN O O
T416P NN O O
) NN O O
was NN O O
found NN O O
in NN O O
a NN O O
homozygous NN O O
state NN O O
in NN O O
one NN O O
family NN O O
and NN O O
in NN O O
a NN O O
heterozygous NN O O
state NN O O
in NN O O
four NN O O
families NN O O
. NN O O

Pendred NN O B-Disease
patients NN O O
in NN O O
three NN O O
non NN O O
- NN O O
consanguineous NN O O
families NN O O
were NN O O
shown NN O O
to NN O O
be NN O O
compound NN O O
heterozygotes NN O O
for NN O O
L236P NN O O
and NN O O
T416P NN O O
. NN O O

In NN O O
total NN O O
, NN O O
one NN O O
or NN O O
both NN O O
of NN O O
these NN O O
mutations NN O O
were NN O O
found NN O O
in NN O O
nine NN O O
of NN O O
the NN O O
14 NN O O
families NN O O
analyzed NN O O
. NN O O

The NN O O
identification NN O O
of NN O O
two NN O O
frequent NN O O
PDS NN O B-Disease
mutations NN O O
will NN O O
facilitate NN O O
the NN O O
molecular NN O O
diagnosis NN O O
of NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
. NN O O

Insertional NN O O
mutation NN O O
by NN O O
transposable NN O O
element NN O O
, NN O O
L1 NN O O
, NN O O
in NN O O
the NN O O
DMD NN O B-Disease
gene NN O O
results NN O O
in NN O O
X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
dilated NN O I-Disease
cardiomyopathy NN O I-Disease
. NN O O

X NN O B-Disease
- NN O I-Disease
linked NN O I-Disease
dilated NN O I-Disease
cardiomyopathy NN O I-Disease
( NN O O
XLDCM NN O B-Disease
) NN O O
is NN O O
a NN O O
clinical NN O O
phenotype NN O O
of NN O O
dystrophinopathy NN O B-Disease
which NN O O
is NN O O
characterized NN O O
by NN O O
preferential NN O O
myocardial NN O B-Disease
involvement NN O I-Disease
without NN O O
any NN O O
overt NN O O
clinical NN O O
signs NN O O
of NN O O
skeletal NN O B-Disease
myopathy NN O I-Disease
. NN O O

To NN O O
date NN O O
, NN O O
several NN O O
mutations NN O O
in NN O O
the NN O O
Duchenne NN O B-Disease
muscular NN O I-Disease
dystrophy NN O I-Disease
gene NN O O
, NN O O
DMD NN O O
, NN O O
have NN O O
been NN O O
identified NN O O
in NN O O
patients NN O O
with NN O O
XLDCM NN O B-Disease
, NN O O
but NN O O
a NN O O
pathogenic NN O O
correlation NN O O
of NN O O
these NN O O
cardiospecific NN O O
mutations NN O O
in NN O O
DMD NN O O
with NN O O
the NN O O
XLDCM NN O B-Disease
phenotype NN O O
has NN O O
remained NN O O
to NN O O
be NN O O
elucidated NN O O
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
identification NN O O
of NN O O
a NN O O
unique NN O O
de NN O O
novo NN O O
L1 NN O O
insertion NN O O
in NN O O
the NN O O
muscle NN O O
exon NN O O
1 NN O O
in NN O O
DMD NN O O
in NN O O
three NN O O
XLDCM NN O B-Disease
patients NN O O
from NN O O
two NN O O
unrelated NN O O
Japanese NN O O
families NN O O
. NN O O

The NN O O
insertion NN O O
was NN O O
a NN O O
5 NN O O
- NN O O
truncated NN O O
form NN O O
of NN O O
human NN O O
L1 NN O O
inversely NN O O
integrated NN O O
in NN O O
the NN O O
5 NN O O
- NN O O
untranslated NN O O
region NN O O
in NN O O
the NN O O
muscle NN O O
exon NN O O
1 NN O O
, NN O O
which NN O O
affected NN O O
the NN O O
transcription NN O O
or NN O O
the NN O O
stability NN O O
of NN O O
the NN O O
muscle NN O O
form NN O O
of NN O O
dystrophin NN O O
transcripts NN O O
but NN O O
not NN O O
that NN O O
of NN O O
the NN O O
brain NN O O
or NN O O
Purkinje NN O O
cell NN O O
form NN O O
, NN O O
probably NN O O
due NN O O
to NN O O
its NN O O
unique NN O O
site NN O O
of NN O O
integration NN O O
. NN O O

We NN O O
speculate NN O O
that NN O O
this NN O O
insertion NN O O
of NN O O
an NN O O
L1 NN O O
sequence NN O O
in NN O O
DMD NN O O
is NN O O
responsible NN O O
for NN O O
some NN O O
of NN O O
the NN O O
population NN O O
of NN O O
Japanese NN O O
patients NN O O
with NN O O
XLDCM NN O B-Disease
. NN O O
. NN O O

Severe NN O O
early NN O O
- NN O O
onset NN O O
obesity NN O B-Disease
, NN O O
adrenal NN O B-Disease
insufficiency NN O I-Disease
and NN O O
red NN O O
hair NN O O
pigmentation NN O O
caused NN O O
by NN O O
POMC NN O O
mutations NN O O
in NN O O
humans NN O O
. NN O O

Sequential NN O O
cleavage NN O O
of NN O O
the NN O O
precursor NN O O
protein NN O O
pre NN O O
- NN O O
pro NN O O
- NN O O
opiomelanocortin NN O O
( NN O O
POMC NN O O
) NN O O
generates NN O O
the NN O O
melanocortin NN O O
peptides NN O O
adrenocorticotrophin NN O O
( NN O O
ACTH NN O O
) NN O O
, NN O O
melanocyte NN O O
- NN O O
stimulating NN O O
hormones NN O O
( NN O O
MSH NN O O
) NN O O
alpha NN O O
, NN O O
beta NN O O
and NN O O
gamma NN O O
as NN O O
well NN O O
as NN O O
the NN O O
opioid NN O O
- NN O O
receptor NN O O
ligand NN O O
beta NN O O
- NN O O
endorphin NN O O
. NN O O

While NN O O
a NN O O
few NN O O
cases NN O O
of NN O O
isolated NN O O
ACTH NN O B-Disease
deficiency NN O I-Disease
have NN O O
been NN O O
reported NN O O
( NN O O
OMIM NN O O
201400 NN O O
) NN O O
, NN O O
an NN O O
inherited NN O O
POMC NN O O
defect NN O O
has NN O O
not NN O O
been NN O O
described NN O O
so NN O O
far NN O O
. NN O O

Recent NN O O
studies NN O O
in NN O O
animal NN O O
models NN O O
elucidated NN O O
a NN O O
central NN O O
role NN O O
of NN O O
alpha NN O O
- NN O O
MSH NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
food NN O O
intake NN O O
by NN O O
activation NN O O
of NN O O
the NN O O
brain NN O O
melanocortin NN O O
- NN O O
4 NN O O
- NN O O
receptor NN O O
( NN O O
MC4 NN O O
- NN O O
R NN O O
; NN O O
refs NN O O
3 NN O O
- NN O O
5 NN O O
) NN O O
and NN O O
the NN O O
linkage NN O O
of NN O O
human NN O O
obesity NN O B-Disease
to NN O O
chromosome NN O O
2 NN O O
in NN O O
close NN O O
proximity NN O O
to NN O O
the NN O O
POMC NN O O
locus NN O O
, NN O O
led NN O O
to NN O O
the NN O O
proposal NN O O
of NN O O
an NN O O
association NN O O
of NN O O
POMC NN O O
with NN O O
human NN O O
obesity NN O B-Disease
. NN O O

The NN O O
dual NN O O
role NN O O
of NN O O
alpha NN O O
- NN O O
MSH NN O O
in NN O O
regulating NN O O
food NN O O
intake NN O O
and NN O O
influencing NN O O
hair NN O O
pigmentation NN O O
predicts NN O O
that NN O O
the NN O O
phenotype NN O O
associated NN O O
with NN O O
a NN O O
defect NN O O
in NN O O
POMC NN O O
function NN O O
would NN O O
include NN O O
obesity NN O B-Disease
, NN O O
alteration NN O O
in NN O O
pigmentation NN O O
and NN O O
ACTH NN O B-Disease
deficiency NN O I-Disease
. NN O O

The NN O O
observation NN O O
of NN O O
these NN O O
symptoms NN O O
in NN O O
two NN O O
probands NN O O
prompted NN O O
us NN O O
to NN O O
search NN O O
for NN O O
mutations NN O O
within NN O O
their NN O O
POMC NN O O
genes NN O O
. NN O O

Patient NN O O
1 NN O O
was NN O O
found NN O O
to NN O O
be NN O O
a NN O O
compound NN O O
heterozygote NN O O
for NN O O
two NN O O
mutations NN O O
in NN O O
exon NN O O
3 NN O O
( NN O O
G7013T NN O O
, NN O O
C7133delta NN O O
) NN O O
which NN O O
interfere NN O O
with NN O O
appropriate NN O O
synthesis NN O O
of NN O O
ACTH NN O O
and NN O O
alpha NN O O
- NN O O
MSH NN O O
. NN O O

Patient NN O O
2 NN O O
was NN O O
homozygous NN O O
for NN O O
a NN O O
mutation NN O O
in NN O O
exon NN O O
2 NN O O
( NN O O
C3804A NN O O
) NN O O
which NN O O
abolishes NN O O
POMC NN O O
translation NN O O
. NN O O

These NN O O
findings NN O O
represent NN O O
the NN O O
first NN O O
examples NN O O
of NN O O
a NN O O
genetic NN O B-Disease
defect NN O I-Disease
within NN O O
the NN O O
POMC NN O O
gene NN O O
and NN O O
define NN O O
a NN O O
new NN O O
monogenic NN O B-Disease
endocrine NN O I-Disease
disorder NN O I-Disease
resulting NN O O
in NN O O
early NN O O
- NN O O
onset NN O O
obesity NN O B-Disease
, NN O O
adrenal NN O B-Disease
insufficiency NN O I-Disease
and NN O O
red NN O O
hair NN O O
pigmentation NN O O
. NN O O
. NN O O

A NN O O
European NN O O
multicenter NN O O
study NN O O
of NN O O
phenylalanine NN O B-Disease
hydroxylase NN O I-Disease
deficiency NN O I-Disease
: NN O O
classification NN O O
of NN O O
105 NN O O
mutations NN O O
and NN O O
a NN O O
general NN O O
system NN O O
for NN O O
genotype NN O O
- NN O O
based NN O O
prediction NN O O
of NN O O
metabolic NN O O
phenotype NN O O
. NN O O

Phenylketonuria NN O B-Disease
( NN O O
PKU NN O B-Disease
) NN O O
and NN O O
mild NN O B-Disease
hyperphenylalaninemia NN O I-Disease
( NN O O
MHP NN O B-Disease
) NN O O
are NN O O
allelic NN O B-Disease
disorders NN O I-Disease
caused NN O O
by NN O O
mutations NN O O
in NN O O
the NN O O
gene NN O O
encoding NN O O
phenylalanine NN O O
hydroxylase NN O O
( NN O O
PAH NN O O
) NN O O
. NN O O

Previous NN O O
studies NN O O
have NN O O
suggested NN O O
that NN O O
the NN O O
highly NN O O
variable NN O O
metabolic NN O O
phenotypes NN O O
of NN O O
PAH NN O B-Disease
deficiency NN O I-Disease
correlate NN O O
with NN O O
PAH NN O O
genotypes NN O O
. NN O O

We NN O O
identified NN O O
both NN O O
causative NN O O
mutations NN O O
in NN O O
686 NN O O
patients NN O O
from NN O O
seven NN O O
European NN O O
centers NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
the NN O O
phenotypic NN O O
characteristics NN O O
of NN O O
297 NN O O
functionally NN O O
hemizygous NN O O
patients NN O O
, NN O O
105 NN O O
of NN O O
the NN O O
mutations NN O O
were NN O O
assigned NN O O
to NN O O
one NN O O
of NN O O
four NN O O
arbitrary NN O O
phenotype NN O O
categories NN O O
. NN O O

We NN O O
proposed NN O O
and NN O O
tested NN O O
a NN O O
simple NN O O
model NN O O
for NN O O
correlation NN O O
between NN O O
genotype NN O O
and NN O O
phenotypic NN O O
outcome NN O O
. NN O O

The NN O O
observed NN O O
phenotype NN O O
matched NN O O
the NN O O
predicted NN O O
phenotype NN O O
in NN O O
79 NN O O
% NN O O
of NN O O
the NN O O
cases NN O O
, NN O O
and NN O O
in NN O O
only NN O O
5 NN O O
of NN O O
184 NN O O
patients NN O O
was NN O O
the NN O O
observed NN O O
phenotype NN O O
more NN O O
than NN O O
one NN O O
category NN O O
away NN O O
from NN O O
that NN O O
expected NN O O
. NN O O

Among NN O O
the NN O O
seven NN O O
contributing NN O O
centers NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
for NN O O
whom NN O O
the NN O O
observed NN O O
phenotype NN O O
did NN O O
not NN O O
match NN O O
the NN O O
predicted NN O O
phenotype NN O O
was NN O O
4 NN O O
% NN O O
- NN O O
23 NN O O
% NN O O
( NN O O
P NN O O
< NN O O
. NN O O
0001 NN O O
) NN O O
, NN O O
suggesting NN O O
that NN O O
differences NN O O
in NN O O
methods NN O O
used NN O O
for NN O O
mutation NN O O
detection NN O O
or NN O O
phenotype NN O O
classification NN O O
may NN O O
account NN O O
for NN O O
a NN O O
considerable NN O O
proportion NN O O
of NN O O
genotype NN O O
- NN O O
phenotype NN O O
inconsistencies NN O O
. NN O O

Our NN O O
data NN O O
indicate NN O O
that NN O O
the NN O O
PAH NN O O
- NN O O
mutation NN O O
genotype NN O O
is NN O O
the NN O O
main NN O O
determinant NN O O
of NN O O
metabolic NN O O
phenotype NN O O
in NN O O
most NN O O
patients NN O O
with NN O O
PAH NN O B-Disease
deficiency NN O I-Disease
. NN O O

In NN O O
the NN O O
present NN O O
study NN O O
, NN O O
the NN O O
classification NN O O
of NN O O
105 NN O O
PAH NN O O
mutations NN O O
may NN O O
allow NN O O
the NN O O
prediction NN O O
of NN O O
the NN O O
biochemical NN O O
phenotype NN O O
in NN O O
> NN O O
10 NN O O
, NN O O
000 NN O O
genotypes NN O O
, NN O O
which NN O O
may NN O O
be NN O O
useful NN O O
for NN O O
the NN O O
management NN O O
of NN O O
hyperphenylalaninemia NN O B-Disease
in NN O O
newborns NN O O
. NN O O

Somatic NN O O
instability NN O O
of NN O O
the NN O O
CTG NN O O
repeat NN O O
in NN O O
mice NN O O
transgenic NN O O
for NN O O
the NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
region NN O O
is NN O O
age NN O O
dependent NN O O
but NN O O
not NN O O
correlated NN O O
to NN O O
the NN O O
relative NN O O
intertissue NN O O
transcription NN O O
levels NN O O
and NN O O
proliferative NN O O
capacities NN O O
. NN O O

A NN O O
( NN O O
CTG NN O O
) NN O O
nexpansion NN O O
in NN O O
the NN O O
3 NN O O
- NN O O
untranslated NN O O
region NN O O
( NN O O
UTR NN O O
) NN O O
of NN O O
the NN O O
DM NN O O
protein NN O O
kinase NN O O
gene NN O O
( NN O O
DMPK NN O O
) NN O O
is NN O O
responsible NN O O
for NN O O
causing NN O O
myotonic NN O B-Disease
dystrophy NN O I-Disease
( NN O O
DM NN O B-Disease
) NN O O
. NN O O

Major NN O O
instability NN O O
, NN O O
with NN O O
very NN O O
large NN O O
expansions NN O O
between NN O O
generations NN O O
and NN O O
high NN O O
levels NN O O
of NN O O
somatic NN O O
mosaicism NN O O
, NN O O
is NN O O
observed NN O O
in NN O O
patients NN O O
. NN O O

There NN O O
is NN O O
a NN O O
good NN O O
correlation NN O O
between NN O O
repeat NN O O
size NN O O
( NN O O
at NN O O
least NN O O
in NN O O
leucocytes NN O O
) NN O O
, NN O O
clinical NN O O
severity NN O O
and NN O O
age NN O O
of NN O O
onset NN O O
. NN O O

The NN O O
trinucleotide NN O O
repeat NN O O
instability NN O O
mechanisms NN O O
involved NN O O
in NN O O
DM NN O B-Disease
and NN O O
other NN O O
human NN O O
genetic NN O B-Disease
diseases NN O I-Disease
are NN O O
unknown NN O O
. NN O O

We NN O O
studied NN O O
somatic NN O O
instability NN O O
by NN O O
measuring NN O O
the NN O O
CTG NN O O
repeat NN O O
length NN O O
at NN O O
several NN O O
ages NN O O
in NN O O
various NN O O
tissues NN O O
of NN O O
transgenic NN O O
mice NN O O
carrying NN O O
a NN O O
( NN O O
CTG NN O O
) NN O O
55expansion NN O O
surrounded NN O O
by NN O O
45 NN O O
kb NN O O
of NN O O
the NN O O
human NN O O
DM NN O B-Disease
region NN O O
, NN O O
using NN O O
small NN O O
- NN O O
pool NN O O
PCR NN O O
. NN O O

These NN O O
mice NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
reproduce NN O O
the NN O O
intergenerational NN O O
and NN O O
somatic NN O O
instability NN O O
of NN O O
the NN O O
55 NN O O
CTG NN O O
repeat NN O O
suggesting NN O O
that NN O O
surrounding NN O O
sequences NN O O
and NN O O
the NN O O
chromatin NN O O
environment NN O O
are NN O O
involved NN O O
in NN O O
instability NN O O
mechanisms NN O O
. NN O O

As NN O O
observed NN O O
in NN O O
some NN O O
of NN O O
the NN O O
tissues NN O O
of NN O O
DM NN O B-Disease
patients NN O O
, NN O O
there NN O O
is NN O O
a NN O O
tendency NN O O
for NN O O
repeat NN O O
length NN O O
and NN O O
somatic NN O O
mosaicism NN O O
to NN O O
increase NN O O
with NN O O
the NN O O
age NN O O
of NN O O
the NN O O
mouse NN O O
. NN O O

Furthermore NN O O
, NN O O
we NN O O
observed NN O O
no NN O O
correlation NN O O
between NN O O
the NN O O
somatic NN O O
mutation NN O O
rate NN O O
and NN O O
tissue NN O O
proliferation NN O O
capacity NN O O
. NN O O

The NN O O
somatic NN O O
mutation NN O O
rates NN O O
in NN O O
different NN O O
tissues NN O O
were NN O O
also NN O O
not NN O O
correlated NN O O
to NN O O
the NN O O
relative NN O O
inter NN O O
- NN O O
tissue NN O O
difference NN O O
in NN O O
transcriptional NN O O
levels NN O O
of NN O O
the NN O O
three NN O O
genes NN O O
( NN O O
DMAHP NN O O
, NN O O
DMPK NN O O
and NN O O
59 NN O O
) NN O O
surrounding NN O O
the NN O O
repeat NN O O
. NN O O
. NN O O

A NN O O
novel NN O O
missense NN O O
mutation NN O O
in NN O O
patients NN O O
from NN O O
a NN O O
retinoblastoma NN O B-Disease
pedigree NN O O
showing NN O O
only NN O O
mild NN O O
expression NN O O
of NN O O
the NN O O
tumor NN O B-Disease
phenotype NN O O
. NN O O

We NN O O
have NN O O
used NN O O
single NN O O
strand NN O O
conformation NN O O
polymorphism NN O O
analysis NN O O
to NN O O
study NN O O
the NN O O
27 NN O O
exons NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
in NN O O
individuals NN O O
from NN O O
a NN O O
family NN O O
showing NN O O
mild NN O O
expression NN O O
of NN O O
the NN O O
retinoblastoma NN O B-Disease
phenotype NN O O
. NN O O

In NN O O
this NN O O
family NN O O
affected NN O O
individuals NN O O
developed NN O O
unilateral NN O B-Disease
tumors NN O I-Disease
and NN O O
, NN O O
as NN O O
a NN O O
result NN O O
of NN O O
linkage NN O O
analysis NN O O
, NN O O
unaffected NN O O
mutation NN O O
carriers NN O O
were NN O O
also NN O O
identified NN O O
within NN O O
the NN O O
pedigree NN O O
. NN O O

A NN O O
single NN O O
band NN O O
shift NN O O
using NN O O
SSCP NN O O
was NN O O
identified NN O O
in NN O O
exon NN O O
21 NN O O
which NN O O
resulted NN O O
in NN O O
a NN O O
missense NN O O
mutation NN O O
converting NN O O
a NN O O
cys NN O O
- NN O O
- NN O O
> NN O O
arg NN O O
at NN O O
nucleotide NN O O
position NN O O
28 NN O O
in NN O O
the NN O O
exon NN O O
. NN O O

The NN O O
mutation NN O O
destroyed NN O O
an NN O O
NdeI NN O O
restriction NN O O
enzyme NN O O
site NN O O
. NN O O

Analysis NN O O
of NN O O
all NN O O
family NN O O
members NN O O
demonstrated NN O O
that NN O O
the NN O O
missense NN O O
mutation NN O O
co NN O O
- NN O O
segregated NN O O
with NN O O
patients NN O O
with NN O O
tumors NN O B-Disease
or NN O O
who NN O O
, NN O O
as NN O O
a NN O O
result NN O O
of NN O O
linkage NN O O
analysis NN O O
had NN O O
been NN O O
predicted NN O O
to NN O O
carry NN O O
the NN O O
predisposing NN O O
mutation NN O O
. NN O O

These NN O O
observations NN O O
point NN O O
to NN O O
another NN O O
region NN O O
of NN O O
the NN O O
RB1 NN O O
gene NN O O
where NN O O
mutations NN O O
only NN O O
modify NN O O
the NN O O
function NN O O
of NN O O
the NN O O
gene NN O O
and NN O O
raise NN O O
important NN O O
questions NN O O
for NN O O
genetic NN O O
counseling NN O O
in NN O O
families NN O O
with NN O O
these NN O O
distinctive NN O O
phenotypes NN O O
. NN O O
. NN O O

Maternal NN O B-Disease
disomy NN O I-Disease
and NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
consistent NN O O
with NN O O
gamete NN O O
complementation NN O O
in NN O O
a NN O O
case NN O O
of NN O O
familial NN O O
translocation NN O O
( NN O O
3 NN O O
; NN O O
15 NN O O
) NN O O
( NN O O
p25 NN O O
; NN O O
q11 NN O O
. NN O O
2 NN O O
) NN O O
. NN O O

Maternal NN O B-Disease
uniparental NN O I-Disease
disomy NN O I-Disease
( NN O I-Disease
UPD NN O I-Disease
) NN O I-Disease
for NN O I-Disease
chromosome NN O I-Disease
15 NN O I-Disease
is NN O O
responsible NN O O
for NN O O
an NN O O
estimated NN O O
30 NN O O
% NN O O
of NN O O
cases NN O O
of NN O O
Prader NN O B-Disease
- NN O I-Disease
Willi NN O I-Disease
syndrome NN O I-Disease
( NN O O
PWS NN O B-Disease
) NN O O
. NN O O

We NN O O
report NN O O
on NN O O
an NN O O
unusual NN O O
case NN O O
of NN O O
maternal NN O B-Disease
disomy NN O I-Disease
15 NN O I-Disease
in NN O O
PWS NN O B-Disease
that NN O O
is NN O O
most NN O O
consistent NN O O
with NN O O
adjacent NN O O
- NN O O
1 NN O O
segregation NN O O
of NN O O
a NN O O
paternal NN O O
t NN O O
( NN O O
3 NN O O
; NN O O
15 NN O O
) NN O O
( NN O O
p25 NN O O
; NN O O
q11 NN O O
. NN O O
2 NN O O
) NN O O
with NN O O
simultaneous NN O O
maternal NN O O
meiotic NN O O
nondisjunction NN O O
for NN O O
chromosome NN O O
15 NN O O
. NN O O

The NN O O
patient NN O O
( NN O O
J NN O O
. NN O O
B NN O O
. NN O O
) NN O O
, NN O O
a NN O O
17 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
white NN O O
male NN O O
with NN O O
PWS NN O B-Disease
, NN O O
was NN O O
found NN O O
to NN O O
have NN O O
47 NN O O
chromosomes NN O O
with NN O O
a NN O O
supernumerary NN O O
, NN O O
paternal NN O O
der NN O O
( NN O O
15 NN O O
) NN O O
consisting NN O O
of NN O O
the NN O O
short NN O O
arm NN O O
and NN O O
the NN O O
proximal NN O O
long NN O O
arm NN O O
of NN O O
chromosome NN O O
15 NN O O
, NN O O
and NN O O
distal NN O O
chromosome NN O O
arm NN O O
3p NN O O
. NN O O

The NN O O
t NN O O
( NN O O
3 NN O O
; NN O O
15 NN O O
) NN O O
was NN O O
present NN O O
in NN O O
the NN O O
balanced NN O O
state NN O O
in NN O O
the NN O O
patients NN O O
father NN O O
and NN O O
a NN O O
sister NN O O
. NN O O

Fluorescent NN O O
in NN O O
situ NN O O
hybridization NN O O
analysis NN O O
demonstrated NN O O
that NN O O
the NN O O
PWS NN O B-Disease
critical NN O O
region NN O O
resided NN O O
on NN O O
the NN O O
derivative NN O O
chromosome NN O O
3 NN O O
and NN O O
that NN O O
there NN O O
was NN O O
no NN O O
deletion NN O O
of NN O O
the NN O O
PWS NN O B-Disease
region NN O O
on NN O O
the NN O O
normal NN O O
pair NN O O
of NN O O
15s NN O O
present NN O O
in NN O O
J NN O O
. NN O O

B NN O O
. NN O O

Methylation NN O O
analysis NN O O
at NN O O
exon NN O O
alpha NN O O
of NN O O
the NN O O
small NN O O
nuclear NN O O
ribonucleoprotein NN O O
- NN O O
associated NN O O
polypeptide NN O O
N NN O O
( NN O O
SNRPN NN O O
) NN O O
gene NN O O
showed NN O O
a NN O O
pattern NN O O
characteristic NN O O
of NN O O
only NN O O
the NN O O
maternal NN O O
chromosome NN O O
15 NN O O
in NN O O
J NN O O
. NN O O

B NN O O
. NN O O

Maternal NN O B-Disease
disomy NN O I-Disease
was NN O O
confirmed NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
analysis NN O O
of NN O O
microsatellite NN O O
repeats NN O O
at NN O O
the NN O O
gamma NN O O
- NN O O
aminobutyric NN O O
acid NN O O
receptor NN O O
beta3 NN O O
subunit NN O O
( NN O O
GABRB3 NN O O
) NN O O
locus NN O O
. NN O O

A NN O O
niece NN O O
( NN O O
B NN O O
. NN O O
B NN O O
. NN O O
) NN O O
with NN O O
45 NN O O
chromosomes NN O O
and NN O O
the NN O O
derivative NN O O
3 NN O O
but NN O O
without NN O O
the NN O O
der NN O O
( NN O O
15 NN O O
) NN O O
demonstrated NN O O
a NN O O
phenotype NN O O
consistent NN O O
with NN O O
that NN O O
reported NN O O
for NN O O
haploinsufficiency NN O O
of NN O O
distal NN O O
3 NN O O
p NN O O
. NN O O

Uniparental NN O B-Disease
disomy NN O I-Disease
associated NN O O
with NN O O
unbalanced NN O O
segregation NN O O
of NN O O
non NN O O
- NN O O
Robertsonian NN O O
translocations NN O O
has NN O O
been NN O O
reported NN O O
previously NN O O
but NN O O
has NN O O
not NN O O
, NN O O
to NN O O
our NN O O
knowledge NN O O
, NN O O
been NN O O
observed NN O O
in NN O O
a NN O O
case NN O O
of NN O O
PWS NN O B-Disease
. NN O O

Furthermore NN O O
, NN O O
our NN O O
findings NN O O
are NN O O
best NN O O
interpreted NN O O
as NN O O
true NN O O
gamete NN O O
complementation NN O O
resulting NN O O
in NN O O
maternal NN O B-Disease
UPD NN O I-Disease
15 NN O I-Disease
and NN O O
PWS NN O B-Disease

Schwartz NN O B-Disease
- NN O I-Disease
Jampel NN O I-Disease
syndrome NN O I-Disease
type NN O I-Disease
2 NN O I-Disease
and NN O O
Stuve NN O B-Disease
- NN O I-Disease
Wiedemann NN O I-Disease
syndrome NN O I-Disease
: NN O O
a NN O O
case NN O O
for NN O O
" NN O O
lumping NN O O
" NN O O
. NN O O

Recent NN O O
studies NN O O
demonstrated NN O O
the NN O O
existence NN O O
of NN O O
a NN O O
genetically NN O O
distinct NN O O
, NN O O
usually NN O O
lethal NN O O
form NN O O
of NN O O
the NN O O
Schwartz NN O B-Disease
- NN O I-Disease
Jampel NN O I-Disease
syndrome NN O I-Disease
( NN O O
SJS NN O B-Disease
) NN O O
of NN O O
myotonia NN O B-Disease
and NN O O
skeletal NN O B-Disease
dysplasia NN O I-Disease
, NN O O
which NN O O
we NN O O
called NN O O
SJS NN O B-Disease
type NN O I-Disease
2 NN O I-Disease
. NN O O

This NN O O
disorder NN O O
is NN O O
reminiscent NN O O
of NN O O
another NN O O
rare NN O O
condition NN O O
, NN O O
the NN O O
Stuve NN O B-Disease
- NN O I-Disease
Wiedemann NN O I-Disease
syndrome NN O I-Disease
( NN O O
SWS NN O B-Disease
) NN O O
, NN O O
which NN O O
comprises NN O O
campomelia NN O B-Disease
at NN O O
birth NN O O
with NN O O
skeletal NN O B-Disease
dysplasia NN O I-Disease
, NN O O
contractures NN O B-Disease
, NN O O
and NN O O
early NN O B-Disease
death NN O I-Disease
. NN O O

To NN O O
test NN O O
for NN O O
possible NN O O
nosologic NN O O
identity NN O O
between NN O O
these NN O O
disorders NN O O
, NN O O
we NN O O
reviewed NN O O
the NN O O
literature NN O O
and NN O O
obtained NN O O
a NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
the NN O O
only NN O O
two NN O O
surviving NN O O
patients NN O O
, NN O O
one NN O O
with NN O O
SJS NN O B-Disease
type NN O I-Disease
2 NN O I-Disease
at NN O O
age NN O O
10 NN O O
years NN O O
and NN O O
another NN O O
with NN O O
SWS NN O B-Disease
at NN O O
age NN O O
7 NN O O
years NN O O
. NN O O

Patients NN O O
reported NN O O
as NN O O
having NN O O
either NN O O
neonatal NN O O
SJS NN O B-Disease
or NN O O
SWS NN O B-Disease
presented NN O O
a NN O O
combination NN O O
of NN O O
a NN O O
severe NN O O
, NN O O
prenatal NN O O
- NN O O
onset NN O O
neuromuscular NN O B-Disease
disorder NN O I-Disease
( NN O O
with NN O O
congenital NN O B-Disease
joint NN O I-Disease
contractures NN O I-Disease
, NN O O
respiratory NN O O
and NN O O
feeding NN O O
difficulties NN O O
, NN O O
tendency NN O O
to NN O O
hyperthermia NN O B-Disease
, NN O O
and NN O O
frequent NN O O
death NN O O
in NN O O
infancy NN O O
) NN O O
with NN O O
a NN O O
distinct NN O O
campomelic NN O B-Disease
- NN O I-Disease
metaphyseal NN O I-Disease
skeletal NN O I-Disease
dysplasia NN O I-Disease
. NN O O

The NN O O
similarity NN O O
of NN O O
the NN O O
clinical NN O O
and NN O O
radiographic NN O O
findings NN O O
is NN O O
so NN O O
extensive NN O O
that NN O O
these NN O O
disorders NN O O
appear NN O O
to NN O O
be NN O O
a NN O O
single NN O O
entity NN O O
. NN O O

The NN O O
follow NN O O
- NN O O
up NN O O
observation NN O O
of NN O O
an NN O O
identical NN O O
and NN O O
unique NN O O
pattern NN O O
of NN O O
progressive NN O O
bone NN O B-Disease
dysplasia NN O I-Disease
in NN O O
the NN O O
two NN O O
patients NN O O
( NN O O
one NN O O
with NN O O
SJS NN O B-Disease
type NN O I-Disease
2 NN O I-Disease
, NN O O
one NN O O
with NN O O
SWS NN O B-Disease
) NN O O
surviving NN O O
beyond NN O O
infancy NN O O
adds NN O O
to NN O O
the NN O O
evidence NN O O
in NN O O
favor NN O O
of NN O O
identity NN O O
. NN O O

The NN O O
hypothesis NN O O
that NN O O
SWS NN O B-Disease
and NN O O
SJS NN O B-Disease
type NN O I-Disease
2 NN O I-Disease
are NN O O
the NN O O
same NN O O
disorder NN O O
should NN O O
be NN O O
testable NN O O
by NN O O
molecular NN O O
methods NN O O
. NN O O
. NN O O

A NN O O
mouse NN O O
model NN O O
of NN O O
severe NN O O
von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
: NN O O
defects NN O O
in NN O O
hemostasis NN O O
and NN O O
thrombosis NN O B-Disease
. NN O O

von NN O B-Disease
Willebrand NN O I-Disease
factor NN O I-Disease
( NN O I-Disease
vWf NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
causes NN O O
severe NN O O
von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
in NN O O
humans NN O O
. NN O O

We NN O O
generated NN O O
a NN O O
mouse NN O O
model NN O O
for NN O O
this NN O O
disease NN O O
by NN O O
using NN O O
gene NN O O
targeting NN O O
. NN O O

vWf NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
mice NN O O
appeared NN O O
normal NN O O
at NN O O
birth NN O O
; NN O O
they NN O O
were NN O O
viable NN O O
and NN O O
fertile NN O O
. NN O O

Neither NN O O
vWf NN O O
nor NN O O
vWf NN O O
propolypeptide NN O O
( NN O O
von NN O B-Disease
Willebrand NN O I-Disease
antigen NN O O
II NN O O
) NN O O
were NN O O
detectable NN O O
in NN O O
plasma NN O O
, NN O O
platelets NN O O
, NN O O
or NN O O
endothelial NN O O
cells NN O O
of NN O O
the NN O O
homozygous NN O O
mutant NN O O
mice NN O O
. NN O O

The NN O O
mutant NN O O
mice NN O O
exhibited NN O O
defects NN O O
in NN O O
hemostasis NN O O
with NN O O
a NN O O
highly NN O O
prolonged NN O O
bleeding NN O O
time NN O O
and NN O O
spontaneous NN O O
bleeding NN O O
events NN O O
in NN O O
approximately NN O O
10 NN O O
% NN O O
of NN O O
neonates NN O O
. NN O O

As NN O O
in NN O O
the NN O O
human NN O O
disease NN O O
, NN O O
the NN O O
factor NN O O
VIII NN O O
level NN O O
in NN O O
these NN O O
mice NN O O
was NN O O
reduced NN O O
strongly NN O O
as NN O O
a NN O O
result NN O O
of NN O O
the NN O O
lack NN O O
of NN O O
protection NN O O
provided NN O O
by NN O O
vWf NN O O
. NN O O

Defective NN O O
thrombosis NN O B-Disease
in NN O O
mutant NN O O
mice NN O O
was NN O O
also NN O O
evident NN O O
in NN O O
an NN O O
in NN O O
vivo NN O O
model NN O O
of NN O O
vascular NN O B-Disease
injury NN O I-Disease
. NN O O

In NN O O
this NN O O
model NN O O
, NN O O
the NN O O
exteriorized NN O O
mesentery NN O O
was NN O O
superfused NN O O
with NN O O
ferric NN O O
chloride NN O O
and NN O O
the NN O O
accumulation NN O O
of NN O O
fluorescently NN O O
labeled NN O O
platelets NN O O
was NN O O
observed NN O O
by NN O O
intravital NN O O
microscopy NN O O
. NN O O

We NN O O
conclude NN O O
that NN O O
these NN O O
mice NN O O
very NN O O
closely NN O O
mimic NN O O
severe NN O O
human NN O O
von NN O B-Disease
Willebrand NN O I-Disease
disease NN O I-Disease
and NN O O
will NN O O
be NN O O
very NN O O
useful NN O O
for NN O O
investigating NN O O
the NN O O
role NN O O
of NN O O
vWf NN O O
in NN O O
normal NN O O
physiology NN O O
and NN O O
in NN O O
disease NN O O
models NN O O
. NN O O
. NN O O

Oral NN O O
contraceptives NN O O
and NN O O
the NN O O
risk NN O O
of NN O O
hereditary NN O B-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

Hereditary NN O B-Disease
Ovarian NN O I-Disease
Cancer NN O I-Disease
Clinical NN O O
Study NN O O
Group NN O O
. NN O O

BACKGROUND NN O O
Women NN O O
with NN O O
mutations NN O O
in NN O O
either NN O O
the NN O O
BRCA1 NN O O
or NN O O
the NN O O
BRCA2 NN O O
gene NN O O
have NN O O
a NN O O
high NN O O
lifetime NN O O
risk NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
. NN O O

Oral NN O O
contraceptives NN O O
protect NN O O
against NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
in NN O O
general NN O O
, NN O O
but NN O O
it NN O O
is NN O O
not NN O O
known NN O O
whether NN O O
they NN O O
also NN O O
protect NN O O
against NN O O
hereditary NN O B-Disease
forms NN O I-Disease
of NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
. NN O O

METHODS NN O O
We NN O O
enrolled NN O O
207 NN O O
women NN O O
with NN O O
hereditary NN O B-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
and NN O O
161 NN O O
of NN O O
their NN O O
sisters NN O O
as NN O O
controls NN O O
in NN O O
a NN O O
case NN O O
- NN O O
control NN O O
study NN O O
. NN O O

All NN O O
the NN O O
patients NN O O
carried NN O O
a NN O O
pathogenic NN O O
mutation NN O O
in NN O O
either NN O O
BRCA1 NN O O
( NN O O
179 NN O O
women NN O O
) NN O O
or NN O O
BRCA2 NN O O
( NN O O
28 NN O O
women NN O O
) NN O O
. NN O O

The NN O O
control NN O O
women NN O O
were NN O O
enrolled NN O O
regardless NN O O
of NN O O
whether NN O O
or NN O O
not NN O O
they NN O O
had NN O O
either NN O O
mutation NN O O
. NN O O

Lifetime NN O O
histories NN O O
of NN O O
oral NN O O
- NN O O
contraceptive NN O O
use NN O O
were NN O O
obtained NN O O
by NN O O
interview NN O O
or NN O O
by NN O O
written NN O O
questionnaire NN O O
and NN O O
were NN O O
compared NN O O
between NN O O
patients NN O O
and NN O O
control NN O O
women NN O O
, NN O O
after NN O O
adjustment NN O O
for NN O O
year NN O O
of NN O O
birth NN O O
and NN O O
parity NN O O
. NN O O

RESULTS NN O O
The NN O O
adjusted NN O O
odds NN O O
ratio NN O O
for NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
associated NN O O
with NN O O
any NN O O
past NN O O
use NN O O
of NN O O
oral NN O O
contraceptives NN O O
was NN O O
0 NN O O
. NN O O

5 NN O O
( NN O O
95 NN O O
percent NN O O
confidence NN O O
interval NN O O
, NN O O
0 NN O O
. NN O O
3 NN O O
to NN O O
0 NN O O
. NN O O
8 NN O O
) NN O O
. NN O O

The NN O O
risk NN O O
decreased NN O O
with NN O O
increasing NN O O
duration NN O O
of NN O O
use NN O O
( NN O O
P NN O O
for NN O O
trend NN O O
, NN O O
< NN O O
0 NN O O
. NN O O
001 NN O O
) NN O O
; NN O O
use NN O O
for NN O O
six NN O O
or NN O O
more NN O O
years NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
60 NN O O
percent NN O O
reduction NN O O
in NN O O
risk NN O O
. NN O O

Oral NN O O
- NN O O
contraceptive NN O O
use NN O O
protected NN O O
against NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
both NN O O
for NN O O
carriers NN O O
of NN O O
the NN O O
BRCA1 NN O O
mutation NN O O
( NN O O
odds NN O O
ratio NN O O
, NN O O
0 NN O O
. NN O O
5 NN O O
; NN O O
95 NN O O
percent NN O O
confidence NN O O
interval NN O O
, NN O O
0 NN O O
. NN O O
3 NN O O
to NN O O
0 NN O O
. NN O O
9 NN O O
) NN O O
and NN O O
for NN O O
carriers NN O O
of NN O O
the NN O O
BRCA2 NN O O
mutation NN O O
( NN O O
odds NN O O
ratio NN O O
, NN O O
0 NN O O
. NN O O
4 NN O O
; NN O O
95 NN O O
percent NN O O
confidence NN O O
interval NN O O
, NN O O
0 NN O O
. NN O O
2 NN O O
to NN O O
1 NN O O
. NN O O
1 NN O O
) NN O O
. NN O O

CONCLUSIONS NN O O
Oral NN O O
- NN O O
contraceptive NN O O
use NN O O
may NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
ovarian NN O B-Disease
cancer NN O I-Disease
in NN O O
women NN O O
with NN O O
pathogenic NN O O
mutations NN O O
in NN O O
the NN O O
BRCA1 NN O O
or NN O O
BRCA2 NN O O
gene NN O O

A NN O O
Japanese NN O O
family NN O O
with NN O O
adrenoleukodystrophy NN O B-Disease
with NN O O
a NN O O
codon NN O O
291 NN O O
deletion NN O O
: NN O O
a NN O O
clinical NN O O
, NN O O
biochemical NN O O
, NN O O
pathological NN O O
, NN O O
and NN O O
genetic NN O O
report NN O O
. NN O O

We NN O O
report NN O O
a NN O O
Japanese NN O O
family NN O O
with NN O O
adrenoleukodystrophy NN O B-Disease
( NN O O
ALD NN O B-Disease
) NN O O
with NN O O
a NN O O
three NN O O
base NN O O
pair NN O O
deletion NN O O
( NN O O
delGAG NN O O
291 NN O O
) NN O O
in NN O O
the NN O O
ALD NN O B-Disease
gene NN O O
. NN O O

A NN O O
variety NN O O
of NN O O
phenotypes NN O O
were NN O O
observed NN O O
within NN O O
this NN O O
family NN O O
. NN O O

While NN O O
the NN O O
proband NN O O
( NN O O
patient NN O O
1 NN O O
) NN O O
was NN O O
classified NN O O
as NN O O
having NN O O
a NN O O
rare NN O O
intermediate NN O O
type NN O O
of NN O O
adult NN O O
cerebral NN O O
and NN O O
cerebello NN O O
- NN O O
brain NN O O
stem NN O O
forms NN O O
, NN O O
his NN O O
younger NN O O
brother NN O O
( NN O O
patient NN O O
2 NN O O
) NN O O
and NN O O
nephew NN O O
( NN O O
patient NN O O
3 NN O O
) NN O O
had NN O O
a NN O O
childhood NN O O
ALD NN O B-Disease
type NN O O
. NN O O

Another NN O O
nephew NN O O
( NN O O
patient NN O O
4 NN O O
) NN O O
of NN O O
patient NN O O
1 NN O O
was NN O O
classified NN O O
as NN O O
having NN O O
an NN O O
adolescent NN O O
form NN O O
. NN O O

The NN O O
tau NN O O
level NN O O
in NN O O
the NN O O
cerebrospinal NN O O
fluid NN O O
( NN O O
CSF NN O O
) NN O O
in NN O O
patient NN O O
1 NN O O
was NN O O
as NN O O
high NN O O
as NN O O
that NN O O
of NN O O
patients NN O O
with NN O O
Alzheimers NN O B-Disease
disease NN O I-Disease
( NN O O
AD NN O B-Disease
) NN O O
. NN O O

His NN O O
brain NN O O
magnetic NN O O
resonance NN O O
image NN O O
( NN O O
MRI NN O O
) NN O O
showed NN O O
abnormalities NN O B-Disease
in NN O I-Disease
the NN O I-Disease
bilateral NN O I-Disease
cerebellar NN O I-Disease
hemispheres NN O I-Disease
and NN O O
brain NN O O
stem NN O O
, NN O O
but NN O O
not NN O O
in NN O O
the NN O O
cerebral NN O O
white NN O O
matter NN O O
, NN O O
where NN O O
marked NN O O
reductions NN O O
of NN O O
the NN O O
cerebral NN O O
blood NN O O
flow NN O O
and NN O O
oxygen NN O O
metabolism NN O O
were NN O O
clearly NN O O
demonstrated NN O O
by NN O O
positron NN O O
emission NN O O
tomography NN O O
( NN O O
PET NN O O
) NN O O
. NN O O

In NN O O
patients NN O O
2 NN O O
and NN O O
3 NN O O
, NN O O
the NN O O
autopsy NN O O
findings NN O O
showed NN O O
massive NN O O
demyelination NN O B-Disease
of NN O I-Disease
the NN O I-Disease
cerebral NN O I-Disease
white NN O I-Disease
matter NN O I-Disease
with NN O O
sparing NN O O
of NN O O
the NN O O
U NN O O
- NN O O
fibers NN O O
, NN O O
compatible NN O O
with NN O O
the NN O O
findings NN O O
of NN O O
childhood NN O O
ALD NN O B-Disease
. NN O O

Oleic NN O O
and NN O O
erucic NN O O
acids NN O O
( NN O O
Lorenzos NN O O
Oil NN O O
) NN O O
were NN O O
administered NN O O
to NN O O
patients NN O O
1 NN O O
and NN O O
4 NN O O
, NN O O
but NN O O
sufficient NN O O
effectiveness NN O O
was NN O O
not NN O O
obtained NN O O
. NN O O

The NN O O
findings NN O O
in NN O O
this NN O O
family NN O O
suggest NN O O
that NN O O
delGAG291 NN O O
is NN O O
part NN O O
of NN O O
the NN O O
cause NN O O
of NN O O
Japanese NN O O
ALD NN O B-Disease
with NN O O
phenotypic NN O O
variations NN O O
. NN O O

Moreover NN O O
, NN O O
although NN O O
the NN O O
scale NN O O
of NN O O
the NN O O
study NN O O
is NN O O
limited NN O O
, NN O O
there NN O O
is NN O O
a NN O O
possibility NN O O
that NN O O
PET NN O O
can NN O O
detect NN O O
an NN O O
insidious NN O B-Disease
lesion NN O I-Disease
which NN O O
is NN O O
undetectable NN O O
by NN O O
computed NN O O
tomogram NN O O
( NN O O
CT NN O O
) NN O O
or NN O O
MRI NN O O
analysis NN O O
, NN O O
and NN O O
that NN O O
the NN O O
higher NN O O
level NN O O
of NN O O
tau NN O O
reflects NN O O
the NN O O
process NN O O
of NN O O
neuronal NN O B-Disease
degeneration NN O I-Disease
in NN O O
ALD NN O B-Disease
. NN O O

Lorenzos NN O O
Oil NN O O
should NN O O
be NN O O
given NN O O
in NN O O
the NN O O
early NN O O
stage NN O O
. NN O O
. NN O O

Nonsense NN O O
mutation NN O O
in NN O O
exon NN O O
4 NN O O
of NN O O
human NN O O
complement NN O O
C9 NN O O
gene NN O O
is NN O O
the NN O O
major NN O O
cause NN O O
of NN O O
Japanese NN O O
complement NN O B-Disease
C9 NN O I-Disease
deficiency NN O I-Disease
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
the NN O I-Disease
ninth NN O I-Disease
component NN O I-Disease
of NN O I-Disease
human NN O I-Disease
complement NN O I-Disease
( NN O O
C9 NN O O
) NN O O
is NN O O
the NN O O
most NN O O
common NN O O
complement NN O B-Disease
deficiency NN O I-Disease
in NN O O
Japan NN O O
but NN O O
is NN O O
rare NN O O
in NN O O
other NN O O
countries NN O O
. NN O O

We NN O O
studied NN O O
the NN O O
molecular NN O O
basis NN O O
of NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
in NN O O
four NN O O
Japanese NN O O
C9 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
patients NN O O
who NN O O
had NN O O
suffered NN O O
from NN O O
meningococcal NN O B-Disease
meningitis NN O I-Disease
. NN O O

Direct NN O O
sequencing NN O O
of NN O O
amplified NN O O
C9 NN O O
cDNA NN O O
and NN O O
DNA NN O O
revealed NN O O
a NN O O
nonsense NN O O
substitution NN O O
( NN O O
CGA NN O O
- NN O O
- NN O O
> NN O O
TGA NN O O
) NN O O
at NN O O
codon NN O O
95 NN O O
in NN O O
exon NN O O
4 NN O O
in NN O O
the NN O O
four NN O O
C9 NN O B-Disease
- NN O I-Disease
deficient NN O I-Disease
individuals NN O O
. NN O O

An NN O O
allele NN O O
- NN O O
specific NN O O
polymerase NN O O
chain NN O O
reaction NN O O
system NN O O
designed NN O O
to NN O O
detect NN O O
exclusively NN O O
only NN O O
one NN O O
of NN O O
the NN O O
normal NN O O
and NN O O
mutant NN O O
alleles NN O O
indicated NN O O
that NN O O
all NN O O
the NN O O
four NN O O
patients NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
mutation NN O O
in NN O O
exon NN O O
4 NN O O
and NN O O
that NN O O
the NN O O
parents NN O O
of NN O O
patient NN O O
2 NN O O
were NN O O
heterozygous NN O O
. NN O O

The NN O O
common NN O O
mutation NN O O
at NN O O
codon NN O O
95 NN O O
in NN O O
exon NN O O
4 NN O O
might NN O O
be NN O O
responsible NN O O
for NN O O
most NN O O
Japanese NN O O
C9 NN O B-Disease
deficiency NN O I-Disease
. NN O O
. NN O O

BRCA1 NN O O
required NN O O
for NN O O
transcription NN O O
- NN O O
coupled NN O O
repair NN O O
of NN O O
oxidative NN O O
DNA NN O O
damage NN O O
. NN O O

The NN O O
breast NN O B-Disease
and NN O I-Disease
ovarian NN O I-Disease
cancer NN O I-Disease
susceptibility NN O O
gene NN O O
BRCA1 NN O O
encodes NN O O
a NN O O
zinc NN O O
finger NN O O
protein NN O O
of NN O O
unknown NN O O
function NN O O
. NN O O

Association NN O O
of NN O O
the NN O O
BRCA1 NN O O
protein NN O O
with NN O O
the NN O O
DNA NN O O
repair NN O O
protein NN O O
Rad51 NN O O
and NN O O
changes NN O O
in NN O O
the NN O O
phosphorylation NN O O
and NN O O
cellular NN O O
localization NN O O
of NN O O
the NN O O
protein NN O O
after NN O O
exposure NN O O
to NN O O
DNA NN O O
- NN O O
damaging NN O O
agents NN O O
are NN O O
consistent NN O O
with NN O O
a NN O O
role NN O O
for NN O O
BRCA1 NN O O
in NN O O
DNA NN O O
repair NN O O
. NN O O

Here NN O O
, NN O O
it NN O O
is NN O O
shown NN O O
that NN O O
mouse NN O O
embryonic NN O O
stem NN O O
cells NN O O
deficient NN O B-Disease
in NN O I-Disease
BRCA1 NN O I-Disease
are NN O O
defective NN O O
in NN O O
the NN O O
ability NN O O
to NN O O
carry NN O O
out NN O O
transcription NN O O
- NN O O
coupled NN O O
repair NN O O
of NN O O
oxidative NN O O
DNA NN O O
damage NN O O
, NN O O
and NN O O
are NN O O
hypersensitive NN O O
to NN O O
ionizing NN O O
radiation NN O O
and NN O O
hydrogen NN O O
peroxide NN O O
. NN O O

These NN O O
results NN O O
suggest NN O O
that NN O O
BRCA1 NN O O
participates NN O O
, NN O O
directly NN O O
or NN O O
indirectly NN O O
, NN O O
in NN O O
transcription NN O O
- NN O O
coupled NN O O
repair NN O O
of NN O O
oxidative NN O O
DNA NN O O
damage NN O O
. NN O O
. NN O O

Truncation NN O O
mutations NN O O
in NN O O
the NN O O
transactivation NN O O
region NN O O
of NN O O
PAX6 NN O O
result NN O O
in NN O O
dominant NN O O
- NN O O
negative NN O O
mutants NN O O
. NN O O

PAX6 NN O O
is NN O O
a NN O O
transcription NN O O
factor NN O O
with NN O O
two NN O O
DNA NN O O
- NN O O
binding NN O O
domains NN O O
( NN O O
paired NN O O
box NN O O
and NN O O
homeobox NN O O
) NN O O
and NN O O
a NN O O
proline NN O O
- NN O O
serine NN O O
- NN O O
threonine NN O O
( NN O O
PST NN O O
) NN O O
- NN O O
rich NN O O
transactivation NN O O
domain NN O O
. NN O O

PAX6 NN O O
regulates NN O O
eye NN O O
development NN O O
in NN O O
animals NN O O
ranging NN O O
from NN O O
jellyfish NN O O
to NN O O
Drosophila NN O O
to NN O O
humans NN O O
. NN O O

Heterozygous NN O O
mutations NN O O
in NN O O
the NN O O
human NN O O
PAX6 NN O O
gene NN O O
result NN O O
in NN O O
various NN O O
phenotypes NN O O
, NN O O
including NN O O
aniridia NN O B-Disease
, NN O O
Peters NN O B-Disease
anomaly NN O I-Disease
, NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
keratitis NN O I-Disease
, NN O O
and NN O O
familial NN O B-Disease
foveal NN O I-Disease
dysplasia NN O I-Disease
. NN O O

It NN O O
is NN O O
believed NN O O
that NN O O
the NN O O
mutated NN O O
allele NN O O
of NN O O
PAX6 NN O O
produces NN O O
an NN O O
inactive NN O O
protein NN O O
and NN O O
aniridia NN O B-Disease
is NN O O
caused NN O O
due NN O O
to NN O O
genetic NN O O
haploinsufficiency NN O O
. NN O O

However NN O O
, NN O O
several NN O O
truncation NN O O
mutations NN O O
have NN O O
been NN O O
found NN O O
to NN O O
occur NN O O
in NN O O
the NN O O
C NN O O
- NN O O
terminal NN O O
half NN O O
of NN O O
PAX6 NN O O
in NN O O
patients NN O O
with NN O O
Aniridia NN O B-Disease
resulting NN O O
in NN O O
mutant NN O O
proteins NN O O
that NN O O
retain NN O O
the NN O O
DNA NN O O
- NN O O
binding NN O O
domains NN O O
but NN O O
have NN O O
lost NN O O
most NN O O
of NN O O
the NN O O
transactivation NN O O
domain NN O O
. NN O O

It NN O O
is NN O O
not NN O O
clear NN O O
whether NN O O
such NN O O
mutants NN O O
really NN O O
behave NN O O
as NN O O
loss NN O O
- NN O O
of NN O O
- NN O O
function NN O O
mutants NN O O
as NN O O
predicted NN O O
by NN O O
haploinsufficiency NN O O
. NN O O

Contrary NN O O
to NN O O
this NN O O
theory NN O O
, NN O O
our NN O O
data NN O O
showed NN O O
that NN O O
these NN O O
mutants NN O O
are NN O O
dominant NN O O
- NN O O
negative NN O O
in NN O O
transient NN O O
transfection NN O O
assays NN O O
when NN O O
they NN O O
are NN O O
coexpressed NN O O
with NN O O
wild NN O O
- NN O O
type NN O O
PAX6 NN O O
. NN O O

We NN O O
found NN O O
that NN O O
the NN O O
dominant NN O O
- NN O O
negative NN O O
effects NN O O
result NN O O
from NN O O
the NN O O
enhanced NN O O
DNA NN O O
binding NN O O
ability NN O O
of NN O O
these NN O O
mutants NN O O
. NN O O

Kinetic NN O O
studies NN O O
of NN O O
binding NN O O
and NN O O
dissociation NN O O
revealed NN O O
that NN O O
various NN O O
truncation NN O O
mutants NN O O
have NN O O
3 NN O O
- NN O O
5 NN O O
- NN O O
fold NN O O
higher NN O O
affinity NN O O
to NN O O
various NN O O
DNA NN O O
- NN O O
binding NN O O
sites NN O O
when NN O O
compared NN O O
with NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
PAX6 NN O O
. NN O O

These NN O O
results NN O O
provide NN O O
a NN O O
new NN O O
insight NN O O
into NN O O
the NN O O
role NN O O
of NN O O
mutant NN O O
PAX6 NN O O
in NN O O
causing NN O O
aniridia NN O B-Disease
. NN O O
. NN O O

Reversal NN O O
of NN O O
severe NN O O
hypertrophic NN O B-Disease
cardiomyopathy NN O I-Disease
and NN O O
excellent NN O O
neuropsychologic NN O O
outcome NN O O
in NN O O
very NN O B-Disease
- NN O I-Disease
long NN O I-Disease
- NN O I-Disease
chain NN O I-Disease
acyl NN O I-Disease
- NN O I-Disease
coenzyme NN O I-Disease
A NN O I-Disease
dehydrogenase NN O I-Disease
deficiency NN O I-Disease
. NN O O

Very NN O B-Disease
- NN O I-Disease
long NN O I-Disease
- NN O I-Disease
chain NN O I-Disease
acyl NN O I-Disease
- NN O I-Disease
coenzyme NN O I-Disease
A NN O I-Disease
dehydrogenase NN O I-Disease
( NN O I-Disease
VLCAD NN O I-Disease
) NN O I-Disease
deficiency NN O I-Disease
is NN O O
a NN O O
disorder NN O O
of NN O O
fatty NN O O
acid NN O O
beta NN O O
oxidation NN O O
that NN O O
reportedly NN O O
has NN O O
high NN O O
rates NN O O
of NN O O
morbidity NN O O
and NN O O
mortality NN O O
. NN O O

We NN O O
describe NN O O
the NN O O
outcome NN O O
of NN O O
a NN O O
5 NN O O
- NN O O
year NN O O
- NN O O
old NN O O
girl NN O O
with NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
who NN O O
was NN O O
first NN O O
seen NN O O
at NN O O
5 NN O O
months NN O O
of NN O O
age NN O O
with NN O O
severe NN O O
hypertrophic NN O B-Disease
cardiomyopathy NN O I-Disease
, NN O O
hepatomegaly NN O B-Disease
, NN O O
encephalopathy NN O B-Disease
, NN O O
and NN O O
hypotonia NN O B-Disease
. NN O O

Biochemical NN O O
studies NN O O
indicated NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
caused NN O O
by NN O O
a NN O O
stable NN O O
yet NN O O
inactive NN O O
enzyme NN O O
. NN O O

Molecular NN O O
genetic NN O O
analysis NN O O
of NN O O
her NN O O
VLCAD NN O O
gene NN O O
revealed NN O O
a NN O O
T1372C NN O O
( NN O O
F458L NN O O
) NN O O
missense NN O O
mutation NN O O
and NN O O
a NN O O
1668 NN O O
ACAG NN O O
1669 NN O O
splice NN O O
site NN O O
mutation NN O O
. NN O O

After NN O O
initial NN O O
treatment NN O O
with NN O O
intravenous NN O O
glucose NN O O
and NN O O
carnitine NN O O
, NN O O
the NN O O
patient NN O O
has NN O O
thrived NN O O
on NN O O
a NN O O
low NN O O
- NN O O
fat NN O O
diet NN O O
supplemented NN O O
with NN O O
medium NN O O
- NN O O
chain NN O O
triglyceride NN O O
oil NN O O
and NN O O
carnitine NN O O
and NN O O
avoidance NN O O
of NN O O
fasting NN O O
. NN O O

Her NN O O
ventricular NN O O
hypertrophy NN O O
resolved NN O O
significantly NN O O
over NN O O
1 NN O O
year NN O O
, NN O O
and NN O O
cognitively NN O O
, NN O O
she NN O O
is NN O O
in NN O O
the NN O O
superior NN O O
range NN O O
for NN O O
age NN O O
. NN O O

Clinical NN O O
recognition NN O O
of NN O O
VLCAD NN O B-Disease
deficiency NN O I-Disease
is NN O O
important NN O O
because NN O O
it NN O O
is NN O O
one NN O O
of NN O O
the NN O O
few NN O O
directly NN O O
treatable NN O O
causes NN O O
of NN O O
cardiomyopathy NN O B-Disease
in NN O O
children NN O O
. NN O O
. NN O O

Cloning NN O O
of NN O O
a NN O O
novel NN O O
member NN O O
of NN O O
the NN O O
low NN O O
- NN O O
density NN O O
lipoprotein NN O O
receptor NN O O
family NN O O
. NN O O

A NN O O
gene NN O O
encoding NN O O
a NN O O
novel NN O O
transmembrane NN O O
protein NN O O
was NN O O
identified NN O O
by NN O O
DNA NN O O
sequence NN O O
analysis NN O O
within NN O O
the NN O O
insulin NN O B-Disease
- NN O I-Disease
dependent NN O I-Disease
diabetes NN O I-Disease
mellitus NN O I-Disease
( NN O O
IDDM NN O B-Disease
) NN O O
locus NN O O
IDDM4 NN O O
on NN O O
chromosome NN O O
11q13 NN O O
. NN O O

Based NN O O
on NN O O
its NN O O
chromosomal NN O O
position NN O O
, NN O O
this NN O O
gene NN O O
is NN O O
a NN O O
candidate NN O O
for NN O O
conferring NN O O
susceptibility NN O O
to NN O O
diabetes NN O B-Disease
. NN O O

The NN O O
gene NN O O
, NN O O
termed NN O O
low NN O O
- NN O O
density NN O O
lipoprotein NN O O
receptor NN O O
related NN O O
protein NN O O
5 NN O O
( NN O O
LRP5 NN O O
) NN O O
, NN O O
encodes NN O O
a NN O O
protein NN O O
of NN O O
1615 NN O O
amino NN O O
acids NN O O
that NN O O
contains NN O O
conserved NN O O
modules NN O O
which NN O O
are NN O O
characteristic NN O O
of NN O O
the NN O O
low NN O O
- NN O O
density NN O O
lipoprotein NN O O
( NN O O
LDL NN O O
) NN O O
receptor NN O O
family NN O O
. NN O O

These NN O O
modules NN O O
include NN O O
a NN O O
putative NN O O
signal NN O O
peptide NN O O
for NN O O
protein NN O O
export NN O O
, NN O O
four NN O O
epidermal NN O O
growth NN O O
factor NN O O
( NN O O
EGF NN O O
) NN O O
repeats NN O O
with NN O O
associated NN O O
spacer NN O O
domains NN O O
, NN O O
three NN O O
LDL NN O O
- NN O O
receptor NN O O
( NN O O
LDLR NN O O
) NN O O
repeats NN O O
, NN O O
a NN O O
single NN O O
transmembrane NN O O
spanning NN O O
domain NN O O
, NN O O
and NN O O
a NN O O
cytoplasmic NN O O
domain NN O O
. NN O O

The NN O O
encoded NN O O
protein NN O O
has NN O O
a NN O O
unique NN O O
organization NN O O
of NN O O
EGF NN O O
and NN O O
LDLR NN O O
repeats NN O O
; NN O O
therefore NN O O
, NN O O
LRP5 NN O O
likely NN O O
represents NN O O
a NN O O
new NN O O
category NN O O
of NN O O
the NN O O
LDLR NN O O
family NN O O
. NN O O

Both NN O O
human NN O O
and NN O O
mouse NN O O
LRP5 NN O O
cDNAs NN O O
have NN O O
been NN O O
isolated NN O O
and NN O O
the NN O O
encoded NN O O
mature NN O O
proteins NN O O
are NN O O
95 NN O O
% NN O O
identical NN O O
, NN O O
indicating NN O O
a NN O O
high NN O O
degree NN O O
of NN O O
evolutionary NN O O
conservation NN O O
. NN O O
. NN O O

The NN O O
APC NN O B-Disease
variants NN O O
I1307K NN O O
and NN O O
E1317Q NN O O
are NN O O
associated NN O O
with NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
, NN O O
but NN O O
not NN O O
always NN O O
with NN O O
a NN O O
family NN O O
history NN O O
. NN O O

Classical NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
is NN O O
a NN O O
high NN O O
- NN O O
penetrance NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disease NN O I-Disease
that NN O O
predisposes NN O O
to NN O O
hundreds NN O O
or NN O O
thousands NN O O
of NN O O
colorectal NN O B-Disease
adenomas NN O I-Disease
and NN O I-Disease
carcinoma NN O I-Disease
and NN O O
that NN O O
results NN O O
from NN O O
truncating NN O O
mutations NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
. NN O O

A NN O O
variant NN O O
of NN O O
FAP NN O B-Disease
is NN O O
attenuated NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
, NN O O
which NN O O
results NN O O
from NN O O
germ NN O O
- NN O O
line NN O O
mutations NN O O
in NN O O
the NN O O
5 NN O O
and NN O O
3 NN O O
regions NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
. NN O O

Attenuated NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
coli NN O I-Disease
patients NN O O
have NN O O
" NN O O
multiple NN O O
" NN O O
colorectal NN O B-Disease
adenomas NN O I-Disease
( NN O O
typically NN O O
fewer NN O O
than NN O O
100 NN O O
) NN O O
without NN O O
the NN O O
florid NN O O
phenotype NN O O
of NN O O
classical NN O O
FAP NN O B-Disease
. NN O O

Another NN O O
group NN O O
of NN O O
patients NN O O
with NN O O
multiple NN O O
adenomas NN O B-Disease
has NN O O
no NN O O
mutations NN O O
in NN O O
the NN O O
APC NN O B-Disease
gene NN O O
, NN O O
and NN O O
their NN O O
phenotype NN O O
probably NN O O
results NN O O
from NN O O
variation NN O O
at NN O O
a NN O O
locus NN O O
, NN O O
or NN O O
loci NN O O
, NN O O
elsewhere NN O O
in NN O O
the NN O O
genome NN O O
. NN O O

Recently NN O O
, NN O O
however NN O O
, NN O O
a NN O O
missense NN O O
variant NN O O
of NN O O
APC NN O B-Disease
( NN O O
I1307K NN O O
) NN O O
was NN O O
described NN O O
that NN O O
confers NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
colorectal NN O B-Disease
tumors NN O I-Disease
, NN O O
including NN O O
multiple NN O O
adenomas NN O B-Disease
, NN O O
in NN O O
Ashkenazim NN O O
. NN O O

We NN O O
have NN O O
studied NN O O
a NN O O
set NN O O
of NN O O
164 NN O O
patients NN O O
with NN O O
multiple NN O O
colorectal NN O B-Disease
adenomas NN O I-Disease
and NN O I-Disease
/ NN O I-Disease
or NN O I-Disease
carcinoma NN O I-Disease
and NN O O
analyzed NN O O
codons NN O O
1263 NN O O
- NN O O
1377 NN O O
( NN O O
exon NN O O
15G NN O O
) NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
for NN O O
germ NN O O
- NN O O
line NN O O
variants NN O O
. NN O O

Three NN O O
patients NN O O
with NN O O
the NN O O
I1307K NN O O
allele NN O O
were NN O O
detected NN O O
, NN O O
each NN O O
of NN O O
Ashkenazi NN O O
descent NN O O
. NN O O

Four NN O O
patients NN O O
had NN O O
a NN O O
germ NN O O
- NN O O
line NN O O
E1317Q NN O O
missense NN O O
variant NN O O
of NN O O
APC NN O O
that NN O O
was NN O O
not NN O O
present NN O O
in NN O O
controls NN O O
; NN O O
one NN O O
of NN O O
these NN O O
individuals NN O O
had NN O O
an NN O O
unusually NN O O
large NN O O
number NN O O
of NN O O
metaplastic NN O B-Disease
polyps NN O I-Disease
of NN O I-Disease
the NN O I-Disease
colorectum NN O I-Disease
. NN O O

There NN O O
is NN O O
increasing NN O O
evidence NN O O
that NN O O
there NN O O
exist NN O O
germ NN O O
- NN O O
line NN O O
variants NN O O
of NN O O
the NN O O
APC NN O B-Disease
gene NN O O
that NN O O
predispose NN O O
to NN O O
the NN O O
development NN O O
of NN O O
multiple NN O O
colorectal NN O B-Disease
adenomas NN O I-Disease
and NN O I-Disease
carcinoma NN O I-Disease
, NN O O
but NN O O
without NN O O
the NN O O
florid NN O O
phenotype NN O O
of NN O O
classical NN O O
FAP NN O B-Disease
, NN O O
and NN O O
possibly NN O O
with NN O O
importance NN O O
for NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
risk NN O O
in NN O O
the NN O O
general NN O O
population NN O O
. NN O O
. NN O O

Genomic NN O O
structure NN O O
of NN O O
the NN O O
human NN O O
congenital NN O B-Disease
chloride NN O I-Disease
diarrhea NN O I-Disease
( NN O O
CLD NN O B-Disease
) NN O O
gene NN O O
. NN O O

Congenital NN O B-Disease
chloride NN O I-Disease
diarrhea NN O I-Disease
( NN O O
CLD NN O B-Disease
) NN O O
is NN O O
caused NN O O
by NN O O
mutations NN O O
in NN O O
a NN O O
gene NN O O
which NN O O
encodes NN O O
an NN O O
intestinal NN O O
anion NN O O
transporter NN O O
. NN O O

We NN O O
report NN O O
here NN O O
the NN O O
complete NN O O
genomic NN O O
organization NN O O
of NN O O
the NN O O
human NN O O
CLD NN O B-Disease
gene NN O O
which NN O O
spans NN O O
approximately NN O O
39kb NN O O
, NN O O
and NN O O
comprises NN O O
21 NN O O
exons NN O O
. NN O O

All NN O O
exon NN O O
/ NN O O
intron NN O O
boundaries NN O O
conform NN O O
to NN O O
the NN O O
GT NN O O
/ NN O O
AG NN O O
rule NN O O
. NN O O

An NN O O
analysis NN O O
of NN O O
the NN O O
putative NN O O
promoter NN O O
region NN O O
sequence NN O O
shows NN O O
a NN O O
putative NN O O
TATA NN O O
box NN O O
and NN O O
predicts NN O O
multiple NN O O
transcription NN O O
factor NN O O
binding NN O O
sites NN O O
. NN O O

The NN O O
genomic NN O O
structure NN O O
was NN O O
determined NN O O
using NN O O
DNA NN O O
from NN O O
several NN O O
sources NN O O
including NN O O
multiple NN O O
large NN O O
- NN O O
insert NN O O
libaries NN O O
and NN O O
genomic NN O O
DNA NN O O
from NN O O
Finnish NN O O
CLD NN O B-Disease
patients NN O O
and NN O O
controls NN O O
. NN O O

Exon NN O O
- NN O O
specific NN O O
primers NN O O
developed NN O O
in NN O O
this NN O O
study NN O O
will NN O O
facilitate NN O O
mutation NN O O
screening NN O O
studies NN O O
of NN O O
patients NN O O
with NN O O
the NN O O
disease NN O O
. NN O O

Genomic NN O O
sequencing NN O O
of NN O O
a NN O O
BAC NN O O
clone NN O O
H NN O O
_ NN O O
RG364P16 NN O O
revealed NN O O
the NN O O
presence NN O O
of NN O O
another NN O O
, NN O O
highly NN O O
homologous NN O O
gene NN O O
3 NN O O
of NN O O
the NN O O
CLD NN O B-Disease
gene NN O O
, NN O O
with NN O O
a NN O O
similar NN O O
genomic NN O O
structure NN O O
, NN O O
recently NN O O
identified NN O O
as NN O O
the NN O O
Pendred NN O B-Disease
syndrome NN O I-Disease
gene NN O O
( NN O O
PDS NN O B-Disease
) NN O O
. NN O O
. NN O O

The NN O O
APCI1307K NN O O
allele NN O O
and NN O O
cancer NN O B-Disease
risk NN O O
in NN O O
a NN O O
community NN O O
- NN O O
based NN O O
study NN O O
of NN O O
Ashkenazi NN O O
Jews NN O O
. NN O O

Mutations NN O O
in NN O O
APC NN O O
are NN O O
classically NN O O
associated NN O O
with NN O O
familial NN O B-Disease
adenomatous NN O I-Disease
polyposis NN O I-Disease
( NN O O
FAP NN O B-Disease
) NN O O
, NN O O
a NN O O
highly NN O O
penetrant NN O O
autosomal NN O B-Disease
dominant NN O I-Disease
disorder NN O I-Disease
characterized NN O O
by NN O O
multiple NN O O
intestinal NN O O
polyps NN O B-Disease
and NN O O
, NN O O
without NN O O
surgical NN O O
intervention NN O O
, NN O O
the NN O O
development NN O O
of NN O O
colorectal NN O B-Disease
cancer NN O I-Disease
( NN O O
CRC NN O B-Disease
) NN O O
. NN O O

APC NN O B-Disease
is NN O O
a NN O O
tumour NN O O
- NN O O
suppressor NN O O
gene NN O O
, NN O O
and NN O O
somatic NN O O
loss NN O O
occurs NN O O
in NN O O
tumours NN O B-Disease
. NN O O

The NN O O
germline NN O O
T NN O O
- NN O O
to NN O O
- NN O O
A NN O O
transversion NN O O
responsible NN O O
for NN O O
the NN O O
APC NN O O
I1307K NN O O
allele NN O O
converts NN O O
the NN O O
wild NN O O
- NN O O
type NN O O
sequence NN O O
to NN O O
a NN O O
homopolymer NN O O
tract NN O O
( NN O O
A8 NN O O
) NN O O
that NN O O
is NN O O
genetically NN O O
unstable NN O O
and NN O O
prone NN O O
to NN O O
somatic NN O O
mutation NN O O
. NN O O

The NN O O
I1307K NN O O
allele NN O O
was NN O O
found NN O O
in NN O O
6 NN O O
. NN O O

1 NN O O
% NN O O
of NN O O
unselected NN O O
Ashkenazi NN O O
Jews NN O O
and NN O O
higher NN O O
proportions NN O O
of NN O O
Ashkenazim NN O O
with NN O O
family NN O O
or NN O O
personal NN O O
histories NN O O
of NN O O
CRC NN O B-Disease
( NN O O
ref NN O O
. NN O O
2 NN O O
) NN O O
. NN O O

To NN O O
evaluate NN O O
the NN O O
role NN O O
of NN O O
I1307K NN O O
in NN O O
cancer NN O B-Disease
, NN O O
we NN O O
genotyped NN O O
5 NN O O
, NN O O
081 NN O O
Ashkenazi NN O O
volunteers NN O O
in NN O O
a NN O O
community NN O O
survey NN O O
. NN O O

Risk NN O O
of NN O O
developing NN O O
colorectal NN O B-Disease
, NN O I-Disease
breast NN O I-Disease
and NN O I-Disease
other NN O I-Disease
cancers NN O I-Disease
were NN O O
compared NN O O
between NN O O
genotyped NN O O
I1307K NN O O
carriers NN O O
and NN O O
non NN O O
- NN O O
carriers NN O O
and NN O O
their NN O O
first NN O O
- NN O O
degree NN O O
relatives NN O O
. NN O O

Sperm NN O O
DNA NN O O
analysis NN O O
in NN O O
a NN O O
Friedreich NN O B-Disease
ataxia NN O I-Disease
premutation NN O O
carrier NN O O
suggests NN O O
both NN O O
meiotic NN O O
and NN O O
mitotic NN O O
expansion NN O O
in NN O O
the NN O O
FRDA NN O B-Disease
gene NN O O
. NN O O

Friedreich NN O B-Disease
ataxia NN O I-Disease
is NN O O
usually NN O O
caused NN O O
by NN O O
an NN O O
expansion NN O O
of NN O O
a NN O O
GAA NN O O
trinucleotide NN O O
repeat NN O O
in NN O O
intron NN O O
1 NN O O
of NN O O
the NN O O
FRDA NN O B-Disease
gene NN O O
. NN O O

Occasionally NN O O
, NN O O
a NN O O
fully NN O O
expanded NN O O
allele NN O O
has NN O O
been NN O O
found NN O O
to NN O O
arise NN O O
from NN O O
a NN O O
premutation NN O O
of NN O O
100 NN O O
or NN O O
less NN O O
triplet NN O O
repeats NN O O
. NN O O

We NN O O
have NN O O
examined NN O O
the NN O O
sperm NN O O
DNA NN O O
of NN O O
a NN O O
premutation NN O O
carrier NN O O
. NN O O

This NN O O
mans NN O O
leucocyte NN O O
DNA NN O O
showed NN O O
one NN O O
normal NN O O
allele NN O O
and NN O O
one NN O O
allele NN O O
of NN O O
approximately NN O O
100 NN O O
repeats NN O O
. NN O O

His NN O O
sperm NN O O
showed NN O O
an NN O O
expanded NN O O
allele NN O O
in NN O O
a NN O O
tight NN O O
range NN O O
centering NN O O
on NN O O
a NN O O
size NN O O
of NN O O
approximately NN O O
320 NN O O
trinucleotide NN O O
repeats NN O O
. NN O O

His NN O O
affected NN O O
son NN O O
has NN O O
repeat NN O O
sizes NN O O
of NN O O
1040 NN O O
and NN O O
540 NN O O
. NN O O

These NN O O
data NN O O
suggest NN O O
that NN O O
expansion NN O O
occurs NN O O
in NN O O
two NN O O
stages NN O O
, NN O O
the NN O O
first NN O O
during NN O O
meiosis NN O O
followed NN O O
by NN O O
a NN O O
second NN O O
mitotic NN O O
expansion NN O O
. NN O O

We NN O O
also NN O O
show NN O O
that NN O O
in NN O O
all NN O O
informative NN O O
carrier NN O O
father NN O O
to NN O O
affected NN O O
child NN O O
transmissions NN O O
, NN O O
with NN O O
the NN O O
notable NN O O
exception NN O O
of NN O O
the NN O O
premutation NN O O
carrier NN O O
, NN O O
the NN O O
expansion NN O O
size NN O O
decreases NN O O
. NN O O
. NN O O

The NN O O
R496H NN O O
mutation NN O O
of NN O O
arylsulfatase NN O O
A NN O O
does NN O O
not NN O O
cause NN O O
metachromatic NN O B-Disease
leukodystrophy NN O I-Disease
. NN O O

Deficiency NN O B-Disease
of NN O I-Disease
arylsulfatase NN O I-Disease
A NN O I-Disease
( NN O O
ARSA NN O O
) NN O O
enzyme NN O O
activity NN O O
causes NN O O
metachromatic NN O B-Disease
leukodystrophy NN O I-Disease
( NN O O
MLD NN O B-Disease
) NN O O
. NN O O

A NN O O
number NN O O
of NN O O
ARSA NN O O
gene NN O O
mutations NN O O
responsible NN O O
for NN O O
MLD NN O B-Disease
have NN O O
been NN O O
identified NN O O
. NN O O

Recently NN O O
, NN O O
the NN O O
R496H NN O O
mutation NN O O
of NN O O
ARSA NN O O
was NN O O
proposed NN O O
to NN O O
be NN O O
a NN O O
cause NN O O
of NN O O
MLD NN O B-Disease
( NN O O
Draghia NN O O
et NN O O
al NN O O
. NN O O
, NN O O
1997 NN O O
) NN O O
. NN O O

We NN O O
have NN O O
investigated NN O O
the NN O O
R496H NN O O
mutation NN O O
and NN O O
found NN O O
this NN O O
mutation NN O O
at NN O O
a NN O O
relatively NN O O
high NN O O
frequency NN O O
in NN O O
an NN O O
African NN O O
American NN O O
population NN O O
( NN O O
f NN O O
= NN O O
0 NN O O
. NN O O
09 NN O O
, NN O O
n NN O O
= NN O O
61 NN O O
subjects NN O O
) NN O O
. NN O O

The NN O O
ARSA NN O O
enzyme NN O O
activity NN O O
in NN O O
subjects NN O O
with NN O O
and NN O O
without NN O O
the NN O O
R496H NN O O
mutation NN O O
was NN O O
determined NN O O
and NN O O
found NN O O
to NN O O
be NN O O
normal NN O O
. NN O O

It NN O O
is NN O O
therefore NN O O
concluded NN O O
that NN O O
the NN O O
R496H NN O O
mutation NN O O
of NN O O
ARSA NN O O
does NN O O
not NN O O
negatively NN O O
influence NN O O
the NN O O
activity NN O O
of NN O O
ARSA NN O O
and NN O O
is NN O O
not NN O O
a NN O O
cause NN O O
of NN O O
MLD NN O B-Disease

Down NN O O
- NN O O
regulation NN O O
of NN O O
transmembrane NN O O
carbonic NN O O
anhydrases NN O O
in NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
cell NN O O
lines NN O O
by NN O O
wild NN O O
- NN O O
type NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
transgenes NN O O
. NN O O

To NN O O
discover NN O O
genes NN O O
involved NN O O
in NN O O
von NN O B-Disease
Hippel NN O I-Disease
- NN O I-Disease
Lindau NN O I-Disease
( NN O O
VHL NN O B-Disease
) NN O O
- NN O O
mediated NN O O
carcinogenesis NN O O
, NN O O
we NN O O
used NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
cell NN O O
lines NN O O
stably NN O O
transfected NN O O
with NN O O
wild NN O O
- NN O O
type NN O O
VHL NN O O
- NN O O
expressing NN O O
transgenes NN O O
. NN O O

Large NN O O
- NN O O
scale NN O O
RNA NN O O
differential NN O O
display NN O O
technology NN O O
applied NN O O
to NN O O
these NN O O
cell NN O O
lines NN O O
identified NN O O
several NN O O
differentially NN O O
expressed NN O O
genes NN O O
, NN O O
including NN O O
an NN O O
alpha NN O O
carbonic NN O O
anhydrase NN O O
gene NN O O
, NN O O
termed NN O O
CA12 NN O O
. NN O O

The NN O O
deduced NN O O
protein NN O O
sequence NN O O
was NN O O
classified NN O O
as NN O O
a NN O O
one NN O O
- NN O O
pass NN O O
transmembrane NN O O
CA NN O O
possessing NN O O
an NN O O
apparently NN O O
intact NN O O
catalytic NN O O
domain NN O O
in NN O O
the NN O O
extracellular NN O O
CA NN O O
module NN O O
. NN O O

Reintroduced NN O O
wild NN O O
- NN O O
type NN O O
VHL NN O B-Disease
strongly NN O O
inhibited NN O O
the NN O O
overexpression NN O O
of NN O O
the NN O O
CA12 NN O O
gene NN O O
in NN O O
the NN O O
parental NN O O
renal NN O B-Disease
cell NN O I-Disease
carcinoma NN O I-Disease
cell NN O O
lines NN O O
. NN O O

Similar NN O O
results NN O O
were NN O O
obtained NN O O
with NN O O
CA9 NN O O
, NN O O
encoding NN O O
another NN O O
transmembrane NN O O
CA NN O O
with NN O O
an NN O O
intact NN O O
catalytic NN O O
domain NN O O
. NN O O

Although NN O O
both NN O O
domains NN O O
of NN O O
the NN O O
VHL NN O B-Disease
protein NN O O
contribute NN O O
to NN O O
regulation NN O O
of NN O O
CA12 NN O O
expression NN O O
, NN O O
the NN O O
elongin NN O O
binding NN O O
domain NN O O
alone NN O O
could NN O O
effectively NN O O
regulate NN O O
CA9 NN O O
expression NN O O
. NN O O

We NN O O
mapped NN O O
CA12 NN O O
and NN O O
CA9 NN O O
loci NN O O
to NN O O
chromosome NN O O
bands NN O O
15q22 NN O O
and NN O O
17q21 NN O O
. NN O O

2 NN O O
respectively NN O O
, NN O O
regions NN O O
prone NN O O
to NN O O
amplification NN O O
in NN O O
some NN O O
human NN O O
cancers NN O B-Disease
. NN O O

Additional NN O O
experiments NN O O
are NN O O
needed NN O O
to NN O O
define NN O O
the NN O O
role NN O O
of NN O O
CA NN O O
IX NN O O
and NN O O
CA NN O O
XII NN O O
enzymes NN O O
in NN O O
the NN O O
regulation NN O O
of NN O O
pH NN O O
in NN O O
the NN O O
extracellular NN O O
microenvironment NN O O
and NN O O
its NN O O
potential NN O O
impact NN O O
on NN O O
cancer NN O B-Disease
cell NN O O
growth NN O O
. NN O O

A NN O O
gene NN O O
encoding NN O O
a NN O O
transmembrane NN O O
protein NN O O
is NN O O
mutated NN O O
in NN O O
patients NN O O
with NN O O
diabetes NN O B-Disease
mellitus NN O I-Disease
and NN O O
optic NN O B-Disease
atrophy NN O I-Disease
( NN O O
Wolfram NN O B-Disease
syndrome NN O I-Disease
) NN O O
. NN O O

Wolfram NN O B-Disease
syndrome NN O I-Disease
( NN O O
WFS NN O B-Disease
; NN O O
OMIM NN O O
222300 NN O O
) NN O O
is NN O O
an NN O O
autosomal NN O B-Disease
recessive NN O I-Disease
neurodegenerative NN O I-Disease
disorder NN O I-Disease
defined NN O O
by NN O O
young NN O O
- NN O O
onset NN O O
non NN O O
- NN O O
immune NN O O
insulin NN O B-Disease
- NN O I-Disease
dependent NN O I-Disease
diabetes NN O I-Disease
mellitus NN O I-Disease
and NN O O
progressive NN O O
optic NN O B-Disease
atrophy NN O I-Disease
. NN O O

Linkage NN O O
to NN O O
markers NN O O
on NN O O
chromosome NN O O
4p NN O O
was NN O O
confirmed NN O O
in NN O O
five NN O O
families NN O O
. NN O O

On NN O O
the NN O O
basis NN O O
of NN O O
meiotic NN O O
recombinants NN O O
and NN O O
disease NN O O
- NN O O
associated NN O O
haplotypes NN O O
, NN O O
the NN O O
WFS NN O B-Disease
gene NN O O
was NN O O
localized NN O O
to NN O O
a NN O O
BAC NN O O
/ NN O O
P1 NN O O
contig NN O O
of NN O O
less NN O O
than NN O O
250 NN O O
kb NN O O
. NN O O

Mutations NN O O
in NN O O
a NN O O
novel NN O O
gene NN O O
( NN O O
WFS1 NN O O
) NN O O
encoding NN O O
a NN O O
putative NN O O
transmembrane NN O O
protein NN O O
were NN O O
found NN O O
in NN O O
all NN O O
affected NN O O
individuals NN O O
in NN O O
six NN O O
WFS NN O B-Disease
families NN O O
, NN O O
and NN O O
these NN O O
mutations NN O O
were NN O O
associated NN O O
with NN O O
the NN O O
disease NN O O
phenotype NN O O
. NN O O

WFS1 NN O O
appears NN O O
to NN O O
function NN O O
in NN O O
survival NN O O
of NN O O
islet NN O O
beta NN O O
- NN O O
cells NN O O
and NN O O
neurons NN O O
. NN O O
. NN O O

Stable NN O O
interaction NN O O
between NN O O
the NN O O
products NN O O
of NN O O
the NN O O
BRCA1 NN O O
and NN O O
BRCA2 NN O O
tumor NN O B-Disease
suppressor NN O O
genes NN O O
in NN O O
mitotic NN O O
and NN O O
meiotic NN O O
cells NN O O
. NN O O

BRCA1 NN O O
and NN O O
BRCA2 NN O O
account NN O O
for NN O O
most NN O O
cases NN O O
of NN O O
familial NN O O
